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SUMMARY
Surgery remains the cornerstone in the treatment of malignant melanoma. The 
surgical treatment of primary and recurrent limb malignant melanoma ranges from 
wide local excision of the primary melanoma to elective and therapeutic lymph node 
dissection. The delivery of a chemotherapeutic agent via an isolated limb perfusion 
circuit has been available since 1957, yet its exact role remains to be defined.
The theme of this thesis is "how can the current management of limb malignant 
melanoma be improved?"
The work in this thesis was carried out in the Vascular Unit, at Gartnavel General 
Hospital, Glasgow and in the Animal and Scientific Laboratories of Glasgow 
University. In 1984 isolated limb perfusion (ILP) using melphalan was made 
available in Glasgow for the treatment of primary and recurrent limb malignant 
melanoma and since then over 250 adjuvant and therapeutic ILPs have been 
performed.
My analysis of the ILP results in the Glasgow unit showed that in the treatment of 
primary melanoma, ILP confers an improved disease free interval and possibly a 
small survival advantage. In the treatment of recurrent limb melanoma, therapeutic 
ILP is effective in the control of local and regional recurrence. I have analysed the 
results in specific subgroups of patients, i.e. when patients with subungual malignant 
melanoma undergoing ILP were matched (for age, site and tumour thickness) with 
patients treated with amputation only, no survival advantage was demonstrated in the 
perfused patients. Having analysed these results, I then addressed the issue of how 
the theoretically attractive concept of ILP could be improved and its role 
convincingly established.
The components of my study are summarised below:
1) Improving the ILP circuit by:
a) Introducing pulsatility to assess if it may be physiologically superior.
b) Avoiding the compartment syndrome.
c) Using a vasodilator to increase transcutaneous oxygen.
2) Assessing laser ablation as an alternative therapy for recurrent melanoma.
3) Accurate staging of malignant melanoma using lymphatic mapping.
4) Targeting radiotherapy in an animal model.
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1) Improving the ILP circuit
Isolated limb perfusion was developed to maximise drug delivery to the target tissue 
while minimising systemic toxicity. It has been shown that an increase in the skin 
oxygen tension in the isolated circuit can potentiate the action of the 
chemotherapeutic agent and may have a selective tumouricidal action.
It was surprising to discover that since the introduction of ILP over 30 years ago, 
there have been virtually no changes in the basic circuit. Performing clinical studies 
on ILP patients is a difficult problem, since even in a regional centre, only 30-40 
patients each year will be treated by ILP and not all these patients are appropriate for 
study. Nonetheless, I was determined to attempt to address several basic issues 
previously ignored:
Pulsatility
1(a) One obvious feature of the ILP circuit that is not physiological is the delivery of 
the perfusate in a non pulsatile manner via a simple roller pump although pulsatility 
is an obvious feature of blood flow in arteries. A non randomised study was 
conducted to investigate if introducing pulsatility into the circuit would confer 
physiological advantages.
Twenty-two patients were studied. Pulsatility was introduced using a Stockert 
Frequency Control Module and blood flow was synchronised to the 
electrocardiogram of the patient. Twenty-two patients matched for sex, age, site and 
level of perfusion using the standard continuous flow circuit were used as controls. 
Using pulsatile flow, the time taken to reach physiological skin oxygen saturation 
was reduced. There was less fluctuation in levels of oxygen tension and there was 
less fluid shift in the circuit compared to the non pulsatile group. However, there was 
no significant difference in the maximum oxygen tension achieved between the 
pulsatile and non pulsatile group. Introduction of pulsatility into the ILP circuit is a 
simple and safe modification that appears to offer physiological advantages over non 
pulsatile blood flow.
Compartment pressure
1(b) Treatment by ILP can predispose to the development of a compartment 
syndrome in the limb and some investigators thus perform routine prophylactic 
fasciotomy after ILP. A non randomised study was conducted to determine if there 
was a significant increase in the compartment pressures during ILP and whether the 
nature of blood flow in the circuit effected these pressures.
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Sixteen patients were studied. Eight patients had non pulsatile ILP whilst 8 had 
pulsatile ILP. The rate of rise of the compartment pressures in the non pulsatile group 
was significantly greater than in the pulsatile group (p < 0.001). The time taken for 
the tissue oxygen levels to rise to physiological values was significantly lower in the 
pulsatile group than in the non pulsatile group (p = 0.002). These results suggest that 
the routinely used mode of non pulsatile blood flow in the ILP circuit has the 
significant disadvantage of greater rate of rise of compartment pressure when 
compared to pulsatile blood flow. Since the introduction of pulsatility in the 
operation of the ILP circuit, neither routine prophylactic nor therapeutic fasciotomy 
has been needed.
Role of Vasodilator
lc) Several reports have shown that vasoactive drugs can significantly affect the 
nature of blood flow in both experimental tumours in rodents and human tumours. A 
study was set up to assess the efficacy of vasodilator agents to improve oxygenation 
in the ILP circuit and potentiate the effects of melphalan. The study was conducted 
using verapamil hydrochloride in twenty-one patients undergoing ILP. Results of 
this study showed that this agent produced a significant fall in the peripheral arterial 
pressure. As the pressures fell, there was a proportional fall in the transcutaneous 
oxygen tension. Despite the theoretical advantage of the use of vasodilators in 
chemotherapy, the present study showed that the use of verapamil hydrochloride 
offers no measurable advantage in the ILP circuit.
2) Assessing laser ablation as an alternative therapy for recurrent 
melanoma
In Glasgow, ILP is the treatment of choice for the control of recurrent limb malignant 
melanoma. However not all patients are suitable for this treatment. When cutaneous 
metastases from malignant melanoma are untreated, they inevitably enlarge in size, 
ulcerate and become painful. A study was carried out to assess whether a carbon 
dioxide laser can be used as an effective alternative to ILP in the control of cutaneous 
metastases. Fourteen patients who were unsuitable for ILP or had failed ILP were 
recruited into this study. Results showed that in patients with non nodal regional 
recurrence, when ILP had failed or was unsuitable, carbon dioxide laser therapy is a 
safe and effective alternative treatment in the palliation of cutaneous recurrence from 
malignant melanoma.
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3) Accurate staging of malignant melanoma using lymphatic 
mapping
The prognosis of malignant melanoma is ultimately related to the stage of the disease. 
If staging is incorrect, the patient may not receive appropriate treatment. Controversy 
surrounds the role of elective of elective lymphadenectomy. If a technique could be 
developed to identify patients with occult nodal disease, these patients may be 
selected for elective lymphadenectomy. Intraoperative lymphatic mapping is such a 
technique which has been developed on the assumption that metastases embolise via 
lymphatic channels to regional nodes.
Although the technique was reported in 1992, no other workers had been able to 
replicate the original results. I therefore studied the method in a group of 30 patients. 
Sentinel nodes were identified in all 30 patients. Eight nodes contained 
micrometastases. Our evaluation of intraoperative lymphatic mapping shows the 
method to be promising. The technique is practical and easy to master. If 32% of 
patients with cutaneous malignant melanoma who are clinically stage 1 have nodal 
disease, this has great importance in the staging and treatment of disease and for all 
therapeutic trials in the future. This technique may have potential application in other 
tumours that metastasise via the lymphatics.
4) Targeting radiotherapy in animal model
The main difficulty for the clinician treating malignant melanoma is that early 
random metastases occur. If a melanoma specific compound could be labelled with 
an appropriate radioisotope, this compound could be used to scavenge and destroy 
melanoma cells beyond the limits of clinical detectability. Targeted radiotherapy is 
such a treatment that allows deposition of a high radiation dose in targeted tissue with 
little exposure to the surrounding structures. Methylene blue has been shown to have 
a high affinity for melanin. A study was designed to assess the efficacy of radioactive 
iodine labelled to methylene blue to target melanoma cells in nude mice.
Radioisotopes of iodine were injected into 3 groups of nude mice with B16/F10 
mouse melanoma. Group A (controls) received tumour cells subcutaneously, Group 
B received a subcutaneous mixture of tumour cells and radioactive labelled 
methylene blue and Group C received tumour cells subcutaneously and on 
macroscopic evidence of tumour growth received intravenous radioactive labelled 
methylene blue into the tail vein.
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Parallel experiments were performed on B16/F10 melanoma cells grown as plate 
cultures. In both the animal experiments and the cell cultures, the effects of different 
isotopes were compared. Tumour growth was delayed in the treated groups and the 
effect was maximal using iodine 125. Targeted radiotherapy using iodine 125 
labelled methylene blue may now be clinically possible. The isolated circuit is the 
obvious vehicle for such a treatment modality.
The overall aim of this thesis was to find ways of improving the efficacy of ILP as a 
treatment for limb malignant melanoma. My studies have shown that:
1) Pulsatile flow is both logical, easy to produce and confers physiological 
advantages. The risk of a compartment syndrome in the perfused limb can be 
considerably reduced.
2) Local laser therapy is a safe and practical alternative for the palliation of local 
recurrence when ILP is not possible or has failed.
3) Accurate disease staging can be achieved using an intraoperative technique which 
may have important implications for future studies.
4) An animal model was successfully established showing that targeted radiotherapy 
is effective and that this mode of treatment may become a clinical possibility for 
patients with malignant melanoma.
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CHAPTER 1 
INTRODUCTION
1.1 HISTORY OF MALIGNANT MELANOMA
1.1.1 18TH AND 19TH CENTURY
John Hunter was the first to publish an account of melanoma in 1787 after removing a 
recurrent lesion from behind the angle of the jaw of a 35 year old man. He did not 
name the disease as such but in describing the lesion stated, 'part of it was white and 
part spongy, soft and black'. He called it "cancerous fungous excrescence." Hunter's 
original specimen in the Royal College of Surgeons of England was examined in 
1968 and confirmed to be a melanoma, probably a secondary deposit from an 
unknown primary tumour1.
It was Rene Laennec, in 1806 who is accredited with the first description of 
melanoma as a disease entity. In 1812 he actually used the word melanosis which he 
said was derived from the Greek word meaning "black"2.
Fourteen years after Laennec's first description of melanotic growth the first 
melanoma was described in England by William Norris. It is interesting to note that 
he was the grandson of John Hunter. Norris, although a country practitioner so loved 
his profession that he would carry out a complete necropsy in private practice and ride 
20 miles for a sight of a case of melanomic sarcoma3. His first patient was a 59 year 
old fair complexioned and light haired man who presented with a tumour midway 
between the umbilicus and pubis4. Norris excised this lesion only to find that it 
recurred six weeks later in the scar. He noted that the patient remained in good health 
until just before his death. Norris performed the post-mortem himself and his 
enthusiasm for pathology can be seen from this account below.
"When the abdomen, chest and cranium were thrown open, it was a most 
extraordinary phenomenon; thousands upon thousands of coal black spots of circular 
shape and various sizes were to be seen clearly dotting the shining mucous, serous 
and fibrous membranes of most vital organs: I should think the most dazzling sight 
ever beheld by the morbid anatomist. I shall never forget the pleasing thrill which 
came over me when I first beheld them. It would have puzzled the most powerful 
descriptive talents to have done full justice to such a novel and striking disease 
displayed so beautifully in the endless profusion everywhere3."
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He later found out that his patient's father had also died of melanoma and commented, 
"he was not acquainted with any case affording so strong probability of the hereditary 
nature of the disease"5.
In the 19th century, many other descriptions of primary melanoma were published. 
In 1834, David William6 probably gave the first description of the horizontal and 
vertical growth phases of a superficial spreading melanoma and in 1837 Isaac 
Parrish7 reported the first case of melanoma in America.
In 1838, Robert Carswell8 in his "Illustrations of Elementary Forms of Disease" sub­
divided melanoma into two groups; true melanosis and spurious melanosis, and 
described four modifications - punctiform, tuberiform, stratiform and liquiform. He 
was the first to coin the term melanoma. In 1851, the first case of surgical excision of 
a metastatic melanoma was published in the Lancet by Mr Ferguson9, who removed a 
groin secondary from a 45 year old woman who two years previously had had a dark 
tumour excised from the mons veneris.
In 1853, Sir James Paget10 presented a relatively large series of 45 patients with 
"melanoma cancer". In his series, there were 27 women and 18 men of whom 20 
were between the ages of 20 and 60 years. The primary lesion was removed in 18 
patients of whom only 5 were alive at two years. In his famous work "Lectures on 
Surgical Pathology10", he reported that in "spurious melanoma" there was blacking of 
various structures whose only common character is that they are not tumours. He
emphasised that "melanomic cancers [were] medullary cancers modified by the
formation of black pigment in their elemental structures".
Oliver Pemberton11 in 1858 presented a further 60 cases of melanoma, 33 men and 
27 women, and described post-mortem appearances in 33 patients. He noted that 
melanotic cancer occurred frequently in or near a "congenital wart or mole". He also 
observed that "in colour melanosis has many shades. In its primary form it is almost 
always brownish. Later the brown shade assumes every intensity of black. 
Sometimes the first change is of a slate colour". Pemberton11 aiso reported the first 
case of melanoma in a black person. The man was a 29 year old Madagascarian 
whose lesion was located on the side of his foot but who despite a below knee 
amputation died from disseminated disease. In 1857, Sir Jonathan Hutchison12 
described the first case of subungual melanoma. He referred to it as a "melanotic 
whitlow" because it resembled a whitlowl3.
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Towards the end of the 19th century more cases of melanoma were being reported 
including an interesting article by Tennent14 in the Glasgow Medical Journal. He 
comments, in a patient with advanced melanoma, that the urine had a greenish black 
tint and felt this was probably the result of absorption of melanin, as at autopsy no 
tumour was found in the urinaiy tract. He concluded, "the mode of origin, 
development and progress of such a case of melanotic sarcoma strongly indicated the 
propriety of the more frequent and prompt complete removal of moles or pigmented 
spots by the hand of the surgeonl4".
Joseph Coats15 echoed Tennent's findings at a presentation to the Pathological and 
Clinical Society of Glasgow where he stated, "outside the obvious boundaries of
tumour there are individual cells planted which are capable of multiplying and
reproducing tumour tissue when the surgeon removes a sarcoma, therefore he
may leave behind many cells ..... capable of forming tumour and so causing
recurrence. The operation should be so executed as to remove the tissue some 
distance outside the apparent limits of the growth".
By the end of the 19th centuiy, wide surgical excision of primary melanoma was well 
established although controversies on lymph node dissection were being debated. 
Herbert Snow16, in his lecture on melanotic cancerous diseases at the Cancer Hospital 
in 1892, emphasised that "in the surgical treatment of melanoma, the skin tumour is 
in the majority of cases very small but there is a tendency to rapidly infect the nearest 
lymph glands. Palpable enlargement of these glands is unfortunately but a late
symptom of deposit therein we thus see the utter futility of operative measures
which are addressed to the primary lesion only we see the paramount importance
of securing whenever possible, the perfect eradication of these lymph glands which 
will necessarily be first infected and before enlargement takes place radical removal 
of such organs before they have undergone appreciable increase in bulk, is a safe and 
easy measure which under the condition indicated should never be neglected".
1.1.2 20TH CENTURY
From the accurate and careful observations made by the 19th century pioneers, it was 
possible for William Sampson Handley3, after only studying a single autopsy 
examination of a patient with melanoma, to present "The Pathology of Melanotic 
Growth in Relation to Their Operative Treatment", at the Hunterian lectures. He 
concluded "that the process of dissemination is initiated by the access of malignant 
cells to the fine lymphatics, followed by the centrifugal spread of permeation along 
the main lymphatic plexus into which the primary growth pours its lymph and by
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secondary permeation of small tributaries of this plexus meanwhile invasion of
the bloodstream takes place either by local infiltration of veins from comitant 
permeated lymphatics or malignant cells carried into the blood along the thoracic duct
from invaded lymphatic glands mesoblastic cells of melanotic sarcoma are able
to thrive when lodged in a blood vessel. Thus, in later stages of melanotic sarcoma, 
the slow process of lymphatic permeation usually recedes into insignificance and the 
patient dies with almost universal deposits resulting from blood embolism". He felt 
able to advocate wide local excision of the primary lesion, regional lymph node 
dissection and amputation in selected cases of melanoma. This was to remain the 
mainstay of treatment for the next fifty years until the question of the effectiveness of 
lymphadenectomy arose.
Although many advances have been made in various aspects of melanoma, we owe a 
lot to the early pioneers such as Norris, Paget, Pemberton and Handley who through 
their dedication, made accurate and detailed observations of the disease and thus laid 
the foundation upon which advances were possible. Many of their observations have 
stood the test of time and are still pertinent in the modem day treatment and 
prevention of melanoma.
1.2 EPIDEMIOLOGICAL FEATURES OF MALIGNANT MELANOMA
1.2.1 INCIDENCE
The world-wide incidence of malignant melanoma is increasing and this upward trend 
has been sustained over several decades. The first increase was noted in Connecticut, 
United States in the 1930's and later in Denmark in the 1940's and is now evident 
world-wide17. In the United Kingdom, this increasing incidence is particularly 
notable in women. Women have twice the incidence of melanoma than men in 
England, Scotland and Wales and three times the incidence in Ireland18. In 1979, 
there were 2,095 new cases of melanoma in the UK. In 1984 this had increased to 
2,624, an increase of 25%. Figure 1 shows changes in the number of patients 
registered by the Scottish Melanoma Group between the years 1979 and 1986.
These figures depict a rise of 75% over seven years equivalent to 10.5% per year and 
similar increases are reported in Scandinavia and Australia. Although it has been 
estimated that approximately 70,000 new cases occur world-wide each yearl9, the 
overall world incidence remains very low due to the small numbers occurring in Asia 
where over half the world population lives. In the Caucasian population, malignant 
melanoma is now an important cause of death20.
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Figure 1 The incidence of cutaneous malignant melanoma in Scotland (1979-1986) 
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1.2.2 ANATOMICAL DISTRIBUTION
Melanoma in the white population occurs most frequently on the lower limb in 
females and the trunk in males21. However in the black population, melanoma is 
commonly seen to affect the soles of the feet22. The anatomical site of malignant 
melanoma is reflected in the histology of the tumour23*24, e.g. superficial spreading 
melanoma and nodular melanoma commonly occur on the trunk and lower limb 
whilst lentigo maligna melanoma frequently occurs on the head and neck region and 
on exposed body surfaces24. t
1.2.3 PLACE OF RESIDENCE AND BIRTH
Place of birth also appears to be an important factor in the incidence of melanoma. 
This is most clearly seen in people who migrate from a country of low to one of high 
incidence; initially such migrants tend to have a lower rate of melanoma than the 
local population25*26 but with increasing duration of stay and an early age of 
migration, the risk increases. Conversely this pattern is not, however, observed in 
white migrants to Hawaii who tend to have a higher incidence of melanoma than 
Hawaiian bom whites27. This may be explained by the Southern European or mixed 
race ancestry of the native whites28. A study conducted in Western Australia showed 
that the age at arrival was a more useful predictor of risk than duration of residence29. 
Those who arrived before ten years of age were exposed to similar risks of developing 
melanoma as native bom Australians whilst arrival after that age conferred a relative 
risk of approximately 0.529.
1.2.4 AGE AND SEX
Melanoma tends to occur in the young and middle aged but is rare before puberty. 
The incidence rate rises steeply until 50 years of age, after which the rise slows 
down30. Figure 2 shows the age-distribution and age-specific incidence of the rate of 
melanoma in Scotland from 1979 to 1986. There is often a relationship between the 
histological type of melanoma and the age at presentation. In the young and middle- 
aged, superficial spreading and nodular melanoma are more common whereas in the 
older patient lentigo maligna melanoma predominates. Although world-wide the 
overall incidence of melanoma does not differ between the sexes, it has been shown 
that in areas of low incidence, melanoma is commoner in males30 whereas female 
predominance is seen in Northern Europe where the ratio of female to male is 2:1. 
Survival after the diagnosis of melanoma is longer in women than in men31»32.
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1.2.5 RACE
Although melanoma is primarily a disease of the white population and is uncommon 
in the black population, there is a variation in the incidence within the white 
population, perhaps reflecting the ethnic background. For example, Hispanics have a 
lower incidence of melanoma than other whites in United States30. It has also been 
shown that people of Southern or Eastern European background have a lower risk of 
developing melanoma than those who originate in Northern European or the United 
Kingdom33*34.
1.2.6 SOCIAL CLASS
Both disease incidence and mortality rates from melanoma are noted as being highest 
in the higher social classes35’36. It has been postulated that this may relate to 
behavioural pattern. A typical representative of the higher social class tends to work 
indoors and is more likely to be exposed to sharp short bursts of sunlight whilst a 
person from a lower social class is often engaged in outdoor work and exposed to 
constant sunlight and therefore at less risk of developing melanoma37.
1.2.7 FAMILY HISTORY AND PIGMENTARY TRAITS
Melanoma has long been known to run in families38. Holman and Armstrong39 
showed that a patient with one affected relative had a increase risk of 2.3 of 
developing melanoma and with two affected relatives this more than doubled to 5.0 
when compared to the patient with no affected relatives. Blue eyes, fair or red hair 
and a pale complexion are risk factors for melanoma. Eye colour is a weak risk factor 
with a relative risk of less than 2. Hair colour is the strongest predictor of all the 
physical characteristics with a relative risk of 3 in persons with blonde or red hair. 
Those with pale white skin who never tan and often bum and those who bum initially 
and tan with difficulty have a relative risk of 3. A history of severe sunburn also 
gives a relative risk of 339. The most practical method currently available for 
screening a large population at risk for skin cancer is by determining the skin 
phenotype. This technique of classifying the sun sensitivity of the skin is based on 
the ability of the skin to tan.
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1.2.8 BENIGN MELANOCYTIC NAEVI
The presence of benign melanocytic naevi increases the risk of melanoma and the 
relative risk increases with increasing number of naevi. Bain et al40 initially showed 
a strong correlation between naevi in the lower limb and the development of 
subsequent melanoma. Weinstock et al41, in a later study, found that the number of 
naevi on any site was not predictive of melanoma at that site. The presence of 
dysplastic naevi is associated with a significant risk of melanoma. The Scottish 
study42 showed that naevi with irregular edges had a seventy fold increase in risk and 
those with colour variation had a thirty fold increase in the risk of developing 
melanoma. Holly et al43 showed that the total number of naevi and atypical naevi 
were both independent predictors of risk. However MacKie et al44 found that the 
total number of naevi was a stronger predictor of risk than the number of atypical 
naevi.
1.2.9 EXPOSURE TO SUNLIGHT
Several aetiologic agents have been proposed for melanoma of which exposure to 
sunlight, especially ultraviolet B radiation, has received most attention. 
Electromagnetic radiation from the sun can be divided into 3 bands: ultraviolet, 
visible and infra-red. The ultraviolet portion is further divided into ultraviolet-C (200 
to 290nm), ultraviolet-B (290 to 320nm) and ultraviolet-A (320 to 400nm). Only 
ultraviolet B and A reach the earth's surface. The solar energy in the ultraviolet-C and 
ultraviolet-B bands are absorbed by the earth's ozone layer. However as our ozone 
layer becomes depleted, more ultraviolet-B rays penetrate the earth's atmosphere and 
this may be one of the reasons for the increased incidence of melanoma.
In animal studies, ultraviolet radiation has been shown to induce neoplasia in 
epidermal cells including melanocytes. In human skin it is absorbed by melanosome 
in the melanocytes and increases melanin activity. The association between 
melanoma and sun exposure is not a simple one. Studies relating risk of melanoma to 
occupational exposure to sunlight have been inconclusive. Gallagher et al45 and 
Holman et al46 showed that with increasing occupational exposure there is a 
decreasing risk of melanoma, whereas several other studies including those by Dubin 
et al47 showed the opposite. Cook et al35 in New Zealand showed that outdoor 
workers had a higher incidence of melanoma affecting the trunk. Holman et al46 
showed that although outdoor workers had a lower incidence of melanoma than 
indoor workers, the incidence of melanoma was higher on sites that were exposed to
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the sun. It is therefore difficult to be dogmatic on the effect of occupational exposure 
to sunlight.
In contrast, in several studies, recreational or intermittent sun exposure has been 
shown to to increase the risk of melanoma. People who sunbathe once or more a 
week in summer have a relative risk of 2.6 of developing a superficial spreading 
melanoma on the back. In women between the ages of 15 and 24, the risk of 
melanoma has been related to the type of bathing suit. Those who wore a one piece 
suit had a relative risk of 4.0 whilst for those who wore a two piece bathing suit or 
none at all, the risk of developing melanoma of the trunk rose to 1346. It is unclear 
whether the use of sunlamps and sunbeds increases the risk of the development of 
malignant melanoma. Different studies have shown the risk to range from 0 to 
2 .948,49,50  ^ it is widely accepted that inappropriate use of such equipment is harmfiil 
to the skin and almost certainly carcinogenic. MacKie et al51 showed a relative risk 
of less than unity. However, none of these studies took into account the pattern of 
exposure to the site at which the melanoma arose.
In summary, the main risk factors for melanoma seem to be high socio-economic 
class, latitude of residence, white race, migration into an area of high incidence and 
intermittent sun exposure. If the destruction of the earth's ozone layer continues then 
ultraviolet-B radiation will increase at a rate of 1% to 2% for every 1% decrease in 
ozone52’53. It has been estimated, provided there are no behavioural changes in the 
population, that the incidence of melanoma will increase between 1% and 2% for 
every 1% decrease in ozone layer53.
1.3 HISTOLOGY OF SKIN
1.3.1 STRUCTURE AND FUNCTION OF SKIN
The skin is the largest organ of the body. It is the frontier with the external 
environment and its structure and functions all reflect this fact. Functions of the skin 
include mechanical protection, melanin production that protects against ultraviolet 
damage, vitamin D synthesis, thermal insulation, fat deposit reserve, 
thermoregulation and sensory function. The skin is essentially divided into two 
layers; the outer layer of ectodermal origin, the epidermis, and the inner layer of 
mesodermal origin, the dermis. Figure 3 is a diagrammatic illustration of the 
histology of skin.
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The epidermis consists of 4 layers - stratum basale, stratum spinosum, stratum 
granulosum and stratum comeum. A fifth layer, stratum lucidum, is only seen in the 
thick skin of the palm and sole. The surface cells of the epidermis are continuously 
being shed and replaced by mitotic division in the basal layer (stratum basale). 
Keratinocytes form 85% of all cells in the epidermis. As the keratinocytes migrate 
from stratum basale to stratum comeum, they mature from nucleated cells to flat 
anucleated squames. Their main function is to provide an impermeable barrier. 
Other cells of the epidermis include melanocytes, Langerhans cells and Merkel cells. 
Melanocyte cells produce melanin, which has a photoprotective action.
The epidermis is firmly attached to, supported and nourished by the dermis, a thick 
layer of fibrous connective tissue. Although epidermis and dermis constitute the skin 
in the strict sense, beneath the dermis is a layer of loose connective tissue that forms 
the subcutaneous adipose tissue.
1.3.2 MELANOCYTE, MELANOGENESIS AND SKIN PIGMENTATION
Melanocytes synthesise the pigment called melanin. They are found deep in the basal 
layer of the epidermis. They are dendritic in form. Melanin appears in their 
cytoplasm in melanosomes which are oval or spherical bodies. These melanosomes 
are transferred to keratinocytes through the end feet of the dendritic processes. Each 
melanocyte is associated with a number of keratinocytes and together they constitute 
an epidermal-melanin unit. Figure 4 shows a diagrammatic illustration of an 
epidermal-melanin unit.
There are about 1000 melanocytes per square millimetre of epidermis. Racial 
difference is not due to increased number of melanocytes but to increased 
melanogenesis with slightly larger melanosomes. Melanosomes transferred to 
keratinocytes are broken down more slowly in Negroid than in Caucasian skin by 
lysosomal enzymes.
Melanocytes contain the copper dependent enzyme tryrosinase (DOPA Oxidase). 
This enzyme stimulates a sequence of reactions that convert the substance tyrosine 
(derived from essential amino acid phenylalanine) to stable insoluble melanin. 
Dihydroxyphenylalanine (DOPA) is formed by oxidation of tyrosine and further 
reaction results in formation of dopaquinone. Eumelanin, a brown or black pigment, 
is then formed by random polymerisation of dopaquinone. Figure 5 illustrates the 
synthetic pathway of melanogenesis.
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Genetic factors act at various stages in the process of melanogenesis but also affect 
migration from neural crest, melanocyte morphology, melanosomal structure, 
tyrosinase activity, types of melanin synthesis, melanin transfer to keratinocyte and 
melanosomal degeneration.
Exposure to sunlight leads to some darkening of skin within five minutes. This is 
due to migration and redistribution of already existing melanosomes from deep to 
more superficial keratinocytes and to oxidation reaction. This immediate darkening, 
which lasts fifteen minutes after cessation of exposure, is responsible for the well 
known 'false tan'. New pigment formation occurs 24 hours after exposure. More 
melanosomes are produced and transferred to surrounding keratinocytes.
Ultraviolet light may act by blocking the action of reduced glutathione, a local 
inhibitor of melanogenesis. It interferes with the function of tyrosinase, combining 
with the copper in the enzyme and forming complexes with intermediates produced 
during the conversion of tyrosine to melanin. Although melanin synthesis is 
stimulated by certain pituitary melanotrophic hormones in animals, this is not so in 
man. Oestrogens and progestogens also stimulate melanocyte function.
1.4 CLINICAL AND PATHOLOGICAL FEATURES OF MALIGNANT 
MELANOMA
Malignant melanoma is a tumour of epidermal melanocytes. The tumour is 
characterised by a biphasic growth pattern, with radial and vertical phases. During 
the radial growth phase, the primary melanoma undergoes centrifugal enlargement. 
The lesions tend to be relatively flat with irregular outlines but their overall shape is 
circular or oval. This phase may persist for years and has little tendency to 
metastasise. Surgery at this stage is likely to be curative.
The vertical growth phase which subsequently appears as a focal nodularity within 
the flat lesion represents a new and distinctive clone of tumour cells. Growth is more 
rapid than the radial phase, with invasion of the underlying connective tissue 
including blood and lymph vessels. Chromosomal studies have shown differences 
between the melanocytes in these two phases. Melanoma cells in the radial phase 
show abnormalities at chromosome 6; melanoma cells of the vertical growth phase 
show deletions, translocations and duplication at chromosomes 1,6 and 7, as do cells 
of metastatic melanoma54.
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There are four major types of malignant melanoma:
1) Superficial spreading melanoma
2) Nodular melanoma
3) Lentigo maligna melanoma
4) Acral melanoma
1.4.1 SUPERFICIAL SPREADING MELANOMA (SSM)
This accounts for about 70% of all melanoma and commonly occurs in the lower 
limbs in women and on the back in men. SSM develops both on sun exposed and 
covered surfaces. The lesion tends to be uniform in contour with an irregular 
indefinite border. It is often multi-coloured, displaying a mosaic of black, brown, tan, 
blue, red and white. Figure 6 shows a typical SSM lesion. During the radial phase of 
growth, atypical melanocytes also spread along the dermal-epidermal junction. It is 
the dermal component that produces the epidermal thickening characteristic of SSM, 
hence the elevated surface and palpable margins.
1.4.2 NODULAR MELANOMA (NM)
Nodular melanoma has the most aggressive clinical course and accounts for 15-30% 
of melanoma and is more common in men than in women. These lesions grow very 
rapidly and are often difficult to diagnose, commonly being mistaken for vascular 
lesions. It occurs most frequently on the trunk, head and neck. Nodular melanoma 
exhibits a monophasic growth pattern with vertical growth phase from the outset. 
NM, as the name suggests, presents as a dome shaped spherical lesion which is 
smooth or ulcerating. The lesion is generally darker and more uniform in colour than 
SSM and may resemble a haemangioma. Bleeding is a relatively early sign. The 
lesions in most cases at the time of clinical detection have already invaded the 
underlying connective tissue. Polypoidal nodular melanoma behaves in a particularly 
aggressive manner. About 5% of nodular melanoma lack pigment altogether. Figure 
7 shows a typical NM lesion.
1.4.3 LENTIGO MALIGNA MELANOMA (LMM)
This form of melanoma is characterised by a prolonged radial growth phase. In this 
radial growth phase, the in situ melanoma is known as lentigo maligna. These lesions
Figure 6 Typical superficial spreading malignant melanoma 
(courtesy of Professor R M MacKie)
Figure 7 Typical nodular malignant melanoma
(courtesy of Professor R M MacKie)
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account for 10% of all melanoma and are typically found in the elderly on sun 
exposed surfaces, especially the head, neck and face.
It is usually a tan to brown patch speckled with minute brown to black flecks. It is 
characteristically impalpable and palpability indicates dermal invasion. The 
proliferation of atypical melanocytes is essentially confined to the epidermis. 
Progression into an invasive lesion clinically presents as one or more blue to black 
nodules or an area of induration. Figure 8 shows a typical LMM lesion.
1.4.4 ACRAL MELANOMA (AM)
Acral melanoma characteristically occurs on the palm or sole. In the United 
Kingdom, eight times as many are found on the side of the sole of the foot as on the 
palm. Acral melanoma has mixed histological features, the common type being acral 
lentigo melanoma. This represents 2% to 8% of melanoma in whites but 
substantially more occur in dark skinned patients (35%-90%). The lesion is typically 
flat with a mosaic pattern of tan, dark brown and black with irregular and ill defined 
borders. Figure 9 shows a typical acral melanoma. As the lesion advances, the 
borders become highly irregular and notched. An important variant of acral 
melanoma is the subungual melanoma. The great toe and thumb are most often 
affected. Subungual melanoma represents 2% to 3% of melanoma in whites but a 
higher percentage in black people. It may present as a split nail, ulceration with 
bloody cmsts or a longitudinal black or brown streak in the nail bed. An irregular tan 
brown colour that diffuses proximally to the cuticle to involve the posterior nail fold 
is an ominous finding associated with advanced disease.
In summary, malignant pigmented lesions exhibit disorganisation, irregular shape and 
chaotic pigmentation whereas benign lesions tend to show order in colour, symmetry, 
regular border and uniformity.
1.5 STAGING AND PROGNOSTIC FACTORS OF 
MALIGNANT MELANOMA
1.5.1 STAGING
The staging of melanoma is of critical importance. It determines appropriate 
treatment, prognostic assessment and makes it possible to compare treatment world­
wide. Unfortunately there is no universally agreed staging system. The first widely 
used staging system recognised three stages55.
Figure 8 Typical lentigo maligna m elanom a 
(courtesy o f  Professor R M MacKie)
Figure 9 Typical acral malignant melanoma
(courtesy of Professor R M.MacKie)
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The greatest asset of the 3-stage system was its simplicity, but it failed to reflect 
prognostic groups. At the M. D. Anderson Cancer Centre56 in Houston, Texas, a 4- 
stage system was devised which addressed a sub stage of melanoma patients with 
local recurrence, in transit metastases or satellite disease who were suitable for 
hyperthermic limb perfusion. This staging was introduced before the importance of 
tumour thickness and level of invasion were appreciated.
In 1978, the Union Internationale Contra le Cancer (UICC)57 incorporated these 
prognostic factors in their staging system. This staging system was in part based on 
the concept that malignant cells tended to spread first to the regional lymph nodes and 
from there via the thoracic duct lymph to the bloodstream and viscera.
In 1983, the Melanoma Subcommittee of the American Joint Committee on Cancer 
(AJCC) derived a 4-stage system based on the TNM System58*59. The AJCC System 
addressed the deficiencies in other systems and was able to produce a system better at 
discriminating risk in patients with early melanoma. Unfortunately, unlike the other 
TNM Staging, the AJCC System was neither accepted nor used universally. The 
failings of all these systems were addressed when the AJCC and the UICC produced a 
mutually acceptable TNM/pTNM Staging for all tumours60*61.
When clinical diagnostic staging is being carried out, a careful examination is 
necessary and should include details of primary tumour size, nodularity, ulceration, 
satellite lesions and palpation for in transit and regional node metastases. To aid 
clinical staging a chest X-ray, CT scan of chest and abdomen and radioisotope studies 
of lymph nodes, gallium scan and lymphangiography may be helpful. The staging 
used in this thesis is the M. D. Anderson Cancer Centre Staging which is listed 
below:
Stage I
Stage II
Primary Melanoma
IA: Intact primary melanoma
IB: Primary melanoma locally excised
IC: Multiple primaries
Local recurrence or local metastases within 3 cm of the primary 
site
Stage m Regional metastases
IILA: Tissues excluding nodes
IIEB: Node(s)
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IIIAB: Skin etc, plus node(s)
Stage IV Distant metastases
IVA: Cutaneous metastases only 
IVB: Any visceral metastases
1.5.2 PROGNOSTIC FACTORS: PATHOLOGICAL FACTORS
The first prognostic parameter for melanoma was identified by Allen and Spitz62 in
1953 when they observed that superficial tumours had a better prognosis than deeply
63invasive ones. Mehnert and Heard introduced a system of four levels of micro­
invasion which later Clark64 modified by introducing a special Level HI and his 
nomenclature became internationally accepted. A year later, Alexander Breslow65 
showed that tumour thickness provided a simpler and more objective method of 
predicting prognosis.
He defined thickness as the distance in millimetres (mm) from the granular layer in 
the epidermis to the deepest invasive tumour cell in the underlying dermis. This has 
been shown to be the single most important factor in the prediction of survival65’66. 
Importantly, this measurement is both objective and reproducible. Several 
investigators have attempted to identify other parameters that have predictive value 
for survival and metastasis. These factors include mitotic rate, ulceration, phase of 
tumour growth, host response, vascular invasion and microscopic satellites67. None 
is as important as Breslow thickness.
TUMOUR THICKNESS - Breslow thickness is the single most important factor for 
prognosis. The determination of tumour thickness is easy and reproducible. 
Thickness may have less predictive value on prognosis in ulcerated melanoma, in 
melanoma with marked hyperplastic epidermis which leads to over-estimation and in 
desmoplastic neurotropic melanoma when over-estimation leads to poorer prognosis. 
It is difficult to measure thickness accurately in subungual melanoma.
LEVEL OF INVASION - The Clark64 system is divided into 5 levels: I - 
intraepidermal, II - papillary dermis, ED - interface between papillary and reticular 
dermis, IV - reticular dermis and V - subcutaneous fat. This method has 
disadvantages in that there are difficulties in identifying landmarks at some sites thus 
making it difficult to reproduce. There is also a greater interobserver variation than 
with Breslow thickness. Clark68’69 level of invasion can be used for microstaging in 
cases when two tumours are of the same thickness, thus giving a different prognosis.
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MITOTIC RATE - many studies have shown a significant relationship between 
mitotic activity and prognosis, especially in the vertical growth p h a s e 70*7  L72. The 
prognostic effect of mitotic rate varies in different thickness and location subsets, and 
appears to be most important in tumours that are of 'intermediate1 thickness (tumours 
1.51 - 3.99mm thick). Elder et al71 showed that the overall five year survival in 
patients with intermediate thickness tumour was 70%. However, patients with a 
mitotic rate of <6/mm2 had an 80% survival whilst the remainder had a 40% 
survival72. Using this argument Schmoeckel and Brown Falco73 suggested an 
alternative prognostic index than thickness alone but this formula has not been widely 
accepted.
PHASE OF TUMOUR GROWTH - The presence of radial and vertical growth has 
some correlation with thickness and level of invasion. The excellent prognosis of 
tumours less than 1.0mm thick and anatomical Level I is primarily related to their 
being in radial growth phase and thus lacking competence for metastasis69. Elder et 
al69 found that in 69 patients with pure radial phase, all survived at 5-12 year follow 
up. Thus in their hands, "phase" was more sensitive than level or thickness in 
identifying low or zero risk melanoma patients.
ULCERATION - This is usually indicative of poor prognosis. One may speculate 
that ulceration might correlate with 'invasiveness1 of tumour into the epidermis or 
with rapid size of growth. Balch et al74 and Day et al75*76 found this to be an 
independent variable and also found ulcer width of greater than 3mm to be of 
significance76. Although ulceration has some cmde correlation to thickness, it may 
also correspond to tumour volume, rate of proliferation, tumour aggressiveness and 
architectural configuration.
VASCULAR INVASION - Although seemingly a sine qua non for metastasis, this 
property is infrequently recognised with certainty in melanoma. It indicates a high 
risk of later metastasis development77*78. While Schmoeckel et al79 found 
"unequivocal" vascular invasion to be associated with impaired survival, he found 
this feature in only about 10% of his cases. It is therefore important to record 
vascular invasion only when it is seen unequivocally, as false positive results can 
occur80. Recent multivariate analyses have demonstrated no significant influence of 
vascular invasion on survival68*80.
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LYMPHOCYTE RESPONSE - Severe cellular atypia and small lymphocyte like 
cell types at the tumour base are signs of poor prognosis81. A cellular inflammatory 
reaction, particularly at the base of the tumour, indicates a favourable prognosis, 
while its absence correlates with a higher recurrence rate and impaired survival79*82. 
In the vertical growth phase the presence of an infiltrative lymphocytic response is 
associated with improved survival81. Thus patients with the most intense degree of 
lymphocyte infiltration had better survival compared to those who had mild 
infiltration8!.
HISTOGENETIC TYPE - Nodular melanoma growth pattern is associated with a 
much poorer prognosis than SSM and LMM, probably due to the lesion being thicker 
at presentation83. There is no significant difference in survival between NM and 
SSM when matched for tumour thickness83*84. The better prognosis of LMM may be 
confounded by it usually being less thick85.
MICROSCOPIC SATELLITES - Satellites are defined as discrete tumour nests > 
0.05mm in diameter separate from the main body of the tumour. Day et al86 studied 
95 patients with stage I melanoma and showed that the five year survival was 36% for 
patients with microscopic satellites compared to 89% for patients without satellites. 
Satellites are best regarded as local lymphatic and/or haematogenous metastases. 
Their presence is a clear indication that the tumour has achieved competence for 
metastasis. This parameter, however failed to demonstrate separate prognostic value 
in a recent study68.
TUMOUR CELL TYPE - Many studies have shown no correlation between cell 
type and prognosis80. It has been suggested that since vertical growth is likely to be 
the determinant of biological behaviour, the cell types in this component are most 
likely to be of prognostic relevance but this however, has not been specifically 
studied. In a few studies, well-differentiated spindle cells are associated with better 
prognosis87*88. Drzewiecki and Anderson89 found a worse prognosis for epitheloid 
cell melanoma.
153  PROGNOSTIC FACTORS: CLINICAL FACTORS
AGE - Blois et al90 found that men aged less than 48 years had a better prognosis 
than older men. Elder et al71 found a favourable prognosis to be associated with 
intermediate age (40-60 years, relative risk 0.49). Advancing age correlated 
significantly with a shortened survival times 89 and melanoma thickness, with older 
patients presenting with thicker melanoma.
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SEX - Numerous studies have shown that female patients with melanoma have a 
better survival rate than males91’92’93. Most of the differences that persist in the 
survival rates between males and females when Clark level is matched are probably 
related to the fact that melanomas in women occur more commonly on the extremities 
(a more favourable prognostic site) and are found to be thinner and less frequently 
ulcerated91.
ANATOMICAL LOCATION OF PRIMARY LESION - The site of the primary 
tumour appears to be one of the most important survival associated variables70*82*93. 
Patients with melanoma of the extremities have a better survival rate than those with 
trunk, head and neck melanoma. Analysis of anatomical lesions of the subsites can 
also reveal a different prognosis, e.g. in head and neck melanoma, the scalp has a 
worse prognosis than those on the ear, face or neck. Although no overall survival 
difference was found for women or men when comparing back versus chest lesions, 
female patients with melanoma on the back had better survival than their male 
counterparts. Patients with melanoma located on hands and feet had a significantly 
worse prognosis than did those with a lesion on the arm or leg72*93.
1.5.4 PROGNOSTIC FACTORS: CONCLUSION
In summary, three dominant factors predict survival in stage I and II melanoma 
patients.
1 Thickness of melanoma.
2 Melanoma ulceration (present or absent).
3 Anatomical location.
Four other variables also correlate with survival in certain groups of patients: type of 
initial surgical management, pathological stage, level of invasion and sex.
In patients with nodal metastases (stage HIB and stage IIIAB) the three dominant 
prognostic variables are the number of nodal metastases, the presence or absence of 
ulceration in the primary lesion and the patient's age.
In patients with distant metastases (stage IV) there are no parameters of the primary 
melanoma that predict the patient's clinical course. The dominant prognostic 
variations are anatomical site of metastases (visceral versus non visceral), the number 
of sites of metastases and the remission duration. The sex and age of the patient do 
not significantly influence survival.
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CHAPTER 2
TREATMENT OF MALIGNANT MELANOMA
2.1 TREATMENT OF PRIMARY MALIGNANT MELANOMA
2.1.1 SURGICAL TREATMENT
The surgical treatment of any primary malignant melanoma consists of wide local 
excision of the tumour with a margin of normal skin. The rationale for wider excision 
margins is the removal of occult foci of melanoma cells that may lead to metastasis or 
local recurrence. The current practice is to excise the primary malignant melanoma 
with surgical margins that are based on tumour thickness and ulceration, as these 
factors correlate with the risk of local recurrence94*95. Breslow and Macht96 
observed that the incidence of local recurrence or metastasis from melanoma less than 
0.76mm thick is not affected by the width of the excision margin.
In the World Health Organisation (WHO)97 randomised study of 612 patients in 
whom excision was randomised to 1 or 3cm, it was demonstrated that a 1cm margin 
was adequate for primary melanoma less than 1mm thick. Optimal excision margin 
for melanoma thicker than 1mm is still controversial. Aitken98 and associates 
showed that for melanoma thicker than 2mm, survival was poor if the excision 
margin was less than 2cm but increasing the margin beyond 3cm did not confer any 
additional survival benefit. Ackerman et a l"  suggested metastases or 
microsatellitosis more than 2cm from the primary tumour may reflect disseminated 
disease and wider local resection may not influence survival outcome.
The current recommendations for surgical margins are as follows:
Type Margin
In situ 0.5-1.0cm
<lmm thick 1cm
>lmm thick 2 - 3cm
Lentigo maligna melanoma 1 cm
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The depth of incision has received less attention than the width. Olsen100 showed 
that melanomas without clinical evidence of metastases had more lymph node 
metastases when the primary excision extended through the underlying fascia than 
when this was left intact. He suggested that resection of fascia allowed dissemination 
of melanoma cell from subdermal lymphatics to subfascial lymphatics.
However, in a review carried out by Kenady et al101 no significant difference in the 
incidence and site of subsequent recurrence or survival in patients in whom the fascia 
was excised compared to those in whom the fascia was left intact. In theory, excision 
of fascia should not affect the incidence of local recurrence or in transit disease since 
lymphatic drainage to the regional nodes occurs in the subcutaneous tissue superficial 
to the deep fascia. Resection of fascia is not routinely indicated except when the 
tumour is deeply invasive in order to ensure that the deep margin is histologically 
negative for melanoma.
In summary, a 1cm margin is adequate for tumours less than 1mm in thickness whilst 
a 2-3cm excision margin is required for tumours of more than 1mm in thickness. It is 
important that the width of excision is tailored to the individual patient based on the 
assessment of tumour thickness and other prognostic factors.
2.1.2 ADJUVANT THERAPY: PRINCIPLES
The concept and efficacy of multimodality therapy have been proven in animal 
models of human tumours, where the best results were achieved by combining local 
treatment with systemic treatment. Experimental models of animal tumours have 
clearly established the principles of adjuvant therapy as reviewed by Balch and 
Maddox102. When animals were inoculated with a known tumour dose and then 
randomly allocated to single treatment modalities or combination modalities, the 
latter produced superior results103*104.
The four principles that are pertinent to designing treatment plans for any human 
tumour are listed below102*103.
1) Effectiveness of any treatment is inversely proportional to tumour burden, i.e. the 
smaller the tumour the better the response.
2) Occult micrometastases are generally more susceptible to drug treatment than the 
larger primary tumour.
3) Agents with activity against moderately advanced disease are more active against 
residual metastatic disease after debulking of tumour by surgery.
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4) Curative treatment of cancer involves destroying all cancer cells as lethal 
metastases may arise even from a single residual malignant cell.
In the clinical situation, patients who are likely to benefit from adjuvant therapy are 
those who are at high risk of harbouring occult metastases, for example those patients 
with thick tumours and lymph node involvement.
2.1.3 ADJUVANT TREATMENT: CHEMOTHERAPY
Dacarbazine [5 - (3, 3 - dimethyl 1 - triazeno) - imidazole - 4 - carboxamide (DTIC)] 
is generally considered to be the most active single agent in advanced disease. It has 
been used extensively on its own as an adjuvant chemotherapeutic agent or in 
combination with other agents or immunotherapy. The two largest studies were 
conducted by the Central Oncology Group (COG)105 and the WHO106. The COG 
study (174 patients) showed no proven benefit for DTIC whilst the WHO study (761 
patients) concluded that adjuvant treatments did not significantly improve either the 
disease free interval or overall survival. An overall review of 21 randomised trials in 
2,850 patients between 1978 and 1986 showed no positive benefit in terms of 
improving the disease free or the survival interval after adjuvant chemotherapy107.
2.1.4 ADJUVANT TREATMENT: ENDOCRINE THERAPY
It has been shown that melanoma tissues and cell lines bind to oestrogen and other 
steroids108. Since the report by Fisher et al109 showing the presence of oestrogen 
receptors in metastases, several trials have been conducted to examine the effect of 
tamoxifen but none have shown definite benefit110»111»112.
2.1.5 ADJUVANT TREATMENT: IMMUNOTHERAPY
Immunotherapy using non specific immune stimulants such as Bacillus Calmette- 
Guerin (BCG) and Corynebacterium parvum (C parvum) is based on the observation 
that tumour antigens on melanoma cells induce relatively weak immune responses. 
To become effective in controlling tumour growth these responses need only to be 
augmented by immunotherapy. Melanoma patients may have weakened immune 
defences that can be restored by immune stimulants. Morton et al113 in a non 
randomised study comparing surgery, surgery + BCG and surgery + BCG + allogenic 
irradiated cells, demonstrated a longer disease free interval and overall survival in 
patients submitted to either adjuvant treatment regimen. The recurrence rate in
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surgically treated patients was 50%, 41% and 34% respectively in patients who 
received immunotherapy.
A positive result by combining BCG and DTIC was also reported by Wood114. 
However, a few reports have suggested that BCG seems to induce earlier recurrence 
or enhanced tumour growth. In a trial conducted by Mclllmurray et al115 4 out of 8 
patients treated with BCG and autologous irradiated cells, died within one year of 
treatment whilst none of the surgically treated patients had a recurrence or died. He 
concluded that adjuvant immunotherapy might be dangerous and discontinued his 
trial.
Overall the results of several large trials have shown no statistical benefit from BCG 
vaccinations as an adjuvant to surgery in patients with stage II and ID disease. 
Similar findings apply to the use of C parvum as adjuvant therapy.
Interferon has also been evaluated as adjuvant treatment. The Southwest Oncology 
Group116 found that adjuvant treatment with interferon daily for 12 months after 
surgery for stage II and HI disease did not show a significant benefit on disease free or 
survival interval.
In recent years, workers have tried to prevent tertiary melanoma using different 
melanoma cell vaccines and purified antigen. Cassel et al117 reported that
prophylactic treatment with Newcastle disease vims lysates of melanoma cells 
significantly improved survival in 32 patients with stage II and m  melanoma when 
compared to controls. A further study also reported survival rates of approximately 
80% at 2 years. Hersey et al118’119 showed treatment with vaccinia viral lysates 
improved survival of 80 patients with stage II and stage in  melanoma compared to 
controls. The results of these studies have prompted a randomised controlled study 
which is now in progress.
2.1.6 ADJUVANT THERAPY: RADIOTHERAPY
Radiotherapy as a primary treatment for cutaneous melanoma is rarely indicated 
except for extensive facial LMM, especially in the elderly. Adjuvant radiotherapy 
can be used to eliminate the need for wide surgical excision at sites where this would 
cause deformity. This approach was first reported by Dickson120 who treated 234 
patients. Seventy-one patients had local excision only, 42 patients had radical surgery 
and 121 patients had adjuvant radiotherapy following surgery. He found the overall 
survival of patients receiving radiotherapy was at least as good as that for patients 
receiving initial radical surgery.
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Studies on the role of adjuvant radiotherapy in the management of regional 
metastases are few. Creagan et al121 reported that on 56 patients with nodal 
metastases who were randomly assigned to receive postoperative radiotherapy or no 
adjuvant treatment following therapeutic dissection, the disease free interval of 
patients receiving adjuvant radiotherapy was longer.
However, he noted these results were attributed to imbalances in patients' ages and 
distribution of nodal metastases between the groups. Two other studies have shown 
encouraging results. Ang et al122 treated patients with stage I and II melanoma of 
head and neck. They reported a local control and survival rate for patients treated 
electively of 95% and 80% respectively compared to those treated before or after 
therapeutic lymph node dissection of 87% and 70% respectively. Although the 
study was not randomised, the results seem encouraging.
Radiotherapy does have a role to play in the adjuvant setting of the treatment of 
melanoma but further prospective randomised studies are needed to evaluate the 
efficacy of radiotherapy.
Another treatment that has been used is endolymphatic isotope therapy using lead 
(P32) or iodine (I131). This method delivers radiation directly to regional lymph 
nodes. The local dose can be high because of the small volumes irradiated. A study 
undertaken by the Medical Research Council (MRC)123 to assess the efficacy of 
this treatment showed that there was no statistical difference between the groups 
randomised to endolymphatic isotope therapy or to standard surgery. The 
impression of this study of 146 cases was that there may have been a reduction in 
the subsequent nodal metastases in the group that had successful endolymphatic 
therapy but this was not reflected in improved survival. Ariel124 produced similar 
results from a series of 120 patients.
2.1.7 ELECTIVE LYMPH NODE DISSECTION: PROS
Although lymphadenectomy had been suggested in the 19th century and later 
emphasised by Handley3 in 1907, there are still controversies surrounding lymph 
node dissection. There is general agreement that all melanoma patients do not need 
elective lymph node dissection. Some surgeons prefer to excise only clinically 
obvious nodal metastases. This is termed therapeutic or delayed lymph node 
dissection. Excision of nodes even when they appear normal is termed elective 
lymph node dissection (ELND), immediate lymph node dissection or prophylactic 
lymph node dissection.
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It is generally agreed that there is no case for ELND for every patient with melanoma. 
The questions that arise are:
1) Is it possible to identify accurately a subgroup of patients with a high risk of 
microscopic regional node metastases?
2) What is the optimal timing of the operation?
The benefits of ELND are based on the hypothesis that microscopic metastases may 
disseminate sequentially from the primary melanoma to the regional lymph nodes 
and then to distant sites. A clear case in favour of ELND exists for patients who have 
occult metastases, i.e. those with primary melanoma with clinically impalpable nodes 
but in whom tumour is found in the lymph node following dissection. The prognosis 
deteriorates if a 'wait and see1 policy is practised and the patient returns with clinically 
involved lymph nodes at a later time.
Elective dissection of clinically negative but pathologically positive nodes confers up 
to 40% 5 year survival advantage in comparison to patients with clinically and 
pathologically positive nodes125,126,127. it has also been shown that the degree of 
lymph node involvement is important, i.e. patients with microscopic metastases in 
only a small portion of one lymph node have a better prognosis than those in whom 
the whole lymph node contains tumour127’128. This is perhaps not surprising in 
relation to reduced tumour burden.
Since there is no method available to detect occult metastases in lymph nodes prior to 
surgery, the logical approach is to dissect nodes with a high likelihood of occult nodal 
metastases, e.g. those with primary tumour thicker than 1.5mm. The major advantage 
of using tumour thickness for choosing patients for ELND is that it can provide a 
quantitative estimate of the risk for occult metastatic melanoma in both regional and 
distant sites91.
Thin melanomas (<lmm) are usually associated with localised disease and a 95% or 
greater cure rate is achieved after local excision alone. Patients with intermediate 
thickness melanoma (1.00mm to 4.00mm) have an increasing risk (up to 60%) of 
occult regional metastases. This group may benefit from ELND74>91>129>130. 
Patients with thick melanoma (>4.00mm) have a high risk of regional nodal 
micrometastases and occult distant disease74’91’129 and prognosis is poor. Therefore 
ELND is not beneficial and is only palliative.
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A large randomised study conducted by the WHO131 further supports the role of 
lymph node dissection. The ten year survival rate of patients having therapeutic node 
dissection was 38%; a corresponding group of patients who had ELND as part of 
their initial treatment had a ten year survival rate of 60%.
The arguments for the 'wait and see1 policy is based on two randomised studies 
conducted by the WHO Melanoma Group131 and the Mayo Clinic132. Opponents of 
this policy maintain both these studies are flawed. They argue that the WHO 
melanoma study131 was restricted to patients with limb melanoma. Most of the 
patients were women who have been shown to have the lowest rate for 
metastases126*133.
On retrospective analysis of the WHO data, when patients were grouped according to 
tumour thickness and ulceration, the subgroup of patients with intermediate thickness 
melanoma undergoing ELND had a 27% higher ten year survival rate than those 
patients without ELND (56% v 39.3%). Patients who had a delayed lymph node 
dissection had only a 15-20% ten year survival. This meant that almost 75% of these 
patients had distant microscopic metastases at the time of the clinically evident 
regional disease and this supports the earlier contention that delayed lymph node 
dissection is inferior to immediate node dissection for those patients with 
micrometastases in the lymph node at the time of presentation.
The Mayo Clinic Study132 also had several flaws. In this study of 173 patients, only 
27 patients fell into the 1.5 - 2.99mm tumour thickness of which 16 had ELND, 4 had 
delayed lymph node dissection and 7 had wide excision only. Thus from such a 
small study it is not possible to provide evidence for or against the value of ELND.
In conclusion, the protagonists argue that it is reasonable to undertake ELND for 
patients with intermediate thickness tumours. In this group, at least 56% will require 
lymph node dissection later and for those in whom lymph node disease is positively 
proven histologically, survival is better than those patients who have delayed lymph 
node dissection for clinically positive nodes. Protagonists argue that a 25% five year 
survival advantage can be expected for intermediate thickness melanoma patients 
who undergo ELND.
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2.1.8 ELECTIVE LYMPH NODE DISSECTION: CONS
The arguments against ELND are based on the following facts: (1) at least 70% of 
clinical stage I patients subjected to node dissection show no evidence of occult 
disease after histological examination; (2) the onset of lymph node metastases after 
treatment of the primary melanoma does not preclude a radical node dissection;
(3) there is some evidence that removal of the lymph node group and of the 
lymphatic vessels may favour local recurrence or of in transit metastases;
(4) removal of the lymph node group may favour the haematogenous spread of any 
tumour cells that may have been left behind in the operative field; (5) not 
performing ELND obviates the need for extensive surgery which may be unnecessary 
and may be complicated by postoperative lymphoedema, which may favour growth 
of residual tumour; (6) it has never been proven that haematogenous spread arises 
from occult regional lymph nodes; (7) it has never been established beyond doubt 
that the survival rate in patients who have ELND is improved.
None of the studies that showed benefit from ELND were prospective or randomised 
trials and may be subject to selection bias129*134*135.
The first prospective randomised trial was conducted by the WHO Melanoma 
Group131. In this trial patients with T i.2 -3 N0M0tumour were randomised to receive 
either: (a) wide excision and ELND, or (b) wide excision and delayed lymph node 
dissection at the time of appearance of regional node metastases. There were 553 
patients in this study and patients with primary lesions located on the extremities 
were chosen because lymph node drainage from these sites is consistent. The study 
concluded that ELND does not improve prognosis131*136*137. The high female:male 
ratio in the study is justified by the fact that both this anatomical site and clinical 
stage of the disease are more common in female patients. The female:male ratios 
were similar to those in other series and were not due to selection bias. When 
efficacy of ELND is evaluated within sexes, no difference in survival is observed137.
In a further study the routes of metastatic spread were studied in 1,164 patients with 
stage I melanoma133. Within this study group, 43% developed local recurrence of the 
disease, 22.7% had regional lymph node metastases as the first recurrence, 7.8% 
developed disease in distant sites and 13.8% had both regional lymph node and 
distant metastases. The pattern of dissemination was evaluated according to sex, 
tumour thickness, ulceration, Clark levels and anatomical site. The disease was more 
aggressive in men than in women, but the pattern of dissemination was quite similar.
48
With reference to Breslow thickness, the thicker the primary melanoma, the more 
frequent were the metastases. The ratio of regional:distant metastases as a first site of 
recurrence was not different in the 3 groups of thickness (0.1-1.5mm, 1.51-4.0mm, 
>4.0mm). The same pattern was detected when ulceration was considered. As 
regards Clark's level, the risk of distant metastases only increased with increasing 
levels, but when the ratio of regional node:distant metastases was evaluated, no 
significant difference was found. The highest incidence of metastases was found in 
patients with melanoma of the trunk but the patterns of dissemination were similar 
irrespective of the anatomical site of the primary lesion.
It is thus reasonable to conclude that prognostic criteria evaluate the patient's chance 
of a cure but does not make it possible to foresee if the first recurrence of the disease 
will be at regional lymph nodes or distant sites since the ratio of regional node:distant 
metastases of 1.05 was not modified at a statistically significant level in any group.
To prove or disprove that dissection of microscopically positive nodes gives better 
results than dissecting clinically palpable nodes, WHO131 compared the survival of 
patients who received ELND and were found to have occult metastases with the 
survival of patients who developed clinically detectable node metastases after wide 
excision of primary melanoma. They showed that survival was similar in both 
groups.
2.1.9 ELECTIVE LYMPH NODE DISSECTION: CONCLUSION
Two major prospective randomised trials have shown that ELND is not beneficial. 
However, proponents of ELND have argued that these trials are flawed.
Currently two surgical trials addressing the efficacy of ELND in selected melanoma 
patients are under way. The first is being conducted by the American National 
Cancer Institute in Washington DC. This trial is confined to patients with 
intermediate thickness melanoma (1.00-4.00mm) who have no evidence of metastases 
in the regional lymph nodes or distant sites by physical examination and laboratory 
tests. Patients are grouped according to melanoma thickness, location of primary 
melanoma (proximal extremity versus trunk or distal extremity versus head and neck) 
and ulceration of epidermis overlying the melanoma on microscopic sections. The 
second trial is being conducted by the WHO Melanoma Group and is confined to 
patients with melanoma of the trunk.
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2.2 TREATMENT OF LOCAL RECURRENCE
A local recurrence is defined as any tumour that occurs within 3 cm of the scar of a 
previously excised melanoma. Local recurrences are not only considered as 
extensions of primary melanoma but also as the first sign of distant metastases. They 
must be distinguished from satellites and in transit metastases that are intralymphatic 
in origin and which occur between the primary tumour and the regional lymph nodes. 
There are four different treatment options: surgical excision, regional chemotherapy, 
radiotherapy and systemic chemotherapy.
In patients with a solitary local recurrence, surgical excision with a l-3cm margin is 
probably adequate. Patients who have multiple recurrences should be considered for 
regional chemotherapy because the risk of additional recurrence and in transit 
metastases is substantially increased. In these patients, regional chemotherapy by 
intra-arterial infusion or intra-arterial infusion using a tourniquet outflow occlusion 
technique may be used.
Transcutaneous intra-arterial infusion achieves high local drug concentrations 
comparable to those obtained by isolated perfusion and this technique does not 
require general anaesthesia. Response rates from cisplatin infusion by this method 
are comparable to those obtained in cisplatin perfusion but this method of treatment is 
associated with major complications including compartment syndrome and arterial 
occlusion138.
In patients in whom surgical excision is not possible, systemic chemotherapy139*140 
or radiotherapy122*141*142 are therapeutic alternatives. There is evidence to suggest 
that isolated limb perfusion is the optimal treatment when local recurrence develops 
on the extremities; 25% to 50% of patients treated with regional perfusion are alive 
five years later143»144»145.
Overall, local recurrence implies a poor prognosis and is usually the first sign of 
metastatic disease 146»147*148*149. In a series from University of Alabama (UAB)150 
in America and Sydney Melanoma Unit (SMU)150, among 95 patients who had local 
recurrences, the median survival time was only 3 years with a ten year survival rate of 
only 20%. In a study carried out at Duke University Medical Centre149, it was found 
that the location of the primary tumour and length of the initial disease free interval 
influenced survival.
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Patients with local recurrence from lesions of the extremities had a median survival of
6.1 years in contrast to patients with lesions of the trunk and head and neck, who had 
median survival times of 2.1 years and 3.0 years respectively.
2.3 TREATMENT OF RECURRENT REGIONAL METASTASES
2.3.1 IN TRANSIT METASTASES
Recurrent regional disease is defined either as metastases arising from lymphatics 
between the site of the primary lesion and the regional nodal basin (in transit 
metastases) or as tumour recurrence within the area of a previous lymph node 
dissection.
The choice of treatment of recurrent regional metastases is influenced by the number, 
anatomical location, size and distribution of in transit metastases. Aggressive local 
treatment is the most effective means of achieving regional disease control151. The 
treatment options are surgery, isolated limb perfusion, regional chemotherapy 
infusion, radiotherapy, cryotherapy, immunotherapy and systemic chemotherapy.
Surgery is reserved for patients with one or two in transit metastases. Isolated limb 
perfusion may be the treatment of choice in this group of patients as it has been 
shown to have a high likelihood of achieving regional control 143>152>153. However, 
this treatment option is limited to patients with recurrent extremity disease distal to 
the upper third of either the arm or thigh.
Intra-arterial infusion of cisplatin has been used as a salvage procedure in patients 
with advanced disease in whom surgery, isolated limb perfusion and systemic 
chemotherapy have failed. Workers at the M. D. Anderson Cancer Centre154, 
achieved an overall partial response rate of 37%. Increased response may be achieved 
using a higher drug concentration, which can also be obtained by using an occlusive 
arterial-infusion (inflow technique) or an intra-arterial infusion with a tourniquet 
(outflow technique).
Radiotherapy using high dose radiation may provide significant palliative benefit and 
occasionally prolongs regional control155*156. Recent studies indicate hyperthermia 
of lesions before or during radiotherapy may enhance response rate157*158. Blake et 
al159 using fast-neutron therapy reported a 71% complete response rate with a 
recurrence rate of only 9% in 68 patients. However, in 22 patients complications 
occurred.
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Cryotherapy using liquid nitrogen can be used in patients whose tumours have not 
responded to other forms of treatment or who are unable to undergo other therapy160. 
It is most effective for intradermal metastases.
BCG has been shown to induce regression when injected into intradermal 
metastases161*162. Bauer et al163 reported a complete response in approximately 67% 
of injected nodules and a significant decrease in size in 29%. Systemic chemotherapy 
using dacarbazine alone or in combination has limited success, usually with a short 
duration of response140.
2.3.2 RECURRENT NODAL METASTASES
Clinically detectable metastases within or adjacent to the area of a previous lymph 
node dissection usually manifests in two clinical situations. The first is in the patient 
with recurrent disease who is known to have undergone a complete lymph node 
dissection initially. Recurrent nodal metastases are often seen at the boundaries of the 
previous surgical site. In this situation, local excision of the recurrence and 
surrounding soft tissue is sufficient. Surgical margins must be histologically clear of 
tumour.
In the second situation, the patient presents with recurrent regional metastases but the 
extent of previous lymph node dissection was incomplete. In this case, a complete 
lymph node dissection is carried out.
The use of pre-operative chemotherapy is being evaluated at the M.D. Anderson 
Centre164. An initial pilot study of 48 patients receiving two cycles of pre-operative 
cisplatin, vinblastine and dacarbazine for advanced nodal disease demonstrated an 
overall response rate of 50%. After nodal surgery, those patients who have at least a 
partial response are continued on chemotherapy. The rationale is to identify patients 
with 'resistant' tumours who are not likely to benefit from further chemotherapy. It is 
not known if patients responding to neoadjuvant chemotherapy have a higher survival 
rate.
In patients with multiple regional metastases the use of adjuvant radiotherapy can 
improve local control although it may not increase survival142.
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2.4 TREATMENT OF ADVANCED MELANOMA
The aim of treatment is to relieve symptoms and prolong life. There are several 
modalities of treatment. The option of not providing treatment is an important one to 
consider, especially in asymptomatic patients, in those who are terminally ill and in 
the elderly.
2.4.1 SURGERY
Surgery is an effective palliative treatment for isolated metastases. It offers effective 
and quick palliation, and in some cases long-lasting survival165*166. It is effective 
only against disease at that local site. Favourable outcomes from surgical resection of 
distant metastases in selected patients have been shown167*168*169. Isolated visceral 
metastases, especially in the brain and lung, may be amenable for surgery in 
exceptional circumstances. The decision to use palliative surgery depends on the site 
of the disease and duration of anticipated survival but each case should be considered 
on its own merit.
2.4.2 RADIOTHERAPY
Radiotherapy has been shown to be beneficial in treatment of symptomatic patients. 
The main indications are treatment of dermal, subcutaneous, lymph node, brain and 
bone metastases. Other indications include spinal cord compression and 
symptomatic isolated visceral metastases not amenable to surgery. High energy 
radiation can relieve the pain of bone metastases within one week. Irradiation from a 
high energy proton beam can effectively treat superficially located metastases in skin 
or soft tissue. In the majority of cases, high dose, low fraction irradiation induces 
significant regression of metastases located on skin, subcutaneous tissue or distant 
lymph node17*1*171.
2.4.3 CHEMOTHERAPY
DTIC remains the most widely used agent for treatment of systemic melanoma. The 
response rate is in the range of 15% to 25%172*173. DTIC is well tolerated with the 
only major side effects being nausea and vomiting. Patients with metastases in skin, 
subcutaneous tissue or lymph node most frequently respond. The median duration of 
response is 5 to 6 months. Complete response is observed in only 5% of the 
patients174.
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The nitrosoureas also have activity against melanoma with response rates between 
10% and 18%175-178. Carmustine (BCNU), lomustine (CCNU), semustin (methyl 
CCNU) and fotemustine are the best studied of this group. Combination therapies 
have been reported to produce higher response rates when compared to single agents, 
although these studies have not directly compared treatments in prospective 
randomised trials nor have they demonstrated a survival advantage.
Drug combinations of DTIC and cisplatin179, DTIC and vindesine180, and vindesine 
and cisplatin181 produced response rates between 20% and 30%. Two other 
combination regimens were also reported to induce responses in 30% to 40% of 
treated patients181*182. These were BHD (BCNU, hydroxyurea and DTIC) and 
BOLD (bleomycin, vincristine, CCNU and DTIC). The Southwest Oncology 
Group183 carried out a randomised study of BHD regimen versus DTIC phis BCG 
and showed a response rate of 31% versus 18% but the overall survival was not 
improved in patients treated with BHD regimen.
More recently a trial was conducted using a three drug regimen containing DTIC and 
cisplatin in combination with vindesine, vinblastine or BCNU. The combination of 
DTIC, cisplatin and vindesine showed a 30% to 40%184*185 response rate and similar 
results were achieved using vinblastine instead of vindesine with DTIC and 
cisplatin186. Most responses were partial with a median duration of 6 to 9 months.
The Dartmouth four drug regimen developed at the Dartmouth Medical Centre in 
America using DTIC, cisplatin, BCNU and tamoxifen has shown a 50% response 
rate186*187. It was also seen that tamoxifen was cmcial as only a 10% response rate 
was achieved when it was deleted from the regimen187.
2.4.4 IMMUNOTHERAPY
Immunotherapy can be considered as an active form of treatment for metastatic 
melanoma. In patients with localised superficial skin metastases without bulk disease 
or visceral metastases, BCG will induce regression of most lesions into which it is 
injected188*189*190.
Interferon-alpha and interleukin-2 have been shown to be active against melanoma 
cells and response rates of 10% to 20%191-194 have been documented, although these 
are not significantly different from single agent DTIC.
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Monoclonal antibodies have also been shown to produce major tumour regression in 
patients with metastatic melanoma195-199. Currently, combinations of interferon- 
alpha, interleukin-2 and chemotherapy are being evaluated.
Tumour vaccine containing irradiated tumour cell, partially or completely purified 
melanoma antigen or tumour cell membrane from melanoma cells infected with vims 
(viral oncolysates) are also being evaluated. The three year survival rate of patients 
with stage II melanoma who received irradiated allogeneic melanoma cell vaccine 
(MCV) was 60%, much higher than that of historical controls200.
In a further study201 of 95 patients with stage HI melanoma who were vaccinated 
with melanoma antigen vaccine (MAV) it was found that 39 patients who developed 
a strong delayed type hypersensitivity to the vaccine had longer disease free intervals 
than the 42 patients who did not respond. The median disease free survival of 
patients who developed an intermediate response was 24 months. Melanoma 
vaccines are still experimental and their clinical effectiveness is yet to be established.
(:
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CHAPTER 3
GLASGOW EXPERIENCE OF ISOLATED LIMB PERFUSION (ILP)
3.1 INTRODUCTION
Surgery is still the treatment of choice for primary cutaneous malignant melanoma 
but the optimal extent of surgery remains controversial. Local excision of the 
primary lesion alone does not always control disease and treatment failure is reflected 
in the development of local, regional or systemic recurrences. Patients with primary 
melanoma greater than 1.5 mm thick carry a poor prognosis and as thickness 
increases, the likelihood of satellite lesions and in transit metastatic disease also 
significantly increases202. Regional chemotherapy is an attractive theoretical option 
as this treatment can eliminate microscopic metastatic cells and deposits not removed 
by primary surgery.
Despite the introduction of isolated regional limb perfusion 30 years ago, there still 
appears to be no consensus for the support of routine use of limb perfusion as 
prophylactic treatment in the management of stage I melanoma patients. This 
problem arises largely as the results quoted in support of adjuvant therapy come from 
non randomised retrospective studies using historical controls that lead to lack of 
credibility. These studies have often failed to withstand statistical scrutiny.
After reviewing results worldwide it was decided to establish a unit, the first and only 
unit of its kind in Scotland and the North of England at Gartnavel General Hospital in 
Glasgow in 1984 to offer ILP to high risk stage I melanoma patients and patients with 
recurrent melanoma of the limb. In many centres ILP has now become established as 
the treatment of choice in the management of patients with recurrent malignant 
melanoma of the extremities. It has been shown to have a high likelihood of 
achieving regional control with an overall objective response of 80%, with similar 
proportions of complete and partial remissions and improved limb salvage 
rates143’152’153. When this unit was established several questions needed to be 
answered.
1) Could ILP be performed safely?
2) Would it have deleterious effects on patient survival or disease free 
interval?
3) Would ILP improve the long term survival rate and disease free interval in 
patients with high risk primary melanoma of the limb?
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3.2 HISTORY OF ISOLATED LIMB PERFUSION
The unpredictable natural history of malignant melanoma renders it unusual among 
human tumours. The tendency to arise from a benign lesion, its capacity to spread 
without regard for anatomical boundaries, its ability to lie dormant for many years 
only to reappear and bring about the death of its host and finally its tendency for 
spontaneous regression contribute to our lack of understanding of melanoma and our 
inability to deal with it more effectively. Until the 1950's, treatment of malignant 
melanoma was almost exclusively surgical, consisting of wide excision of primary 
tumour and regional lymphadenectomy.
In 1940, Gilman and Philips203 first reported the use of nitrogen mustard in the 
treatment of cancer and within five years, Kloops et al204 and Bierman et al205 
independently administered intra-arterial nitrogen mustard through a small indwelling 
polyethylene catheter placed in the artery supplying the tumour bearing area. 
Responses were seen but the technique was fraught with complications. The best 
results were obtained when venous return from the area involved was blocked. In 
1956, at Tulane University, Ryan et al206 successfully isolated the limbs, mid gut and 
livers of dogs and perfused them.
In 1957, Creech et al207 combined these procedures and formed an isolated circuit 
with an extra corporeal circulation using a pump-oxygenator which made it possible 
to administer large drug doses. The first patient was treated at the Charity Hospital of 
Louisiana, New Orleans207*208. Luck et al209 discovered that melphalan was the 
most active agent to inhibit the growth of malignant melanoma in man and since then 
it has become the agent of choice. In 1967, Cavaliere et al210 laid the foundation for 
perfusion with hyperthermia when they described the susceptibility of cancer cells to 
high temperatures.
Since 1961, many investigators have treated patients with a variety of solid tumours 
with isolated perfusion. The best response rates were seen in malignant melanoma 
and sarcoma and encouraging results were achieved without undue toxicity. Only in 
melanoma was complete remission seen. During the development of the isolation 
perfusion technique, oxygenation and heparinization were reported to have 
therapeutic potential. Hyperoxygenation of perfused tissue was shown to potentiate 
the radiomimetic effect of the alkylating agent211*212.
Heparin was shown to inhibit deposition of metastatic tumour cells and could limit a 
potential source of in transit metastasis213. Cavaliere210 studied hyperthermic
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isolated regional perfusion in 18 patients using no chemotherapy and no tourniquet 
and noted tumour regression in 14 of 18 patients with 10 complete remissions 
following perfusion with hyperthermia of 39°C to 41°C for 4 hours. Stehlin214 also 
reported an increased response rate using hyperthermic perfusion with the same drug. 
The application of heat not only has selective tumouricidal action but also enhances 
the action of chemotherapeutic agents. Thus lower chug doses can be used without 
loss of therapeutic potential, reducing the risk of local and systemic toxicity.
The most commonly used drug in treating melanoma of the limb is L-phenylalanine 
mustard (melphalan), an alkylating agent. It is related to nitrogen mustard but 
melphalan has a longer duration of action and is less of a vesicant. Melphalan was 
originally selected because phenylalanine, a metabolite of melanin, was thought to 
carry the attached cytotoxic alkylating radical into the melanin producing neoplastic 
cell. Dosage is determined on the basis of body weight, limb volume or haematocrit.
3.3 ADVANTAGES OF ISOLATED LIMB PERFUSION
Isolated perfusion was originally developed to increase chug dosage in the treated area 
over that which could be achieved by systemic administration while avoiding major 
systemic toxicity. Dose was limited by toxicity to the nerves, blood vessels and 
muscles in the perfused area.
The advantages of hyperthermic isolated regional perfusion are:-
1) A 6 to 10-fold increase in chug concentration in the isolated limb over that 
obtained by systemic administration.
2) Improved perfusion of the tumour and surrounding area including the regional 
lymph nodes
3) An increase in the PO2  in the isolated tissue which may potentiate the action of 
alkylating agents and have selective tumouricidal action.
4) Hyperthermia may increase the chemical activity of a chug, increase the 
metabolism of tumour cells, produce vasodilatation for better perfusion and have a 
selective tumouricidal action.
5) Heparin used in the extracorporeal circulation may have both antimetastatic 
effect and selective tumouricidal action.
6) Isolation of the treated area decreases the systemic toxicity and protects "host 
resistance".
7) There is some evidence that destmction of tumour cells in situ initiates an 
autoimmunization process.
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3.4 RESULTS OF APPLICATION OF MILD HYPERTHERMIA IN 
ISOLATED LIMB PERFUSION FOR STAGE I MELANOMA OF THE 
EXTREMITIES
3.4.1 PATIENTS
Between August 1985 and June 1993, 99 patients with clinical stage I malignant 
melanoma of the upper and lower limb were treated with hyperthermic isolated 
regional limb perfusion using melphalan in a prospective non-randomised case 
control study. All the patients in the study had been referred following surgical 
biopsy or excision from hospitals throughout Northern Britain for ILP. After 
discussion with statisticians and relevant clinicians, it was decided that a randomised 
trial could not be completed within a reasonable time scale.
The criteria for inclusion into the study included patients with stage I melanoma 
affecting the upper or lower limb excluding high posterolateral and deltoid region 
which are outside the effective perfusion zone, absence of in transit, regional or 
distant metastatic disease, vascular suitability for catheterisation and adequate 
medical status for general anaesthesia.
Of the 99 patients, 31 (31.3%) were males and 68 (68.7%) were females with a mean 
age of 56 (range 21-84) years. The lower limb was involved in 72 (72.7%) and the 
upper limb in 27 (27.3%). Histology of the tumour included 30 superficial spreading 
melanoma, 30 nodular melanoma, 3 acral lentiginous melanoma and 5 lentiginous 
maligna melanoma. On 31 patients no information on the type of tumour was 
available. The mean Breslow tumour thickness was 3.4 mm (range 0.9-10.0mm). 
Clark level was available on 71 patients. Table 1 summarises details of the 99 
patients.
3.4.2 PROCEDURE OF ILP
ILP is carried out under general anaesthesia. The patient is positioned so that a 
tourniquet can be placed around the base of the limb. Since this technique uses 
hyperthemia, the operating room is kept at 21SC and the patient is placed on a heated 
water blanket (Hawksley Ripple Heat System with custom blanket) at 40QC. 
Temperature is monitored by placing four to six thermistor probes (Yellow Springs) 
on the skin surface and the temperature readings are displayed continuously on a 
monitor screen (Siemann Sirecust).
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An arterial line is placed in the radial or dorsalis pedis artery of the affected limb to 
monitor arterial pressure. The transcutaneous oxygen tension in the skin is measured 
using the Radiometer TCM2 System (Figure 10) at several points in the treated and 
untreated opposite limb. The leg is placed in a cotton stockingette and a gamgee is 
placed around the foot to protect the skin from the direct heat and then the heated 
water blanket is wrapped around the limb (Figure 11).
To carry out perfusion on the lower limb, the external iliac vessels are approached 
retroperitoneally via an oblique incision in the iliac fossa parallel to the inguinal 
ligament. Iliac lymph nodes along the vessels are removed. Figure 12 shows the iliac 
vessels exposed and isolated prior to the perfusion. All the minor branches of the 
external iliac artery and all tributaries of the external iliac vein are ligated and divided. 
The inferior epigastric vessels are ligated but the obturator vein is dissected and 
temporarily occluded to decrease leakage from the perfused limb. The internal iliac 
vein is clamped throughout the perfusion.
Prior to cannulating the vessels, systemic heparin (150 iu/kg) is given intravenously. 
A longitudinal arteriotomy and venotomy are carried out and a 16 or 18 French 
polyvinyl chloride cannula (Bard) is placed in the artery and an 18 or 20 French 
cannula in the vein. It is important that the tip of the cannula lies in the femoral 
triangle inferior to the inguinal ligament and distal to where the lower edge of the 
tourniquet will lie. The cannulae are secured in place using two cotton snares per 
cannula. A tourniquet is applied using Esmarch's bandage along the gluteal crease, 
drawing it up through the crotch and over the upper lateral hip (Figure 13). A 
Steinmann pin is driven into the iliac crest to hold the tourniquet in position.
Perfusion of the upper limb is carried out through the distal part of the axillary vein 
and artery. The vessels are exposed through an incision in the skin of the axilla. 
Lymph nodes on the first portion of the axillary vein are removed. A 12 to 16 French 
cannula is used in the artery and a 16 to 18 French cannula in the vein. A tourniquet 
is placed around the root of the limb and a Steinmann pin is placed in the head of the 
humerus to prevent dislodgement of the tourniquet.
The perfusion apparatus traditionally consists of a simple roller pump (Stockerte 
instrument) attached in series to a disposable hybrid oxygenator (Bard) which 
incorporates an integral heat exchanger. Figure 14 is a diagrammatic illustration of 
the isolated limb perfusion circuit. The pump oxygenator is primed with 500 ml 
lactated Ringer solution and 400 ml of matched packed cell to which is added 3,000 
units of heparin prior to connecting the arterial and venous cannula to the circuit.
TC OXYGEN MONITOR
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Figure 10 Radiometer TCM 2 System for measuring transcutaneous oxygen
Figure 1 1 Leg wrapped in a cotton stockingette and gam gee with water blanket 
wrapped around the limb
Figure 12 Iliac vessels exposed and isolated prior to the perfusion
Figure 13 Esmarch's bandage along the gluteal crease
Tourniquet
60
Once the circuit has been established, 5 ml of 20% fluorescein is injected into the 
arterial line and with the room darkened, a portable ultraviolet lamp is used to inspect 
the skin above and below the tourniquet. Any significant leak from the limb to the 
systemic circulation can be noted and corrected. The perfusate inflow temperature is 
maintained at 40-41°C resulting in a limb skin temperature of up to 40°C (mild 
hyperthermia). The limb pressure is ideally maintained just below the systemic 
arterial pressure and flow rates range from 250 to 900 ml per minute.
Once the limb temperature reaches 38QC, melphalan is administered into the arterial 
port of the bubble oxygenator. The dosage used is 1.75 mg per kilogram body weight 
for the lower limb and 0.75mg per kilogram body weight for the upper limb and is 
given as a bolus. Perfusion is carried out for one hour during which continuous 
monitoring of flow rate, oxygen saturation, perfusion pressure and temperature is 
undertaken. The perfusate is oxygenated using 100% oxygen.
At the completion of perfusion, the circuit is washed out with 2 litres of Ringer 
lactate, after which the tourniquet is released, the cannulae withdrawn and the vessels 
repaired with 5'0' non absorbable sutures. The effect of heparin is reversed with the 
appropriate dose of protamine sulphate. The approximate length of the operation is 
between 120 and 180 minutes. At the end of the operation, where appropriate, a wide 
local excision of the primary tumour is carried out.
Postoperatively, the patient is nursed with the leg elevated in the high dependency 
area of the ward. On day 1 patients are encouraged to mobilise. Daily measurements 
of full blood count and electrolytes are carried out. Patients with haemoglobin less 
than 9 g/dl are transfused. The average length of stay is 9 days (range 6-12). Patients 
are followed up at a perfusion clinic 6 weeks postoperatively and at three monthly 
intervals thereafter for 5 years.
3.4.3 RESULTS
Survival and disease free survival was estimated using the Kaplan-Meier method on 
all the data. Significance tests of differences among subgroups such as those defined 
by sex and site were carried out by means of Log-Rank Tests or Proportional Hazards 
Models as appropriate.
Survival
Nine patients have died from the disease at the time of writing. The 2 and 5 year 
survival was 96% and 82% (Figure 15) respectively and the disease free survival 83%
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and 61% (Figure 16) respectively. The mean follow up to recurrence was 37 months 
(range 9-95) and to death was 35 months (range 17-63). There were 20 patients who 
developed local regional recurrences; 14 lymph node recurrences and 6 patients 
developed local skin recurrences. Seven patients developed distant metastases. The 
mean time to recurrence was 21 months (range 1-52 months).
Survival by sex
The 5 year survival and disease free survival for females was 84% and 66% 
respectively and for males 77% and 50% respectively. For both survival and disease 
free survival, females appear to have better prospects than males, but this is not 
confirmed by Log-Rank Tests (p value for survival = 0.284, p value for disease free 
survival = 0.372)
Survival by site
The 5 year survival and disease free survival in patients with lower limb melanoma 
was 76% and 57% respectively when compared to 95% and 74% respectively for 
patients with upper limb melanoma. Although the patients with upper limb 
melanoma seemed to have a better prognosis than patients with lower limb 
melanoma, the difference was not statistically significant for either 5 year survival (p 
= 0.582) or disease free survival (p = 0.101).
When all the effects of the six prognostic risk factors, i.e. sex, age, site, Breslow 
tumour thickness, Clark level and histogenetic type, were considered through a 
proportional hazards model, none of these prognostic factors proved significant for 
either survival or disease free survival.
Overall, survival and disease free survival prospects appear reasonable, although there 
are indications of poorer survival and disease free survival for males and for those 
with lesions on the legs. These, however fall far short of any significance, possibly 
due to the small numbers in the different subgroups.
COMPLICATIONS
There were no hospital deaths associated with ILP in the study. No patient required 
amputation either as a complication of the perfusion or from their disease. Immediate 
complications included deep vein thrombosis, pulmonary embolus, wound infection, 
bleeding and haematoma. Systemic complications included leucopenia, 
thrombocytopenia and pancytopenia, all of which resolved spontaneously (Table 2).
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REGIONAL NO. OF PATIENTS
Severe Cellulitis 9
Nerve Symptoms 6
Muscle Symptoms 4
SYSTEMIC
Leucopenia 18
Thrombocytopenia 6
Pancytopenia 12
GENERAL
DVT 3
PTE 4
Wound Infection 4
Haemorrage 1
Haematoma 1
Table 2 Postoperative complications following ILP for 
primary melanoma
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Toxicity after perfusion was graded according to the Wierberdink215 Scale as shown 
in Table 3. Fifteen (14%) patients were graded I, 42 (40%) graded n, 39 (43%) 
graded IQ and 3 (3%) patients were graded IV.
3.4.4 DISCUSSION
Following the publication by Krementz et al216 in 1962 of the clinical improvement 
in patients having received isolated limb perfusion, the idea of a prospective 
randomised study was shelved. In retrospect this was unfortunate in view of the 
changing nature of the disease and the improvement in survival rates being reported 
with other therapeutic modalities.
A literature review of adjuvant ILP for stage I malignant melanoma of the extremities 
is presented in Table 4. None of these studies were randomised and most authors 
compared their results with literature reports; in only three studies were there any 
controls. It is, however, important to interpret historical controls with caution.
The only prospective randomised study of adjuvant ILP was reported by Ghusen et 
al152 in West Germany. The study consisted of 107 patients with melanoma of the 
extremities who were randomised to having wide local excision with regional lymph 
node dissection (RLND) or wide local excision, RLND and hyperthermic isolated 
perfusion with melphalan. The disease free survival time was chosen as the criterion 
for evaluation.
Intermediate analysis revealed a highly significant difference between the two groups, 
with 21 recurrences in the control group and 4 in the perfused group, i.e. recurrence 
rate in the control group was 27.8% in stage I, 31.6% in stage Q and 58.5% in 
stage IQ compared to 5.6% in stage I, 5.5% in stage Q and 12.5% in stage IQ in the 
perfused group.
This study was discontinued prematurely as the authors concluded that adjuvant 
regional hyperthermic perfusion had been shown to be superior to surgery alone. 
Five years later, Ghusen et al227 reported the disease free survival of patients who had 
perfusion to be still superior. The retrospective breakdown into different risk groups 
according to tumour thickness also demonstrated a significant difference. They 
concluded that the overall 5 year survival rate of 90% in the perfused group compared 
to 60% in the control group and interpreted these results to demonstrate the benefits 
of adjuvant hyperthermic regional isolated limb perfusion.
GRADE DESCRIPTION OF REACTION
I No subjective or objective evidence of reaction.
n Slight erythema and/or oedema.
m Considerable erythema and/or oedema with some 
blistering; slightly distributed motility possible.
IV Extensive epidermolysis and/or obvious damage to the 
deep tissues, causing definite functional disturbances, 
threatening or manifest compartment syndromes.
V Reaction which may necessitate amputation.
Table 3 Wierberdink grading system for the 
reaction of normal tissue to ILP
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Sadly, this study has several flaws. Firstly it was prematurely closed, which resulted 
in a small number of patients being recmited. Thus the data are suggestive but do not 
show statistically significant evidence for the efficacy of adjuvant ILP. The p value 
for the difference between the perfused and non perfused groups was at a significance 
level of P = 0.09 (single factor) and a multivariate analysis had not been done. It was 
also not clear from the study whether randomisation was according to tumour 
thickness or not. Furthermore no reference was made to survival or disease free 
interval with respect to the number of positive lymph nodes. Although this is the 
only prospective randomised study, the results should be cautiously interpreted.
There are only three studies that have matched patients by prognostic factor. The first 
study228 consisted of 120 patients, all women with stage I disease who had ILP and 
they were matched by sex and tumour location with 116 patients undergoing local 
excision only in the Sydney Melanoma Unit in Australia.
The second study229 compared 227 patients with stage I disease having ILP with 238 
matched controls (age and site) who had wide local excision only from the same 
geographical area in the Netherlands. The last study230 compared 151 patients with 
stage I disease treated with wide local excision and ILP with melphalan and also 
DTIC with 151 patients matched for prognostic factors undergoing wide local 
excision alone from University of Alabama, USA and the Sydney Melanoma Unit, 
Australia.
The first study228 showed that women who had ILP and wide local excision had a 
significantly higher ten year disease free interval, higher ten year survival rate and 
significantly fewer local regional recurrences than there were in the group treated with 
wide local excision only. These results should be interpreted with caution as all the 
patients were female and in stage I disease, females have a better prognosis. 
Furthermore, all tumours were confined to the lower limb, a site associated with 
improved survival.
In the second study229, it was not possible to demonstrate a statistically significant 
effect of ILP in terms of time to limb recurrence, time to regional lymph node 
metastases, time to distant metastases, disease free interval and survival. There was 
no significant difference in prognostic factors of age, sex, ulceration or tumour 
thickness.
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In the third study230 a subset of patients with lesions > 2.00 mm in thickness showed 
a significant improvement in disease free and overall survival rates with melphalan 
but not with DTIC.
Interestingly, in the first study, when the perfused patients in The Netherlands were 
matched using controls from Australia, there was a significant improvement in 
survival rates but this was not demonstrated in the second study when the control 
group came from the same geographic area. This phenomenon, however, was not 
observed in the third study when controls were taken from another area.
It was also noted that the 5 year disease free survival rate for the non-perfused patients 
in America and Australia was very low compared to that of the non-perfused patients 
in The Netherlands. This finding is interesting as the questions that arise are: are 
there different forms of the disease in different latitudes of the world, or is the 
difference due to the genetic make-up of individual races?
From these studies, no definite advantage of ILP over wide local excision could be 
established.
The result from the Glasgow unit is unique in that this is a single centre, single 
surgeon unit. Thus the treatment of ILP is uniform with no interoperator variation to 
account for differences in results. It was an interesting finding of this study that there 
were no significant prognostic factors with relation to either survival or disease free 
survival. This included the Breslow thickness that has been quoted as the single most 
important prognostic factor with relation to survival (section 1.5.2).
A possible explanation is that, since in this unit routine lymphadenectomy is not 
performed, there may be a significant group of patients who may have nodal 
metastases. The presence of nodal involvement would immediately alter the staging 
of the patient and subsequently effect the prognosis of the disease. The importance of 
the proper staging of patients especially those with stage I disease will be shown and 
fully discussed in chapter 6.
The results of the present study show that ILP can be performed safely with 
acceptable morbidity. There were no deleterious effects on survival following ILP. 
The intermediate analysis of the results show that ILP patients appear to have 
acceptable survival and disease free survival rates. Although there may be a survival 
advantage, it does not reach statistical significance. Full evaluation must await longer 
term follow up.
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3.5 RESULTS OF ISOLATED LIMB PERFUSION FOR RECURRENT LIMB 
MELANOMA
3.5.1 PATIENTS AND METHODS
ILP was made available in Scotland in August 1984. Between then and June 1993, 
103 patients with stage II-DI malignant melanoma underwent therapeutic limb 
perfusion for recurrent melanoma of upper and lower limb. All patients in the study 
were referred from hospitals throughout Northern Britain and Ireland. The criteria for 
inclusion were patients with recurrent or advanced melanoma confined to a single 
limb, vascular suitability for catheterisation and adequate medical status for general 
anaesthesia. Disseminated disease was generally considered to be a contraindication, 
unless the local disease was so gross that ILP was considered justifiable to achieve 
local disease control.
There were 25 males and 78 females with a mean age of 62 (range 21-92) years. The 
lower limb was involved in 95 patients and the upper limb in 8 patients. The clinical 
details of the patients are summarised in Table 5. Prior to the treatment with ILP, 75 
patients had primary tumour and recurrences treated with excision, 24 patients had 
had excision and groin dissection at the time of presentation with the primary tumour, 
2 patients presented with satellite lesions with the primary intact, 1 patient had had 
excision, radiotherapy, followed by groin dissection and further chemotherapy and 1 
patient was diagnosed following a groin dissection and later admitted that he had a 
"warty" mole on his thigh that had fallen off one year prior to the groin dissection.
The number of recurrences prior to ILP was 1 in 45 patients, 2 in 33 patients, 3 in 12 
patients, 4 in 5 patients and 5 in 4 patients and more than 5 recurrences in 4 patients. 
The mean recurrence interval prior to ILP was 20 months (range 1-129). Six patients 
had other associated malignancies. These included breast cancers in 2, chronic 
lymphatic lymphoma in 1 prior to developing the primary melanoma, and 3 patients 
developed breast, uterine and ovarian tumours following ILP. One patient developed 
a second primary melanoma.
The technique of regional isolated limb perfusion was performed as described on 
pages 58-60. For upper limb recurrence, axillary perfusion and reperfusion was 
performed if necessary. In the lower limb, the perfusion was carried out at the iliac 
level and if reperfusion was needed, it was done at iliac, femoral or popliteal level. 
The mean time to ILP was 48 months (range 1-290) from the time of surgery for their 
primary melanoma.
SEX - SITE DISTRIBUTION
UPPER LIMB LOWER LIMB TOTAL
MALE 3 22 25
FEMALE 5 73 78
TOTAL 8 95 103
LEVEL OF PERFUSION
LEVEL FIRST REPEAT
PERFUSION PERFUSION
Iliac 95 11
Femoral 5
Popliteal 3
Axillary 5
Subclavian 2
Table 5 Details of patients undergoing ILP for recurrent 
limb malignant melanoma
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3.5.2 RESULTS
One hundred and twenty-two therapeutic perfusions were performed on 103 patients. 
The response rates were classified according to the Union Internationale Contra le 
Cancer (UICC) Criteria231 (Table 6). Eighty-seven patients had complete response, 
34 had partial response and 1 had no response from the perfusion (Table 7). Figures 
17-20 show the sequence of changes in a single recurrent malignant melanoma 
nodule following ILP. Sixty-six patients have died at the time of writing. The mean 
time to death was 22.5 months and the average follow up time of the 37 survivors 
was 34.5 months. The overall 2 and 5 year survival was 50% and 26% respectively 
(Figure 21). Eight patients died from other causes including myocardial infarction, 
uterine carcinoma, ovarian carcinoma and pneumonia.
Survival according to limb: The overall 2 and 5 year survival for the lesions in the 
upper limb was 38% and 18% respectively whilst in the lower limb the survival was 
52% and 27% respectively.
Survival according to sex: The overall 2 and 5 year survival for the females was 
60% and 35% respectively and 18% and 4% respectively for the males.
Survival according to sex and limb involved: There were no survivors in the 
males with upper limb lesions at 2 years whilst in the females with upper limb lesions 
the 2 year survival was 75%. In the group with lower limb lesions, the 2 and 5 year 
survival was 18% and 6% respectively in the males compared to 61% and 34% 
respectively in females (Figure 22).
Survival according to local recurrence
Of the 42 patients who developed a local recurrence, 36 patients were dead within the 
first 24 months of the perfusion; of the 11 who developed both systemic and local 
recurrences, none were alive after twelve months.
Rate of local recurrence
Local recurrence in this study is defined as having recurrence either in or around the 
scar of the primary lesion, regional lymph node recurrence or a combination of these 
findings.
Of the 103 patients, 42 developed local recurrences after perfusion, of these 29 were 
regional skin recurrence and 13 were regional lymph node recurrence. Thirty-six 
patients developed non local recurrence or systemic metastases, of whom 9 also
Complete Response (CR) Disappearance of all known disease
Partial Response (PR)
50% decrease in measurable lesions and 
objective improvement in evaluable but 
non measurable lesions. No new lesions. It 
is not necessary for every lesion to have 
regressed to qualify for partial response, 
but no lesion should have progressed
Table 6 Union Internationale Contra le Cancer (UICC) grading response following 
therapeutic ILP
Response Rate rfo Therapeutic Isolated Limb Perfusion
CR PR NR TOTAL
First Perfusion 78 24 1 103
Repeat Perfusion 9 10 0 19
87 34 1 122
Table 7 Measurable response according to UICC grading following ILP
A single  recurrent m alignant m e la n o m a  nodu le
The same nodule three days after ILP treatment
Figure 19 The same nodule one week after ILP treatment
Figure 20 The same nodule one month after ILP treatment
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developed skin recurrence and 2 developed regional lymph node recurrence 
simultaneously. The 2 and 5 year disease free survival was 23% and 12% 
respectively (Figure 23).
Interval between perfusion and local recurrence: The mean time to local 
recurrence was 12 months with a mean time of 10 months to skin recurrence and 16 
months to regional lymph node recurrence. The mean time to non local recurrence 
was 18 months. The mean follow up for the patients with no recurrence was 37 
months.
Local recurrence according to sex: The sex distribution of the 42 local recurrence 
was 34 females and 8 males. The time to local recurrence in the female was 9 months 
and in the male was 12 months. The 2 and 5 year disease free survival for the female 
group was 26% and 16% respectively and in the male group of 16% and 0% 
respectively.
Local recurrence according to limb involved: 3 recurrences occurred in the upper 
limbs and 39 in the lower limbs. There was no difference in the rate of recurrence 
between the limbs.
Local recurrence according to sex and site: The 2 and 5 year disease free survival 
for females with a lesion in the lower limb was 28% and 16% compared to 14% and 
0% respectively in males with a lower limb lesion (Figure 24).
For both survival and disease free survival, females appear to have a better prognosis 
than males and this is confirmed by Log Rank Tests (p value for survival < 0. 0001, p 
value for disease free survival <0.01). With respect to site, the lower limb seems to 
show a slightly better prognosis but this is not significant for either survival (p = 
0.49) or disease free survival (p = 0.52).
When the four subgroups of sex and site were compared, there was a significant 
difference for both survival (p < 0.0001) and disease free survival (p < 0.001) 
intervals. These differences, however were between the sexes rather than between 
sites. A Stepwise Proportional Hazards Analysis was also carried out and this 
confirmed the effect on sex, but not of site.
COMPLICATIONS
There were no intraoperative complications during the procedure. There was one 
death within a month of surgery from an upper gastrointestinal bleed.
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No amputations were necessary either as a result of complication from the perfusion 
or from the disease. Immediate complications included deep vein thrombosis in 3, 
wound infections in 4, leucopenia in 16, thrombocytopenia in 3 and pancytopenia in 
18 patients, all of which resolved spontaneously.
Skin reaction to isolated perfusion was recorded according to Wieberdink215 grading 
system. The majority of patients showed Grade II reactions. Figure 25 shows the 
typical appearance of a grade ID skin reaction according to the Wieberdink scale.
3.5.3 DISCUSSION
The usual treatment offered to patients with recurrent malignant melanoma located on 
an extremity has been surgical excision of vaiying extent. Amputation has been 
applied less often despite the fact that this is about the only method for the definite 
cure of all patients without distant metastases. Since the introduction of ILP, it is 
being increasingly used on patients with recurrent melanoma on an extremity. Thus 
when analysing ILP, the results should be compared with those results obtained by 
excisional surgery alone or by amputation.
All the reports on regional perfusion treatment of melanoma are afflicted with the 
weakness that they lack adequate control groups. The literature consists of numerous 
reports of the results of treatment with ILP of recurrent malignant melanoma of the 
extremities (Table 8). The survival rates range from 29% to 71%. With regard to 
survival rates for recurrent malignant melanoma following ILP, the 5 year survival is 
26% in this unit.
The low 5 year survival rate in this study needs explanation. Fifty-eight patients (i.e. 
over 50%), received two or more surgical excisions as the treatment for their 
recurrences prior to being referred for ILP. When McNeer and Cantin148 reviewed 
local failure following surgery in the treatment for melanoma, they stated "Once local 
failure develops after definite treatment for melanoma, the prognosis, while not 
hopeless, is grave". They reported a 20% five year survival rate for 64 patients 
following surgical resection alone in the treatment for recurrences clinically confined 
to an extremity.
Fortner et al147 reported a 40% five year survival after resection of local recurrence 
and 8.6% five year survival after surgical treatment of intransit disease. Amputation 
for stages H-HIA has failed to produce better results than more conservative surgeiy.
Figure 25 A grade III reaction according to the Wieberdink scale
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Bowers236, McPeak et al237 and Cox238 reported 5 year survivals of 18%, 33% and 
15% respectively following amputation.
Even when the survival rate from amputation, which is the most radical of form of 
treatment, are compared, the 5 year survival rate from ILP is superior.
When the disease free survival following ILP is compared with surgical excision 
alone, in this study it was 12% when compared with 11% and 27% in the series 
published by McNeer and Cantinl48 and Fortner et al147. The mean time to local 
recurrence was 20 months prior to ILP and was 12 months following ILP. This result 
may be explained by the fact that over 50% of the patients were being treated after 
more than two recurrences and received ILP at a mean interval of 48 months from the 
primary excision.
The result of this study reinforces the fact that patients with recurrences have a poor 
prognosis. Since they did not receive any treatment to modify the progress of the 
disease at an earlier stage, ILP in these patients was used to control local disease 
rather than to improve survival or disease free survival. Avoiding amputation is a 
clear benefit.
In many of the studies published on the treatment of recurrent melanoma of the limb 
with ILP, the treatment of ILP was performed at the time of first recurrence. In this 
study over 50% of the patients had at least two or more surgical excisions prior to 
treatment of their recurrence with ILP. Thus results from this study cannot be directly 
compared with other published series as ILP in most of these studies were carried out 
when the patient developed the first recurrence.
In the early years when the Glasgow unit was being established, the patients that were 
referred were those with intolerable limb disease following failed surgical treatment 
and various other therapies. The only other option for many of these patients was 
amputation. With time, and as the referring surgeons and physicians gained more 
insight and confidence in the treatment of ILP, patients were being referred earlier in 
the course of their disease. The unit now treats more patients at first recurrence and 
also patients with primary disease for adjuvant ILP.
Hansson et al239, showed that perfusion plus excisional surgery prolongs the 
recurrence free interval in comparison to surgery alone. Stehlin et al233 also was able 
to demonstrate that perfusion and surgery was superior to surgery alone.
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The objective response rates from this study are encouraging. A complete response 
of 75% and 48% and a partial response of 23% and 52% in the first and second 
perfusions respectively is comparable to other studies239*240. It is interesting to note 
that repeat perfusion can also achieve good control of recurrence. ILP offers effective 
palliative control of the disease.
The objective response achieved using ILP is high and the use of ILP is easily 
justified for recurrent melanoma. As Au and Goldman241 stated, "the disease has 
already demonstrated aggressive behaviour in these cases, and will progress unless it 
can be modified". The original clinical report by Creech et al242 described the effects 
of perfusion without excision in 6 patients with recurrent cutaneous metastases 
involving the extremity. They described a characteristic post perfusion sequence of 
changes in these lesions, including darkening, flattening, crusting, and slough of the 
cmst, with persistence of a freckle at the tumour site.
Several investigators undertook similar studies and have achieved reasonable long 
term survivals in selected patients with recurrent limb melanoma treated by surgical 
excision and adjuvant perfusion.
Female patients had a significantly better survival than males. Although there is a 
slightly better prognosis for lesions on the lower limb, this is not statistically 
significant in terms of either survival or disease free survival.
To summarise, results from this unit show that ILP is effective in the control of 
recurrent melanoma confined to a limb with high objective response rates. The 
achievement of ILP has been that amputation, a procedure that was used widely in the 
treatment of this disease 20 years ago is seldom, if ever needed to control limb 
melanoma. In this centre, to date, there has been no amputation performed to control 
recurrent limb melanoma.
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3.6 RESULTS OF ISOLATED LIMB PERFUSION FOR SUBUNGUAL 
MELANOMA
3.6.1 INTRODUCTION
Hutchison11 has been attributed with the first description of a subungual melanoma 
although it was reported earlier by Bayer243 in 1854 and Dermargnay and Manod244 
in 1855. It was Hutchison who realised the malignant nature of the disease and 
recommended radical surgery in the form of amputation of the digit involved. 
However, it was much later, in 1976, that the description and definition of most volar 
and subungual melanoma as a fourth clinical variety of cutaneous malignant 
melanoma was reported by Reed245.
Although the incidence of malignant melanoma is rising, subungual melanoma is 
very rare and represents only approximately 1% to 3% of all diagnosed melanoma in 
the Western World246*247*248. It is, however, commoner in dark skinned and oriental 
populations, representing 8% to 31% of all cutaneous melanoma249*250*251. Because 
of its rarity, subungual melanoma is often mistaken for benign conditions such as 
subungual haematoma, pyogenic granuloma, chronic paronchyia and 
onchymysosis252. This delay in diagnosis is quoted as a reason for the poor 
prognosis when compared with melanoma at other sites.
Metacarpophalangeal or metatarsophalangeal amputation has long been considered 
the treatment of choice for subungual melanoma247*253. Although adjuvant isolated 
limb perfusion has not been proven to improve survival in the treatment of stage I 
melanoma229*254, perfusion has been advocated in deeply infiltrating subungual 
lesions following amputation50*255*256. The results of regional isolated limb 
perfusion in the treatment of subungual melanoma carried out in this unit are 
presented in this section.
3.6.2 PATIENTS AND METHODS
Between August 1987 and April 1993, 24 patients with subungual malignant 
melanoma were treated with ILP following amputation. Of the 24 patients, 11 were 
men and 13 were women, with a mean age of 66 years (range 33-84). The lesions 
were situated on a finger in 11 patients and on a toe in 13 patients. The great toe was 
involved in 8 of the 13 lesions occurring in the foot whilst the thumb was involved in 
5 of the 11 lesions occurring in the hand. Two patients gave a history of trauma prior 
to the onset of symptoms.
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All patients were treated with either axillary or iliac perfusion and sampling of lymph 
nodes carried out if indicated. The histological specimens were microstaged 
according to Breslow thickness and Clark levels. One patient could not be staged. 
The median Breslow thickness was 4.0 mm (range 1.5- 8.0 mm).
The disease was classified according to the M. D. Anderson classification: stage I 
(primary tumour )17 patients; stage IDA (satellitosis and/or in transit metastases) 1 
patient; stage HEB (regional node metastases) 2 patients and stage IILAB (satellitosis 
and/or in transit metastases with regional lymph node metastases) 4 patients.
Acral lentiginous melanoma was the most common histological type (15/23), 
followed by superficial spreading melanoma (5/23), nodular melanoma (2/23), and 
lentiginous maligna melanoma (1/23). In one patient the histology of the tumour was 
not available. Tables 9 and 10 summarises the details of the patients. For statistical 
analysis the Kaplan-Meier method was used.
The technique of regional isolated perfusion has been described previously on pages 
58-60. The patients were perfused using melphalan, 1.75 mg/kg body weight for the 
lower limb and 0.75 mg/kg body weight for the upper limb. The patients were all 
treated with mild hyperthermia (39-40°C). Eleven perfusions were carried out using 
the axillary vessels and thirteen using the iliac vessels. At the end of the perfusion, 
amputation of the involved digit was carried out whenever indicated. 
Metatarsophalangeal joint amputation was carried out for lesions of the toes and 
proximal interphalangeal joint amputation for lesions on the fingers. The mean 
overall follow up of the entire group was 30 months (range 6- 109). The median 
follow up for the surviving patients was 32 (range 6-104) months.
3.6.3 RESULTS
There were no intraoperative complications and no deaths as a result of the perfusion. 
Two to three days after the perfusion, using the Wieberdink215 grading system, 3 
patients showed Grade I reaction, 17 showed Grade II reaction and 4 showed 
Grade III reaction. Post operative complications included wound infection in 1 
patient, seroma in 1 patient and diminished sensation in the index finger in one 
patient, probably as a result of tourniquet trauma to the brachial plexus.
In patients with stage II and HI disease, 5 (5/7) patients had a complete response and 2 
(2/7) patients had a partial response classified according to the UICC Criteria231.
fao
fao
a
fa
&H
X
faca
o<
fa
cn
a
On
fa fa
»n
fa
3
cn
a
ON
ON
fa
3
Ta
ble
 
9 
De
tai
ls 
of 
pa
tie
nt
s 
wi
th 
sta
ge
 
I s
ub
un
gu
al
 m
al
ig
na
nt
 m
el
an
om
a
DA
TE
 
O
F 
IL
P
16
/1
1/
84
02
/0
5/
86
03
/0
6/
88
17
/0
2/
89
18
/0
4/
90
10
/0
7/
90
31
/0
5/
91
28
/0
8/
91
25
/0
3/
93
02
/1
2/
92
DA
TE
 
O
F 
DI
AG
NO
SI
S
25
/0
5/
73
12
/1
1/
86 Ovoo
o
oqv
00
o 06
/0
6/
91
31
/1
2/
92
11
/1
1/
92
ST
AG
E
III
AB
III
AB
III
AB
III
AB III
B VIII III
B
BR
ES
LO
W
TH
IC
K
NE
SS
© 00
p o en
vq ©
r*~>
©
vr!
C
LA
R
K
LE
V
EL
ES > > > >
TY
PE
SS
M
N
M
AL
M
SS
M
AL
M
AL
M
SI
TE
(R
) 
G
RE
AT
 
TO
E
2N
D 
TO
E
(L)
 G
RE
AT
 
TO
E
(L)
 I
ND
EX
 
FI
NG
ER
(R
) 
G
RE
AT
 
TO
E
(L
)4
TH
TO
E
(R
) 
G
RE
AT
 
TO
E
SE
X h h s 2 b 2
A
G
E
00 oVO co 00 oVO VO CNVO
Ta
ble
 
10 
De
tai
ls 
of 
pa
tie
nt
s 
wi
th 
sta
ge
 
III
 s
ub
un
gu
al
 m
al
ig
na
nt
 m
el
an
om
a
73
These two patients underwent further ILP with partial response only. The mean 
hospital stay after perfusion was 9 (range 6-15) days.
There were 7 local and regional recurrences, 5 in the perfused limb and 2 in the 
regional lymph nodes. No skin recurrence was seen in the stage I patients with two 
regional node recurrences only. Seven patients developed distant metastases 
including 4 patients with stage I and 3 patients with stage DI disease. Two patients 
developed a bowel carcinoma (Duke B) and one bronchial carcinoma a year following 
diagnosis and another patient had a successful pregnancy eighteen months following 
perfusion.
Survival and disease free survival were estimated using the Kaplan-Meier method. 
Significance tests of differences among the subgroups such as those defined by sex 
and/or site were carried out by means of Log-Rank Tests or by Proportional Hazards 
Models as appropriate.
The overall 2 year and 5 year survival was 77% and 46% (Figure 26) respectively 
with a 2 and 5 year survival for stage I of 92% and 54% and for stage ID of 42% and 
21% respectively (Figure 27). The overall 2 and 5 year disease free survival was 58% 
and 51% respectively with a 2 and 5 year disease free survival for stage I of 78% and 
70% respectively. Figure 28 shows the survival by sex and site.
Log Rank Tests were carried out to assess any prognostic significance for sex, site or 
stage. Only the clinical stage was found to be significant for both survival and 
disease free survival (p value = 0.01 for survival, and p-value <0.01 for disease free 
survival). A stepwise Proportional Hazards Analysis confirmed that only the clinical 
stage significantly affected survival and neither sex nor site influenced survival 
outcome. Fourteen patients are currently alive and disease free, 1 patient is alive with 
metastatic disease and 9 patients have died of metastatic disease and 1 from bronchial 
carcinoma.
The outcome of 24 patients in this study was then compared with 111 patients with 
subungual melanomas treated with amputation only. These 111 patients formed part 
of the Scottish Melanoma Group data base which registers all malignant melanoma in 
Scotland.
First, the survival prospects for the perfused and non perfused patients were analysed 
without correcting for other prognostic variables. This was done by obtaining a 
Kaplan-Meier survival probability of each groups separately and then carrying out a 
Log Rank Test to see if there was any difference in survival between them. This
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analysis gave a p value of 0.90 which was non significant, i.e. there was no evidence 
of difference in survival between perfused and non perfused patients.
A Stepwise Porportional Hazards Analysis was then performed to investigate if there 
was a difference in survival between perfused and non perfused patients, this time 
correcting for any variables found to be significant. Again, perfusion did not make 
any difference to survival.
3.6.4 DISCUSSION
Since subungual melanoma is rare in the Western World, there are only a few 
published series in the literature. Table 11 summarises the published series. 
Subungual melanoma commonly occurs in the sixth and seventh decades and has no 
sex preponderance. It occurs with equal frequency on the hand and the foot, with the 
thumb and big toe being most commonly affected. In our series 65% (13/20) were 
found on the big toe or thumb. The majority of lesions are acral lentiginous 
melanoma but nodular, superficial spreading and lentiginous maligna melanoma can 
also occur.
There are only 3 studies of patients with subungual treated with ILP. None of the 
studies was randomised. Baaset et al253 reported in 22 patients a 5 year survival of 
56% for stage I disease and 27% for stage HI disease; there was no loco regional 
recurrence. Muchmore et al250 reported a 61% 5 year survival rate for stage I and 
17% for stage ID patients. Neither, however, were able to demonstrate a marked 
improvement in survival compared with historic patients not perfused. Although 
Vrouenraets et al257 have reported an improved survival in patients treated with ILP 
their results should be reviewed with caution as the follow up is short and the number 
of patients small.
In this series, the 5 year survival was 54% for stage I patients and 21% for stage in  
patients. These results are comparable to other studies. When these results are 
compared to the 111 patients with subungual though unmatched lesions from the 
Scottish Melanoma Group, no survival advantage was demonstrated for patients who 
were perfused.
The control of local regional disease was better in the perfused group than in the non 
perfused group with only 5 patients in the perfused group developing recurrence in 
the affected limb. Although there is no survival benefit, ILP prolongs the disease free 
interval and is effective in controlling local limb recurrence, which in many cases can
AUTHOR YEAR TREATMENT MD 5 YEAR
STAGE SURVIVAL
BASS253 1989 ILP + Amputation I 56
m 27
i& m 40
MUCHMORE250 1990 ILP + Amputation i 61
m 17
i& m 35
VROUENRAETS257 1993 ILP + Amputation i 68
m 19
i& m 54
DAS GUPTA247 1965 Amputation + RLND i 52
m 15
PACK24^ 1967 Amputation + RLND i 46
PAPACHRISTOU258 1982 Amputation + RLND i& m 53
TAKOMATSU259 1985
Amputation + RLND
i& m 40
Table 11 Published series on the treatment of subungual malignant melanoma
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pose a difficulty. None of the patients in this study needed amputation to control 
local disease.
How then should this tumour be treated? Pack and Adaur260 advocated amputation 
at the metocarpophalangeal joint and metatarsophalangeal joint, but this was later 
found to be inadequate as far as local recurrence is concerned. Most recently 
Krementz et al256 suggested that this lesion should be treated with distal phalangeal 
amputation, whilst in those with extensive involvement a ray amputation is 
recommended.
The practice in this unit is to amputate at the metatarsophalangeal joint for lesions of 
the toes and to amputate at the metacarpophalangeal joint for lesions of the thumb 
and proximal interphalangeal joint for lesions on the fingers. Ray amputation is 
reserved for cases when the lesion has not been completely excised or for local 
regional recurrence. At present, ILP for patients with subungual melanoma is not 
recommended.
The results from this unit show that there is no significant survival advantage in the 
adjuvant treatment of stage I subungual lesions in comparison to non perfused 
patients. However with the encouraging reports261 on the use of Tumour Necrosis 
Factor (TNF) and melphalan for recurrent melanoma, the use of this combined 
treatment may be justified for patients with subungual lesions. It will also be the 
practice in this unit to carry out lymphatic mapping using blue dye (see chapter 6) on 
all patients to try and select those patients with microscopic nodal disease, so that 
early nodal clearance can be offered.
3.7 CONCLUSION
At the time of writing, over 300 ILPs have been performed in Glasgow. It has been 
shown that ILP can be performed safely with minimal morbidity. There has only 
been one death within 30 days from a gastrointestinal bleed. ILP has not adversely 
affected the prognosis of patients. In the treatment of adjuvant ILP of stage I 
melanoma there is a trend towards survival advantage in the perfused group but this 
does not reach significance. Longer follow up is required to show significant 
improvement in survival.
The European Organisation for Research and Treatment of Cancer (EORTC) and the 
WHO are conducting a multicentre prospective randomised trial evaluating adjuvant 
ILP. The patient randomisation is based on patient and tumour parameters such as 
sex, age, anatomical location, Clark level, Breslow thickness and ulceration of
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tumour. Hopefully this EORTCAVHO ILP trial will add to our knowledge. As yet, it 
is not possible to exclude the possibility that a small subgroup of patients will benefit 
from adjuvant ILP.
Isolated limb perfusion is now an established treatment for recurrent malignant 
melanoma in Glasgow. An objective response is seen in more than 80% of patients 
with improved limb salvage rate. The five year survival rate is 30-70% for patients 
with local recurrence, satellitosis and in transit metastases with or without lymph 
node metastases.
Even in patients with in transit and regional metastases, five year survival is about 
35%. More recently patients are being referred for ILP at an earlier stage in their 
disease and in the next few years, it may be possible to show an improved survival.
In the small group of patients affected by subungual melanoma, treatment with ILP 
did not demonstrate survival benefits and thus it is not possible to recommend 
adjuvant ILP. This may be related to the fact that it is difficult to accurately measure 
tumour thickness resulting in underestimation of the thickness and thus affecting 
survival. Furthermore, there is often a delay in the diagnosis from the time of 
appearance of the lesion. A combination of these two factors may contribute to the 
poor survival seen. However these patients may benefit from a combined treatment 
with TNF and melphalan.
In conclusion, a small subgroup of patients with stage I melanoma may benefit from 
adjuvant ILP. In the treatment of recurrent limb melanoma, ILP is the treatment of 
choice. It is a treatment that can alter the progress of the disease and may thus 
improve the patient's survival and disease free survival.
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CHAPTER 4 
OPTIMISING THE ISOLATED LIMB PERFUSION CIRCUIT
4.1 INTRODUCTION
Given my own experience of ILP and having reviewed the published literature on the 
works of others, it was clear that many questions remained unanswered in relation to 
the current methods used in the ILP circuit. Optimising the efficacy of the circuit has 
the potential to improve the results of ILP. I therefore decided to analyse various 
aspects of the circuit in an attempt to derive objective criteria that could be applied to 
establish the efficiency of the perfusion.
When an oxygenator was incorporated into the ILP circuit, attention was focused on 
the necessity for oxygenating the blood perfusate. It was originally presumed that 
oxygenation was necessary to ensure the viability of the perfused tissues262*263*264. 
Since regional perfusion usually lasts for not more than 60 minutes, the lack of 
oxygen during this time should not be dangerous. But when hyperthermia was 
introduced and the time of the perfusion lengthened, viability of the tissues may 
become compromised.
Furthermore, it has been established that the effects of ionising radiation can be 
enhanced by increasing the tissue oxygen tension265*266*267. It has also been noted 
that many chemotherapeutic agents are thought to exert effects on the cell similar to 
that of ionising radiation268. High oxygen tension in the tissues may thus potentiate 
the tumouricidal effects of these agents. Ryan et al269 showed a response to 
chemotherapy beyond that expected by intra-arterial administration of the drug by 
isolated perfusion utilising a bubble oxygenator that raised the oxygen tension of the 
blood to 400-600 mmHg. On the dog's hind leg they showed that the toxicity of 
fluorouracil was increased by oxygenation of the perfusate.
Later, Krementz et al270 carried out a controlled experiment utilising standard 
transplantable tumours in mice to study the effect of increased tissue oxygen tension 
on the tumouricidal action of alkylating agents. They found that the tumouricidal 
effect of nitrogen mustard was enhanced by increased tissue oxygen tension.
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Based on this principle that increased oxygen tension was necessary not only for 
viability of the tissues but also improved the tumouricidal effect of the 
chemotherapeutic agent, I decided to evaluate several factors in the isolated limb 
perfusion circuit to see if the oxygen tension achieved in the circuit could be 
optimised. Clearly, only factors that could be modified or measured, were studied.
The factors examined were the time taken to achieve maximum flow rate, time to 
maximum oxygen, maximum oxygen and volume change in the reservoir.
There is usually considerable variation in the flow rates in the isolated circuit. There 
is no preset value and normally the perfusion is commenced with a low flow rate of 
50-100ml/min and is increased until a maximum stable flow rate is achieved. This 
stable level is judged to be adequate when there is no rapid change in the reservoir 
volume and the level of oxygenation is adequate with minimal fluctuation. It is not 
clear whether there is any benefit from very high flow rates but it is important that 
physiological flow rates are achieved to prevent ischaemia of normal tissues. Thus it 
is beneficial if the maximum flow rate could be achieved quickly with minimal 
fluctuation.
The reservoir volume is important in the maintenance of flow rate and tissue 
oxygenation. When there is vasodilatation or fluid loss from the circuit, there is a fall 
in the reservoir volume. This has the effect of resetting the circuit and maintaining 
stable conditions. The reservoir thus behaves as an "auto regulator" in the isolated 
limb perfusion circuit. It is obvious that a constant need to add additional fluid into 
the reservoir, indicates significant loss of the fluid from the circuit into the 
extravascular space of the isolated tissues. This can be detrimental to the tissues.
Thus maximising tissue oxygen tension is important as it will not only prevent 
ischaemia of normal tissue, but more importantly, the antitumour action of melphalan 
may be enhanced.
The chapter presents the results of the study on:
1) The introduction of pulsatile flow (never before attempted in the ILP circuit).
2) Measurement of compartment pressure (never before attempted in the ILP circuit).
3) Use of vasodilator agents (never before attempted in the ILP circuit).
79
4.2 PULSATILE VERSUS NON PULSATILE FLOW IN THE ISOLATED 
CIRCUIT
4.2.1 INTRODUCTION
Pulsatility is the most obvious feature of blood flow in the arteries.
Over one century ago Ludwig and Schmidt271 initially ascribed physiological 
significance to the pulsatile nature of blood flow. Since then several studies have 
shown that pulsatile perfusion is necessary to maintain a proper function of the 
microcirculation. Recent evidence indicates that normal capillary blood flow is 
pulsatile272. Studies of the brain273 and omental274 microcirculation during cardiac 
bypass suggest that pulsatile perfusion maintains better capillary and venule 
perfusion than non pulsatile blood flow. Pulsatile perfusion of isolated organs causes 
less damage and maintains better organ function than non pulsatile perfusion275.
The concept of an extracorporeal circulation was first described by Le Gallois276 in 
1812 and the first artificial oxygenation of blood is credited to Ludwig276 in 1869. 
The first report of an isolated organ perfusion system using a blood film spread on a 
rotation cylinder was by Frey and Grubber276 in 1885. However the pioneering work 
of Gibbon277 in the 1930's advanced cardiopulmonary bypass (CPB) from the 
laboratory into clinical reality, when in 1953 he performed the first successful cardiac 
operation. This was followed by the development of the bubble oxygenator by De 
Wall278.
By the time ILP was introduced for use in the treatment of malignant melanoma of 
the limb, CPB had become a routine procedure in many countries. At that time non 
pulsatile CPB was the method of choice. Inevitably therefore, the pioneers of ILP 
based their technique on the non pulsatile circuit. However since the introduction of 
this technique over 30 years ago, changes were seen in the CPB circuit that now 
utilises the pulsatile nature of blood flow. Attracted by the theoretical advantages of 
pulsatile flow in the ILP circuit, the author was determined to investigate whether 
such a change would confer physiological benefit.
The ILP circuit is very similar to the cardiopulmonary bypass circuit but it differs in 
certain respects. Pulsatility in the CPB circuit is created with the use of a pulsatile 
assisted device (PAD) which is inserted in the arterial line during CPB and the PAD 
is synchronised with the electrocardiogram of the patient in diastole.
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Both the CPB and the isolated circuit utilise the bubble oxygenator where oxygen is 
bubbled through the circulating blood and gas exchange occurs at a direct blood gas 
surface. In the ILP circuit, a heat exchanger is used to create hyperthermia whereas 
CPB utilises hypothermia. The pump oxygenator in the ILP circuit utilises a 
combination of blood and Hartmann's solution as the priming fluid unlike CPB that 
uses isotonic dextrose-saline solution.
4.2.2 PHYSIOLOGY OF BLOOD FLOW
The arterial system is considered as being in steady state oscillation. A wave can be 
regarded either as an isolated phenomenon or as a repetitive one. Regularity of the 
heart beat is one of its most characteristic features and this leads to a condition of 
steady state oscillation. In its simplest form, circulation consists of a pump (the 
heart) which forces blood periodically and rhythmically into a branching system of 
elastic tubes. The pulsations generated travel centrifugally but are partially reflected 
to travel backwards at points of discontinuity. The pulsations are damped by the time 
they reach the smallest branches (the capillaries) which are in intimate contact with 
the cells of the tissues.
Blood returns in a more or less steady stream to the heart with secondary pulsations 
imposed by muscular activity and by the heart itself. In reality the human circulation 
is extremely complicated. In the arterial tree allowances must be made for the varied 
geometric patterns of branching, non uniform elasticity of arteries, non linear wall 
properties and anomalous viscosity of blood in smaller blood vessels.
As blood travels away from the heart, the mean pressure falls slowly but the pulsatile 
pressure variation increases until in the femoral artery it may be double that at the 
root of the aorta. Flow oscillation, on the contrary, diminishes markedly. Such 
behaviour is due to the presence of a 'closed' type reflection in the small peripheral 
vessels. In the absence of reflections, damping would cause a parallel fall in pressure 
and flow oscillations. Ultimately pressure oscillation is damped out in the region of 
the smaller arteries.
The increase in the ratio of the pulsatile pressure amplitude to that of the flow 
amplitude is largely determined by the increase in the fluid impedance of the low 
frequency components: the change in impedance of the various frequency 
components in terms of their distance from the main reflecting sites is at a minimum 
at a quarter wavelength distance from these peripheral sites.
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The shape of the arterial pressure wave is dependent on a number of factors including 
duration of systole, mean arterial pressure, vasomotor tone, pulse wave velocity and 
wave reflections. In the abdominal aorta and the lower limb arteries, the foot of the 
wave is progressively delayed whereas the peak of the pressure wave is almost 
synchronous in time. The diastolic pressure fluctuations are reciprocal with those in 
the proximal aorta. With ageing, the pulse wave velocity increases markedly. This 
single factor accounts for the change in the arterial pressure wave constant and 
pressure wave transmission with ageing.
Diastolic flow waves are usually apparent in the thoracic and abdominal aorta and in 
the iliac and femoral arteries. The diastolic flow wave is associated with backflow in 
these vessels and is related to the diastolic pressure wave. Backflow is more apparent 
below the major branches of the abdominal aorta. Such backflow is reduced when 
these vessels are clamped and reappear when they are unclamped. In small peripheral 
arteries, there is no backflow and flow fluctuations are very small.
The major factors that determine blood flow are pressure difference and resistance to 
flow. The pressure difference (perfusion pressure) can be altered by a change in 
inflow (arterial pressure) or a change in outflow pressure (venous pressure). 
Resistance can be calculated as analogous to Ohm's Law relating to electrical 
resistance, potential difference and current. Total vascular resistance (TVR) thus can 
be calculated from the ratio:
TVR = (arterial pressure - venous pressure)
Blood Flow
4.2.3 PATIENTS AND METHODS
Forty-two patients undergoing isolated limb perfusion for malignant melanoma 
between January and June 1993 were recruited into the study. Twenty-one patients 
underwent pulsatile perfusions and 21 patients matched for site, age and type of 
perfusion received non pulsatile isolated limb perfusions. There were 36 females and 
6 males with a mean age of 61 (range 35 to 76) years. There were 32 lower limb 
perfusions and 10 upper limb perfusions.
All patients underwent isolated limb perfusion by the technique described in pages 
58-60. To create pulsatile blood flow in the circuit, a Stockert Frequency Control 
Module (Figure 29) was used. This pulsatile creating machine was employed 
externally in series with the isolated limb perfusion circuit as shown in figure 30.
Figure 29 Stockert Frequency Control Module
(courtesy of Cardiothoracic Department, Western Infirmary, Glasgow)
Pulsatile
Module
To Artery
/ From Vein
i
Heater
Thermal
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Oxygenator
Temperature
Recorder
Tourniquet
Figure 30 A diagrammatic illustration of the pulsatile ILP circuit
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The frequency created by the machine was synchronised to the electrocardiogram of 
the patient in diastole. Skin perfusion was monitored using the Radiometer TCM2 
transcutaneous monitor.
During perfusion, recordings of the time to maximum flow rates, volume shift in the 
reservoir, time taken to achieve maximum skin oxygen concentration and maximum 
oxygen achieved were made.
4.2.4 RESULTS
The results of the pulsatile and the non pulsatile data were compared in relation to:
1) Time to maximum flow.
2) Time to maximum oxygen achieved.
3) Volume shift in the reservoir.
4) Maximum oxygen achieved.
5) All the variables were then compared with relation to the effect on the limb.
Time to maximum flow.
The time to maximum flow rate was shorter in the pulsatile group than in the non 
pulsatile group. There was also less fluctuation in the flow rates in the pulsatile than 
in the non pulsatile group. There was a strong correlation between pulsatile and non 
pulsatile matched observation (0.79). This strong correlation was seen even when the 
proportional differences between the matched pulsatile and non pulsatile values were 
analysed. On average, the non pulsatile values were higher than their pulsatile 
equivalents by 8 - 41% (95% confidence intervals).
Time to maximum oxygen achieved
The time to maximum oxygen achieved was shorter in the pulsatile than in the non 
pulsatile group. There was also less fluctuation in the oxygen tension in the pulsatile 
than in the non pulsatile group. However when the correlation between the pulsatile 
and the non pulsatile values were calculated, the matching was poor (0.17). The 
correlation between the difference (pulsatile minus non pulsatile) and the raw 
measurements were then calculated and from this analysis it was clear that there was a 
dependence on the magnitude of the measurement. Accordingly the proportional 
difference between the matched pulsatile and non pulsatile values were analysed.
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Analysis of the results showed that the non pulsatile values were higher than the 
pulsatile values. These results were formally verified by producing 95% confidence 
intervals for the mean proportional difference. This showed that the non pulsatile 
values were higher than their pulsatile equivalents by 16-74%.
Volume shift in the reservoir
In the group undergoing pulsatile perfusion, less additional fluid was required to 
maintain the reservoir volume than in the non pulsatile group. There was less 
fluctuation in the pulsatile group than in the non pulsatile group. When the 
proportional differences were analysed between the matched pulsatile and the non 
pulsatile values, the non pulsatile values were higher than the matched pulsatile 
values. The 95% confidence intervals for the mean proportional differences were 3- 
75% higher in the non pulsatile group than their pulsatile equivalents.
Maximum oxygen achieved
Although the maximum oxygen level achieved in the pulsatile group appeared to be 
overall higher than in the non pulsatile group, there was no significant difference 
between the matched pulsatile and the non pulsatile values when the proportional 
differences were analysed. The 95% confidence interval was between -42 to 26% 
(not significant as it contains zero in the range, i.e. in some cases the pulsatile values 
were lower than the non pulsatile values). Table 12 shows the summary of the 
statistical analysis.
Measurements between the upper and lower limb
With respect to the time to maximum flow, time to maximum oxygen achieved and 
the volume shift in the reservoir, there was no difference between the values seen in 
the upper limb from that seen in the lower limb.
In the upper limb, the maximum oxygen level achieved in the non pulsatile group 
was greater than the pulsatile group but in the lower limb, the maximum oxygen level 
was greater in the pulsatile group than the non pulsatile group.
The above results were validated using 95% confidence intervals for the difference 
across limbs between the proportional differences of the non pulsatile versus the 
pulsatile. There was no difference between limbs for the time to maximum flow, time 
to maximum oxygen achieved and volume shift in the reservoir. However, there was 
a significant difference for maximum oxygen. On average, the pulsatile values were 
greater than the non pulsatile values in the lower limbs but pulsatile values were 
lower than non pulsatile values in the upper limb.
Correlations between Pulsatile and Non-Pulsatile matched observations.
Variable Correlation
Time to max Flow 0.79
Volume Shift -0.22
Time to Max Oxygen 0.17
Maximum Oxygen -0.11
This suggests strongly that the matching is POOR for all variables except Time to 
Max Flow.
Correlations between the DIFFERENCE (i.e. Pulsatile minus Non-Pulsatile) and 
the RAW measurements are
Variable Name Correlation with 
Pulsatile
Non-Pulsatile
Time to Max Flow 0.423 0.229
Volume Shift 0.716 0.841
Time to Max Oxygen 0.694 0.594
Maximum Oxygen 0.662 0.757
All further calculations are carried out on the Proportional differences,
i.e. Pulsatile - Non-Pulsatile 
(Pulsatile + Non-Pulsatile) /2
expressed as a Percentage 
to remove this Dependence on the Magnitude of the measurement.
Summary of Proportional Differences (i.e. Percentage means)
Variable Lower limb Upper limb Total
Time 28.3 11.6 24.3
Volume 42.5 27.4 38.9
Time to max 
oxygen
62.7 **16 0** 45.2
Max. Oxygen **28.6** 56.3 8.4
Values with ** around them denote samples where the Pulsatile group are higher 
than Non-Pulsatiles.
Table 12 Stastistical analysis of the pulsatile study
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The overall results showed that the time to maximum flow, volume shift in the 
reservoir and time to maximum oxygen level were significantly greater in the 
matched non pulsatile than the matched pulsatile values for both limbs.
4.2.5 DISCUSSION
Many of the studies showing the advantages of pulsatile flow have been based on the 
CPB circuit. There have been no studies on the effect of pulsatile blood flow in the 
isolated limb perfusion circuit. However, isolated organ perfusion has been studied 
in kidney and brain where a significant advantage of pulsatile perfusion over non 
pulsatile perfusion has been demonstrated.
The advantage of pulsatile over non pulsatile perfusion during isolated organ or 
whole body perfusion has been the subject of continuing controversy. Wesolowski et 
al279 and Selkurt et al280 found no difference in renal function with pulsatile and non 
pulsatile perfusion. Randall et al281 detected no significant difference in blood flow 
in the hind limb of dogs perfused with non pulsatile and pulsatile blood flow at equal 
blood pressures. Harken et al282 showed that oxygen consumption in the isolated 
perfusion of the hind limb of the dog was independent of the pulsatile nature of the 
perfusing blood.
On the other hand, the preponderance of data seems to point to the superiority of 
pulsatile perfusion. Parsons and McMaster283 demonstrated superior lymph flow and 
function with pulsatile perfusion. Sanderson et al284 found signs of ischaemic nerve 
cells in animals subjected to non pulsatile perfusion. These signs were not present in 
animals undergoing pulsatile perfusion.
Dalton et al285 demonstrated moderate to severe hydropic degeneration of kidney 
tubules after non pulsatile perfusion. Many et al286 found that sodium excretion and 
urine volume decreased during non pulsatile perfusion.
In studies on the whole body perfusion by Jong-Bloed287 and Thomas et al288 
pulsatile flow was found to be superior to continuous flow. Ogata et al289 and 
Nonoyama290 demonstrated increased acidosis, oedema and splanchnic pooling with 
continuous rather than pulsatile flow in dogs. Recently Dunn et al291 showed that 
pulsatile flow during CPB offers significant advantages over continuous flow. 
Oxygen consumption was higher in dogs that were perfused with pulsatile flow. This 
meant better cellular oxygenation and is reflected in the more alkalotic blood found in 
the pulsatile circuit.
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A theoretical advantage of pulsatile over non pulsatile flow has been suggested by 
Shepard292. He suggested that it is an energy gradient and not a pressure gradient 
that produces blood flow. For this purpose he defined an 'energy equivalent pressure1 
that is the pressure which represents the effect of pulsatile energy.
It has been hypothesised that the increased 'energy equivalent pressure' of pulsatile 
flow may enhance interstitial diffusion by oscillating cell-fluid boundary layers and 
thus ensuring the patency of end arterioles which may otherwise collapse during non 
pulsatile flow. This analysis predicts higher mean flow for pulsatile than for non 
pulsatile flow at equal mean arterial blood pressure.
Jacobs et al293 and Trinkle et al294 found increased oxygen consumption, improved 
tissue and acid base status and lower peripheral vascular resistance in animals 
subjected to pulsatile CPB compared to those subjected to non pulsatile perfusion.
The results of this present study confirm that there is a consistent difference between 
pulsatile and non pulsatile perfusion in the ILP circuit. Firstly, in the pulsatile 
perfusion, time to maximum flow in the circuit was significantly shorter than the non 
pulsatile perfusion with less fluctuation in the flow. This is important as there is 
steady and stable tissue oxygenation once the maximum flow rate is achieved.
Secondly, the volume shift in the reservoir was significantly greater during non 
pulsatile perfusion than during pulsatile perfusion. The blood in the reservoir 
functions to maintain a constant flow and oxygenation in the circuit. The greater 
change in the reservoir volume seen in the non pulsatile perfusion reflects an unstable 
circuit with significant loss of fluid and fluctuating oxygen levels. Since this is an 
isolated circuit, it implies that the fluid must be lost into the surrounding tissue. The 
amount of volume shift from the reservoir is important as will be seen in section 4.3.
Thirdly, the time to maximum oxygen in the circuit was significantly greater during 
non pulsatile perfusion than during pulsatile perfusion. The time to maximum 
oxygen is dependent on flow rate. The sooner the optimal flow rate is established, the 
sooner maximum tissue oxygenation is achieved, thus maximising the oxygen 
enhancing effect of the chemotherapeutic agent.
However, there was no significant difference in the overall maximum oxygen level 
eventually achieved between pulsatile and non pulsatile perfusion.
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There is no ready explanation for this result. It is possible that high flow rates in this 
study prevented the detection of a difference in the oxygen concentration between the 
two groups. The final high flow rate in both the groups may have compensated for 
any intrinsic disadvantage that occurs with the non pulsatile perfusion.
In conclusion, pulsatile perfusion in the ILP circuit improves tissue oxygenation by 
reducing the time to maximum oxygen, the time to maximum flow rate and the 
volume shift in the reservoir thereby producing a more stable circuit with minimal 
fluctuation. This effect may enhance the antitumour effect of melphalan by providing 
a constant level of tissue oxygenation. The results of this study support the other 
studies described above in that pulsatile perfusion, similar to blood flow in normal 
vessels in nature, is superior to non pulsatile perfusion. Introduction of pulsatile 
blood flow into the ILP circuit thus confers physiological advantages.
4.3 COMPARTMENT PRESSURES IN THE ISOLATED CIRCUIT
4.3.1 INTRODUCTION
Compartment syndrome is characterised by increased tissue hydrostatic pressure 
within a closed fascial space and by secondaiy compromise of skeletal muscle 
capillary perfusion with resultant ischaemia, tissue necrosis and potential systemic 
toxicity. The term compartment syndrome has also been referred to as Volkmann's 
ischaemia, muscle compartment syndrome, anterior tibial syndrome, rhabdomyolysis 
and many others. The above definition is useful because it can be employed 
whenever increased tissue pressure produces similar circulatory and functional 
effects, irrespective of the location of the process and the initiating cause.
The isolated limb perfusion circuit is a closed circuit where oxygenated blood is 
circulated under pressure. In theory, in such a closed circuit where a large amount of 
blood is being circulated in a limited space under pressure and at temperatures higher 
than normal body temperature, the possibility of increased compartment pressure 
exists. Some investigators perform routine prophylactic fasciotomy to avoid the 
complication of compartment syndrome. A study was designed to establish if there 
was a significant increase in the compartment pressure during ILP and whether 
pulsatile or non pulsatile blood flow in the circuit affected these pressures.
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4.3.2 PATHOPHYSIOLOGY OF INCREASED TISSUE PRESSURE
the tissue's metabolic need. However, when tissue pressure increases in osteofascial 
compartments, the ability to accommodate changes in the volume is limited. This 
compromises local circulation to a point where metabolic needs of the tissues are no 
longer met and functional abnormalities ensue.
The fact that increased tissue pressure compromises local circulation was 
demonstrated by Ashton295, Rorabeck and Clarke296 and other investigators297. All 
these studies indicate that pressure as low as 20mmHg applied to a limb can 
significantly reduce local blood flow. This reduction in blood flow becomes 
increasingly severe at higher pressures. However, in none of these studies was there 
evidence for a "critical pressure" above which tissue blood flow suddenly became 
compromised.
One of the most important functions of the local circulation is to deliver oxygen to 
the tissue. It has been shown in both animal and human studies that higher tissue 
pressures result in lower muscle PO2  values and muscle PO2  is significantly reduced 
by an applied pressure of 20 mm Hg298*299. Muscle PO2  values decrease essentially 
linearly as the applied pressure is increased300. No critical pressure was observed but 
greater compromise of muscle PO2  was seen at higher tissue pressures. Increased 
tissue pressure also compromises neuromuscular function298. Higher pressures and 
longer periods of pressure application produce more frequent functional losses.
There are several proposed mechanisms of pressure induced circulatory compromise. 
These include arterial spasm301*302*303, critical closure theory295*304*305 and tidal 
wave theory297. However, the theory currently accepted is the arteriovenous gradient 
theory306*307*308*309. According to this theory, increase in tissue pressure reduces 
the local arteriovenous gradient and thereby reducing local blood flow. When blood 
flow is reduced to the point where it no longer meets the metabolic demands of the 
tissue, functional abnormalities and thus the compartment syndrome results. The 
relationship between arteriovenous gradient and local blood flow is as below310:
The normal function of tissue is maintained by circulation that is sufficient to meet
LBF = 
LBF
PA -PV / R
local blood flow 
local arterial pressure 
local venous pressure 
local vascular resistance
pa
Py
R
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Because veins are collapsible, the pressure inside them cannot be less than local tissue 
pressure. Thus when tissue pressure increases, the pressure in local veins must also 
rise. This increased venous pressure results in a reduction in the arteriovenous 
gradient. Some reduction in this gradient can be compensated for by changes in the 
local vascular resistance. This process of autoregulation maintains local blood flow 
over a range of arteriovenous gradients31
When the arteriovenous gradient is significantly reduced, the process of 
autoregulation becomes relatively ineffective312. At this point, local blood flow is 
determined primarily by the local arteriovenous gradient. When the tissue pressure 
increases further, local blood flow is reduced to the point where it no longer meets the 
metabolic demands of the tissue and functional abnormalities ensue.
This theory predicts that a reduction in local arterial pressure (e.g. by limb elevation) 
will exaggerate the circulatory effect of any increase in tissue pressure. Lowering 
local venous pressure by decompressing the tissue is an effective method of restoring 
circulation if the compartment syndrome ensues. This theory also predicts the 
preservation of pulses and distal circulation frequently seen in compartment 
syndrome. What is more important is the amount of pressure the tissue can tolerate 
before its function becomes abnormal. The pressure tolerance of tissue depends on 
several factors:
i) The specific effect of increased tissue pressure on local blood flow in the tissue.
ii) The metabolic demand of the tissue.
iii) The duration of increased tissue pressure.
The specific relationship of tissue pressure and tissue blood flow is affected by the 
presence of hypertension, shock, limb elevation and arterial occlusion. The metabolic 
demands are related to the presence and severity of local tissue injury. The duration 
of increased pressure depends on the rate of onset of the compartment syndrome and 
the promptness with which it is treated. Thus the tolerance of tissue for increased 
tissue pressure varies considerably from patient to patient.
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4.3.3 AETIOLOGY AND CLINICAL FEATURES OF COMPARTMENT 
SYNDROME
There are two pre-requisites for the development of compartment syndrome:
i) an envelope limiting the available space;
ii) increased pressure within that envelope.
A limiting envelope may be any structure of limited compliance that surrounds tissue, 
e.g. in the anterior compartment of the leg, the envelope consists of fascia and bone. 
A limiting envelope may also be produced iatrogenically in the form of a tight 
external dressing or casts.
The second pre-requisite may be a decrease in the volume of the envelope (e.g. 
closure of fascial defects), an increase in the content of the envelope (e.g. bleeding, 
trauma, bums, intra-arterial drug injection), or application of pressure to the outside 
of the envelope.
The diagnosis of compartment syndrome may be made on clinical symptoms and 
signs alone. These include pain out of proportion to what is anticipated from the 
clinical situation, weakness of muscle in the compartment, pain on passive stretching 
of the muscle of the compartment, hypoaesthesia in the distribution of the nerves 
coursing through the compartment and tenseness of the compartment envelope. The 
period of risk for compartment syndrome appears to extend at least to three and 
possibly to six days after the initial cause of compartment swelling3!3.
4.3.4 MEASUREMENT OF TISSUE PRESSURE
Several methods of tissue pressure measurement have been described. These include 
the capsule method314’315, the collapsible segment method316*317, servonull 
technique318, injection technique319’320 and continuous infusion technique321*322. 
The technique that has been used in this study is the wick technique295*323*324 which 
will be described in detail.
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4.3.5 PATIENTS AND METHODS
Over a period of six months, from January 1993 to July 1993,16 patients undergoing 
isolated limb perfusion with melphalan were recruited into the study. There were 12 
females and 4 males with mean age of 62 (range 42-80) years. All patients underwent 
iliac perfusion. Eight patients underwent ILP in the pulsatile mode whilst 8 had ILP 
in the non pulsatile mode.
To measure compartment pressure a soluble braided vicryl suture of fibre diameter of 
8 to 16 micrometer and a vascular access cannula is used (Figure 31). The cannula is 
of gauge size 12, and 20 cm long. It is made of two components, a needle with a 
valve at the end to which a cap is attached and a plastic sleeve that is placed over the 
needle. The long end of the suture is passed through the cannula and this is done by 
removing the cap and threading the suture through from the back to the tip of the 
needle with the plastic sleeve in situ. The cannula with the wick in position is filled 
with heparinised saline (10 units) and calibrated to zero hydrostatic fluid pressure. 
Then the two ends of the vicryl suture are held taut (the suture is now doubled back) 
and the skin is pierced with the needle under a sterile technique.
Once the deep fascia is penetrated (approximately 2-3 cm in depth), the needle is 
withdrawn leaving the suture and plastic sleeve in place. The suture is placed in the 
anterior tibial muscle compartment. The system is then flushed with heparinised 
saline. The cannula is secured by taping it to the skin (Figure 32) after which it is 
connected to a pressure transducer and the system is filled with heparinised saline 
solution. The circuit is tested by raising the limb above the level of the heart and by 
this manoeuvre the pressure will be seen to rise and on lowering the limb, the 
pressure falls.
The wick increases the surface area in contact with the tissue. The system is 
heparinised to minimise clotting around the fibres. If patency is in question, it may 
be flushed with the flushing syringe. Continuity of the fluid column between the 
tissue and the transducer is necessary for accurate pressure measurement. The wick 
prevents tissue blockage of the orifice of the cannula and allows free exchange of 
fluid between the interstitium and the fluid filled catheter. Figure 33 is a 
diagrammatic illustration of the wick technique showing the tip of the wick catheter 
in the muscle and its connection to the pressure transducer and recorder.
Figure 31 Apparatus used in the wick technique
Figure 32 Wick in position in the lower limb
Cannula
Vicyrl Suture
Transducer
Tissue
Compartment
Tibia
Fibula
B Cross section of human leg
\
Compartment
Pressure
Recorder
Figure 3 3 Diagrammatic illustration of the wick technique
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Measurement of compartment pressure was carried out as described above. 
Recordings were made preoperatively and at 5 minute intervals during the hour of the 
perfusion. Pressures were measured in the anterior compartment of the leg. 
Continuous transcutaneous oxygen measurements, circuit flow rates and reservoir 
volumes were recorded. The transcutaneous oxygen tension in the skin was measured 
using the TCM2 System (radiometer) at several points in the limb.
4.3.6 RESULTS
The compartment pressures in patients undergoing pulsatile ILPs were compared with 
the compartment pressures in patients undergoing non pulsatile ILPs. The two 
groups were studied in relation to:
1) compartment pressure and time.
2) compartment pressure and reservoir volume.
3) compartment pressure and flow rate.
4) compartment pressure and maximum oxygen tension.
Compartment pressure with time
Analysis showed that there was an increase in the compartment pressure with time 
and this increase was quicker in the non pulsatile group (Figure 34). The strong 
positive relationship between pressure and time (pooled correlation of 0.97) for both 
groups were confirmed in formal analysis using an F-test. Although the two groups 
appeared to start at the same average value (i.e. there were no significant differences 
in the intercepts, p = 0.65), there was a significant difference in the rate of increase of 
pressure with time, i.e. significant difference in the slopes between the pulsatile and 
non pulsatile group p < 0.001.
The general rate of increase of pressure with time was 0.242 mmHg per minute in the 
non pulsatile group whereas it was only 0.106 mmHg per minute in the pulsatile 
group (i.e. the rate of increase was effectively at least doubled in the non pulsatile 
group).
Compartment pressure and reservoir
When the reservoir volume was analysed with respect to compartment pressure 
(Figure 35), in both the pulsatile and the non pulsatile groups, a negative relationship 
was seen. A formal analysis based on estimating individual correlation for each 
subject was carried out and then pooled across subjects' first within their own group 
and then across both groups together.
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The overall estimated correlation was -0.85 with the individual correlation ranging 
from -0.99 to +0.05. Overall there was evidence of a fairly strong negative 
relationship between volume and pressure in general across individuals, i.e. for most 
individuals, as the compartment pressure increased, the volume in the reservoir 
decreased.
Compartment pressure with flow rate
The relationship between flow rate and compartment pressure was also studied 
(Figure 36). A positive relationship was seen between flow and pressure in both the 
pulsatile and the non pulsatile groups. The spread of both variables was greater for 
the non pulsatile group but the correlation was in general very similar (pooled 
correlation of 0.94 and 0.95 respectively for the two groups).
Compartment pressure and oxygen
When the relationship between oxygen and compartment pressure (Figure 37) was 
analysed, the pooled correlation for the pulsatile group was 0.24 and 0.52 for the non 
pulsatile group. When the F-Test was applied, there was a significant difference (p < 
0.005) between the pulsatile and the non pulsatile group suggesting that there was a 
moderately stronger relationship between oxygen and compartment pressure for the 
non pulsatile group when compared to the pulsatile group.
In summary, there was a significant rise in the compartment pressure with time and 
the rate of rise was at least twice that in the non pulsatile group than in the pulsatile 
group. As the compartment pressure rose, there was a significant fall in the reservoir 
volume along with a significant increase in the flow rate in both the pulsatile and the 
non pulsatile group. There was also a significant decrease in the tissue oxygen 
tension with the decrease being more significant in the non pulsatile group when 
compared to the pulsatile group.
4.3.7 DISCUSSION
The wick technique employed in this study for the measurement of compartment 
pressure has several advantages. The wick allows a relatively large volume of tissue 
fluid to permeate and permits transmission of interstitial fluid pressure into the fluid 
filled catheter. The wick keeps the orifice open and no artefact of injected fluid exists 
around the end of the catheter. The wick is completely permeable allowing even the 
passage of red blood cells324. The wick cannot act as an osmometer, and is an ideal 
means of measuring hydrostatic pressure in the muscle. The wick technique is easy 
to master, inexpensive and its component parts are readily available in most hospitals.
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The results of this study show that there is a significant increase in the compartment 
pressure in the ILP circuit with time in both the pulsatile and the non pulsatile group. 
The oxygen levels also drop inversely to the compartment pressure and the fall is 
significantly greater in the non pulsatile group. This is not suprising as the rate of 
increase of the compartment pressure is greater in the non pulsatile group and is at 
least double that of the pulsatile group.
The flow rate rises with the rise in the compartment pressures. But the opposite 
relationship is seen between the reservoir volume and the compartment pressure i.e. 
as the compartment pressure increases, the reservoir volume decreases.
These observed results are perhaps not suprising. As flow is increased in the 
perfusion circuit to achieve high oxygen levels, the compartment pressure also rises 
because as flow rates increase, an increased fluid volume is being perfused in a closed 
compartment causing an inevitable increase in the pressure in a fixed volume 
compartment. This resultant increase in compartment pressure alters the balance 
between the venous pressure and interstitial pressure, resulting in fluid being pushed 
into the interstitial space.
This loss of fluid from the circuit is seen as a decrease in the reservoir volume as fluid 
from the reservoir is pumped into the circuit to maintain the flow rate necessary to 
prevent fall in tissue oxygenation. Initially the rise in the compartment pressure does 
not affect the oxygen saturation achieved, but with time, as the flow rate increases and 
the volume loss into the interstitial space increases, compartment pressure rises 
significantly compromising local circulation and oxygen delivery.
These observations are in keeping with the arteriovenous gradient theory. As the local 
tissue pressure rises, the local venous pressure also rises causing a resultant decrease 
in the arteriovenous gradient. When this happens, the local blood flow is 
compromised and tissue oxygenation is affected. Thus at higher compartment 
pressures, it is not surprising to find that the oxygen level decreases.
Furthermore, in this study there was a highly significant difference in the time to 
maximum oxygen with the non pulsatile group taking on average 2 to 7 minutes 
longer. This reinforces the finding of the first study of the advantage of pulsatile 
blood flow over non pulsatile blood flow.
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The maximum compartment pressure did not rise above 20 mmHg in both groups of 
patients. Compartment syndrome is normally seen when pressures exceed 20 mmHg. 
Only one patient undergoing non pulsatile perfusion developed postoperative 
compartment syndrome and this was due to arterial occlusion secondary to an 
artheromatous plaque that was dislodged during the surgery.
Heppenstall et al325 compared tolerance of skeletal muscle to tourniquet application 
(ischaemia) with acute compartment syndrome (ischaemia and pressure). They 
showed that during ischaemia cellular levels of phosphocreatinine decreased at an 
identical rate in both groups. In contrast, the level of adenosine triphosphate 
diminished rapidly in animals with the compartment syndrome but remained 
unchanged in the tourniquet group.
Elevated tissue pressure appears to act synergistically with ischaemia to produce more 
severe cellular deterioration than ischaemia alone. This study of the ILP circuit 
reinforces the fact that even though ischaemia is important, increasing tissue pressure 
in a fixed volume space such as in the ILP circuit can compromise the local 
circulation.
For many years the ILP circuit operated under normothermia. When Cavaliere et 
al210 reported biochemical and clinical studies showing selective sensitivity of cancer 
cells to heat, hyperthermia then became the "norm" for ILP. Although these changes 
brought about improved results, a greater number of complications were seen 
including injuries to nerves. Schraffordt Koops326 observed these complications and 
on the basis of his experience, he recommended routine prophylactic fasciotomy to 
prevent loss of function on the perfused limb.
Fasciotomy is currently the only treatment available for the treatment of compartment 
syndrome. Fasciotomy facilitates micro vascular circulation327 but in the 
fasciotomised muscle, mitochondria are unable to resynthesise phosphocreatinine due 
to either intrinsic metabolic alteration or limited oxygen available325. Although 
fasciotomy may be effective, it is an imperfect treatment with associated morbidity.
This study has shown that there is a significant rise in the compartment pressure with 
time in the current ILP circuit where blood flow is non pulsatile. The rate of rise of 
the compartment pressure is at least twice in the ILP circuit operated in the non 
pulsatile mode as in the pulsatile mode. Introducing pulsatile perfusion into the ILP 
circuit may be an effective alternative to performing prophylactic fasciotomy and its 
attendant morbidity. As a result of this study, pulsatile perfusion has been introduced
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into the ILP circuit and to date there has been no necessity to perform fasciotomy 
either prophylactically or therapeutically.
4.4 EFFECT OF VASODILATORS IN THE ISOLATED CIRCUIT
4.4.1 INTRODUCTION
There have been several reports of vasoactive drugs significantly affecting the nature 
of blood flow in experimental rodent and human tumours328’329’330. It is 
theoretically possible that in the isolated limb perfusion circuit, the use of such drugs 
may be beneficial. By decreasing the blood pressure and the peripheral arterial 
resistance, these drugs can be used to enhance blood flow with the resultant effect of 
increased tissue oxygenation at lower flow rates. It has already been shown in the 
previous section that high flow rates predispose to higher compartment pressures and 
ultimately lower oxygen levels.
These vasodilators could also have potential benefits in certain patients in whom a 
significant transcutaneous oxygen level cannot be achieved by the current techniques 
employed. Furthermore, as effective concentration of melphalan is dependent on the 
volume of perfusate, a lower flow rate is more favourable as the concentration of the 
drug can be increased with higher tissue concentration of melphalan being achieved.
The aim of this study was to investigate if vasodilators could be used to advantage in 
following situations:
1) To increase the transcutaneous oxygen tension in patients whom a sufficiently high 
transcutaneous oxygen cannot be achieved.
2) The disadvantages of high flow rates are overcome by the ability to lower flow rate 
while maintaining a similar level of oxygenation.
4.4.2 PHARMACOLOGY OF VASODILATORS
Verapamil hydrochloride is a calcium channel blocker and is classified as a Class IV 
anti-arrhythmic agent. A calcium channel blocker acts by inhibiting the inward 
movement of calcium in the smooth muscle cells of the systemic and coronary 
arteries and in the cells of cardiac muscle and the intracardiac conduction system. It 
lowers peripheral vascular resistance with little or no reflex tachycardia. Its efficacy 
in reducing both raised systolic and diastolic blood pressure is thought to be primarily 
due to this mode of action.
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When verapamil is given intravenously, a dose of 5 to 10 milligrams is injected over 
a period of 30 seconds and if necessary a further 5 milligrams may be injected 5 to 10 
minutes after the first.
4.4.3 PATIENTS AND METHODS
Twenty-one patients who were undergoing isolated limb perfusion for malignant 
melanoma of the lower and upper limb during the period January 1993 to August 
1993 were recruited. There were 13 women and 8 men with a mean age of 60 (range 
50-77) years. They underwent isolated limb perfusion as described in chapter 3. 
Sixteen patients had ILP carried out in the non pulsatile mode whilst 5 patients had 
ILP in the pulsatile mode. There were 15 iliac perfusions, 4 axillary perfusions and 2 
popliteal perfusions.
Once the circuit had been stabilised, 10 milligrams of verapamil was given intra- 
arterially into the arterial line of the circuit over 30 seconds. Perioperative and 
intraoperative recordings of dorsalis pedis/radial artery pressures and transcutaneous 
oxygen tensions were made at five minute intervals. Transcutaneous oxygen was 
measured using the Radiometer TCM2 System transcutaneous oxygen meter and 
dorsalis pedis/radial artery pressures were measured by using an intra-arterial cannula 
that was connected to a transducer and a recorder. The transducer used in this study 
was a complete pressure monitoring kit directly attached to the intra-arterial line. For 
safety reasons, the transducer was used only once and disposed.
4.4.4 RESULTS
The results were analysed with respect to the following parameters:
1) Peripheral arterial pressure with time.
2) Transcutaneous oxygen with time.
3) Flow rate with time.
4) Flow rate with oxygen.
Peripheral arterial pressure with time
Following injection of the vasodilator, there was a fall in dorsalis pedis and radial 
artery pressures and a steady state was reached on average after five minutes (Figure 
38). When the pressure with time was formally analysed, there was an overall 
negative relationship between pressure and time with pooled correlations of -0.42 and 
-0.37 respectively for the pulsatile and non pulsatile groups.
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Since the fall in pressure with time occurred within the first five minutes, the change 
in pressure from 0 to 5 minutes was then analysed using the paired sample t-test. 
This test showed that in both the pulsatile and the non pulsatile group, there was a 
significant but equal decrease in pressure from 0 to 5 minutes.
Transcutaneous oxygen with time
Following injection of verapamil, (Figure 39), there was a fall in the oxygen level 
with time with a steady state reached on average between 5 and 10 minutes. When 
the relationship between transcutaneous oxygen tension and time was formally 
analysed, there was a negative relationship between oxygen and time with pooled 
correlations of -0.73 and -0.59 respectively for the pulsatile and non pulsatile groups.
Flow rate with time
When the flow rate was plotted against time (Figure 40), an increase with time was 
seen. When the relationship between flow rate and time was formally analysed, there 
was a strong but fairly constant positive relationship between flow and time with 
pooled correlations of 0.95 for both the pulsatile and non pulsatile groups.
Flow rate with oxygen
When the relationship between flow and oxygen was analysed, there was a moderate 
negative correlation between flow and oxygen with pooled correlations of -0.68 and - 
0.67 respectively for the pulsatile and the non pulsatile groups.
4.4.5 DISCUSSION
Changes in the blood flow in and around tumour masses can significantly alter the 
effectiveness of chemotherapy, radiotherapy and thermotherapy. The distribution of 
anticancer drugs to the tumour is influenced by blood flow to the tumour as compared 
with blood flow to other tissues331. This is because there are selective structural and 
functional abnormalities of tumour vasculature in relation to the surrounding normal 
vasculature that could provide a potential target for selective cancer therapy.
The destruction of tumour cells in the ILP circuit is temperature dependent. Heat 
dissipation during local hyperthermia treatment depends largely on blood circulation 
and a relatively low perfusion of tumour tissue is essential for selective heating of 
tumour masses332. Vasoactive drugs could be used to increase blood cooling of 
normal tissues thus allowing greater overall temperature rise in the tumour. This is 
because tumours are nourished by sinusoidal capillary beds that have poorly 
developed smooth muscle wall333 and thus will show little response to vasoactive
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agent acting on smooth muscle whilst the normal capillaries of the surrounding 
tissues will respond to these agents. Thus vasoactive agents could be used to achieve 
differential blood flow between the tumour and normal tissue.
The aim of this study was to assess whether a vasoactive agent could be used to 
reduce the peripheral resistance thus improving local blood flow with resultant 
increase in transcutaneous oxygen levels. This study demonstrated the expected fall 
in arterial pressure and increase in the flow rates in the perfused limbs following 
injection of the vasodilator. However, the expected increase in the transcutaneous 
oxygen level was not seen. Instead, a significant fall in the transcutaneous oxygen 
level resulted.
From our results, we found that the use of vasodilators to increase inflow and 
possibly oxygen in the tumour circulation in situations of high flow rates, high 
pressure states and low transcutaneous oxygen still remains a theory. Although 
verapamil did reduce peripheral resistance and arterial pressure, this was not 
associated with an increase in transcutaneous oxygen levels. This was reflected in the 
negative correlation seen between flow and oxygen.
Robinson334 and associates studied the effect of verapamil and alcohol on blood 
flow, melphalan uptake and cytotoxicity in murine fibrosarcoma and human 
melanoma xenograft. They showed that in subcutaneous human melanoma 
xenograft, verapamil had no effect on the fractional distribution of cardiac output, nor 
on melphalan uptake and did not effect blood melphalan levels, suggesting absence of 
effects on the cytotoxicity and cellular uptake.
Although in theory there may be several advantages in using a vasodilator, in practice 
it may be a disadvantage because if the tumour resistance remains constant, the fall in 
arterial blood pressure, as demonstrated in this study, will cause a drop in the tumour 
blood flow and this may ultimately effect the uptake of melphalan.
From this study, it can be concluded that the use of verapamil confers no advantage 
with respect to the transcutaneous oxygen levels necessary for enhancing the 
antitumour action of melphalan. Verapamil may reduce tumour blood flow and 
uptake of melphalan in the isolated circuit.
However there may still be a place for vasodilators in hyperthermia treatment. They 
may help by acting on smooth muscle in the capillaries of the normal tissues thereby 
increasing blood flow and causing cooling of the normal tissue without affecting the 
vasculature of the tumour with overall greater input and temperature rise in the
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tumour cells, optimising the cytotoxic effect of the treatment and reducing the effect 
of hyperthermia in normal tissues335.
4.5 CONCLUSION
The effectiveness of ILP with melphalan is dependent on several factors.
When pulsatile blood flow was introduced into the ILP circuit, the time to maximum 
flow and the time to maximum oxygen was significantly shorter. There was also 
significantly less volume shift in the reservoir, indicating less "leak" from the circuit. 
Since the ILP circuit is a closed system, the fluid that leaked could increase the 
volume in a fixed compartment producing detrimental effects on the local blood flow 
and possibly tissue oxygenation. The next study was to see how this effected the 
compartment pressure and tissue oxygenation.
Compartment pressure in the ILP circuit was found to increase with time. The rate of 
increase was double in the non pulsatile perfusion. The rate of rise of the 
compartment pressure was directly related to the volume shift in the reservoir. With 
the increase in the compartment pressure, there was a significant fall in the 
transcutaneous oxygen level with the fall being greater in the non pulsatile blood flow 
mode.
From the first two studies it was clear that pulsatile blood flow in the ILP circuit, had 
definite advantages over non pulsatile blood flow. The next step was to determine if 
the high pressures and flow rates in the isolated circuit could be reduced with the use 
of vasodilators. There were also patients in whom tissue oxygenation continued to be 
low despite high flow rates. Several published studies had shown that tumour blood 
flow could be increased with the use of vasoactive agents.
However, in the third study, it was not possible to show that verapamil could be used 
to increase tissue oxygenation despite a significant decrease in arterial pressure and 
increase in flow rates.
In conclusion, introduction of pulsatile blood flow into the ILP circuit is a simple and 
safe modification that has significant physiological advantages over non pulsatile 
blood flow in the current CLP circuit. It also reduces the risk of developing 
compartment syndrome and is an effective alternative to carrying out routine 
prophylactic fasciotomy.
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CHAPTER 5
CLINICAL EXPERIENCE OF CARBON DIOXIDE LASER ABLATION 
AS AN ALTERNATIVE TREATMENT FOR CUTANEOUS 
METASTASES FROM MALIGNANT MELANOMA
5.1 INTRODUCTION
Metastatic melanoma has a remarkably variable clinical course. There is a diverse 
pattern of metastatic spread via lymphatic and haematogenous routes. Metastases to 
skin and subcutaneous tissues are often the first sign of haematogenous spread. Local 
recurrence implies a poor prognosis and is often the first sign of metastatic 
disease146-148. Although the overall outlook for patients with local recurrence is 
poor, the probability of long term control exists.
Several studies have shown that isolated limb perfusion is the optimal treatment when 
local recurrence develops on the extremities. Twenty-five to fifty percent of patients 
treated with this therapy are alive 5 years later. In Glasgow, for patients presenting 
with local recurrence of the extremities, the treatment of choice is isolated limb 
perfusion. This form of treatment can modify the already aggressive nature of the 
disease and improve the survival and disease free survival in these patients.
Ideally all patients with local recurrence confined to the extremities should be 
considered for isolated limb perfusion treatment with melphalan. However not all 
patients respond to isolated hmb perfusion or are suitable for this treatment. Even if 
long term cure in these cases is not possible, the opportunity for palliation is 
considerable, since subsequent regional recurrence can be disabling.
Skin and subcutaneous metastases are generally 0.5cm to 2.0cm in diameter and are 
readily detectable on examination. Metastases can be single or multiple and can 
occur anywhere on the body. The choice of treatment is influenced by the number, 
anatomical location, size and distribution of the cutaneous metastases and by the 
presence of disease at other sites. Aggressive local therapy is the most effective 
means of achieving regional disease control151. The treatment options available are 
surgery, chemotherapy, radiotherapy, immunotherapy and cryotherapy.
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Surgery is feasible only when a few cutaneous metastases are present. Regional 
chemotherapy, radiotherapy and systemic chemotherapy have limited success in 
controlling local disease336. Cryotherapy has been used successfully for treating 
intradermal metastases but no studies have been carried out to assess the efficacy of 
the treatment.
In patients with a poor prognosis in whom ILP is not suitable or has failed, the use of 
carbon dioxide laser treatment might offer control of local recurrence. The present 
study was designed to assess the efficacy of the carbon dioxide laser treatment as an 
alternative to ILP in the control of the local recurrence of melanoma on the 
extremities.
The aim of treatment in this group of patients is not to cure, but to produce relief of 
symptoms and local control of disease with minimal disruption to the patient's life.
5.2 PHYSICS OF LASER
5.2.1 GENERAL PRINCIPLES
Atoms and molecules can only exist in certain strictly defined energy levels. The 
transition and resultant photon energies are therefore strictly defined. Einstein 
showed that the relaxation of an excited atom to release a photon could happen not 
only spontaneously but also as a result of interaction with another photon of the 
correct energy. The incident photon remains unchanged and the newly emitted 
photon is identical to the incident photon with respect to wavelength, phase, 
polarisation and direction of propagation. This process is called 'stimulated emission' 
and is the principle upon which the laser action is based.
Nikolai Basov, Alexander Prokhorov and Charles Townes realised that a photon 
emitted by an excited atom could, by initiating a chain of repeated interactions with 
other excited atoms of the same species, stimulate the emission of numerous other 
identical photons. Thus the intensity or flux of the electromagnetic wave associated 
with the original photon would be amplified.
To achieve this, more atoms in the upper level high energy state than in the lower 
level low energy state are needed, otherwise photons would tend to be absorbed by 
the lower level rather than stimulate emission of further photons from the upper level.
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This 'population inversion1 could not be easily obtained but this difficulty was 
overcome by Townes, who constructed the first MASER, the acronym for Microwave 
Amplification by Stimulated Emission of Radiation. The first LASER, acronym for 
Light Amplification by Stimulated Emission of Radiation, was constructed by 
Theodore Mainman in 1960.
5.2.2 PROPERTIES OF LASER LIGHT
1) Divergence of a laser beam is very small. The full power of the laser beam can 
therefore be focused onto a very small spot.
2) Due to the high collimation of a laser beam, the power per unit cross-sectional 
(irradiance) area of the beam is very high and remains so to great distances. Again, 
due to low divergence the laser can be focused onto a very small spot to produce still 
greater irradiance.
3) Laser light is monochromatic. The output of a laser, therefore, is a beam of light 
the entire output power of which is centred on one wavelength.
5.2.3 INTERACTION OF LASER LIGHT WITH TISSUE
Laser-tissue interactions are thermal. There are three types of laser currently used for 
their thermal effects. They are the carbon dioxide (CO2 ) laser, the neodymium 
yttrium aluminium garnet (Nd YAG) laser and the argon laser. The absorption 
characteristics of these lasers vary enormously due to the differing wavelengths. The 
CO2  laser beam is strongly absorbed in water whereas the other two lasers are 
absorbed more in pigmented cells.
Initially, heating of soft tissue causes thermal contraction, higher energies kill the 
cells and ultimately vaporise cellular material leaving a crater. Since the CO2  laser is 
very strongly absorbed by water, it causes explosive vaporisation of intracellular 
water and this phenomenon forms the basis of the use of CO2  laser as a tissue cutter 
or laser 'scalpel'.
The effect of laser on tissue can be maximised if the light energy is delivered using a 
pulsed laser in which the duration of the pulses is shorter than the time it takes for 
heat to diffuse out of the capillaries and the surrounding dermis.
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5.2.4 ADVANTAGES OF CO2 LASER
The CO2  laser generates electromagnetic radiation at a wavelength of 10.6pm. The 
laser medium of CO2  laser is a mixture of carbon dioxide, nitrogen and helium gas. 
Because of the affinity of water for mid-infrared radiation such as generated by the 
CO2  laser, this laser displays unique surgical properties3 3 7 -3 4
a) Diseased tissue volumes can be vaporised under precise visual control.
b) There need be little or no mechanical contact with the intended target.
c) Heat propagation to adjacent tissue can be minimal.
d) Micro-organisms at the site of treatment are automatically destroyed.
e) Vessels smaller than 0.5mm will be thermally sealed.
5.2.5 PRINCIPLES OF USING CO2 LASER
1) Choice of Appropriate Wavelength.
This parameter defines both type of interaction and volume of tissues that will be 
denatured. CO2  laser is an ideal choice for vaporising sharply localised tissue 
volumes to a shallow depth.
2) Rapid Delivery of the Required Energy Dose.
It is important to realise that a given amount of energy will denature the same mass of 
tissue, regardless of the rate of energy delivery. But different rates of energy delivery 
produce different surgical effects. Since lateral heat propagation to adjacent tissues 
depends on exposure, slow rates will produce conduction bums. Thus when using 
CO2  laser, the surgeon must learn to use high power outputs342.
3) Choice of the Best Temporal Mode.
Thermal spread can be decreased by selecting a superpulse mode at the expense of 
reduced average power to about one third of the output attainable in the continuous 
mode. A compromise between the high precision of rapid superpulse and the higher 
power of the continuous mode is obtained from the chopped mode which preserves 
most of the power output at the expense of allowing more lateral heat conduction.
4) Selection of an Appropriate Power Density.
Power density is defined as the number of watts used for a given spot size. This is 
expressed as watts/cm?
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The number of watts used is controlled by the power output of the laser to the desired 
level. The area of the spot size is equal to pi times the radius of the spot size squared. 
Laser energy can be focused through lenses of different focal lengths. The greater the 
focal length the larger the spot size. Larger spot sizes are produced by defocusing the 
laser beam or increasing the distance from the focal point to the tissue.
5) Adjusting Beam Geometry to Produce a Crater of an Appropriate Shape.
The crater shape mirrors the intensity profile of the incident energy and thus the 
geometry of the beam is important. Sharply focused beams have narrow spot 
diameters and high amplitudes, producing impact craters like drill holes. Enlarging 
spot diameter by partially defocusing the beam will reduce the central amplitude, 
thereby "flattening" the geometric shape of the intensity profile343. Incisions are best 
made with a tightly focused beam geometry whilst surface ablation should be done at 
a point of partial defocus. Fully defocused beams cause extensive char with 
negligible penetration and therefore have no surgical applications.
5.2.6 SURGICAL PRINCIPLES OF CONTROL OF CO2  LASER
a) Choice of an Appropriate Beam Delivery System.
- See above.
b) Minimising Thermal Damage by Tissue Cooling.
Chilling the tissues with iced saline has been shown to diminish postoperative pain 
and swelling and contributes to a two thirds reduction in healing time344. Tissue 
should be chilled prior to initial laser treatment and at frequent intervals during the 
operation with reapplication of iced saline immediately following laser irradiation.
c) Control of Intraoperative Bleeding.
This problem can be overcome by using vasoconstrictor injections. Most bleeding 
arises when the laser punches a hole in the side of a small vessel. Resealing the 
bleeding point with a high powered beam for 2 to 3 seconds will secure haemostasis 
by transecting the perforated arteriole and sealing the cut ends345.
d) Good exposure and a perpendicular beam impact.
e) Accurate delineation of the treatment margins.
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The laser used in this study was the Sharplan 1030 CO2  laser with 80 watts 
maximum output (Figure 41). It generates a wavelength of 10.6pm and 98% of the 
incident energy is absorbed within 0.01mm of tissue338. The CO2  laser causes 
heating of cellular water and subsequent vaporisation. Thermal transmission to 
adjacent tissue is minimal and extends to no more than 0.3-0.5mm from the laser 
impact site340’345. Since the CO2  laser beam wavelength is in the invisible range of 
the spectrum, a visible helium-neon beam is incorporated.
The CO2  laser is focused through a manoeuvrable handpiece containing the lens 
which is used for freehand laser surgery. This handpiece has a focal point guide tip 
and when the handpiece is drawn away from the tissue in the defocus mode, the spot 
size will increase. The surgeon controls the power density by controlling the watts 
and spot size
5.3 PATIENTS AND METHODS
Between September 1992 and March 1994, fourteen patients (ten females and four 
males) with median age of 69 ( range 45-94) years with cutaneous metastases from 
malignant melanoma which were too numerous or too large for local surgical 
excision, were recruited for laser ablation. All patients except two had had isolated 
limb perfusion in the past. Eight patients had previously had one ILP, three patients 
had two ILP and one patient had three ILP.
There was no clinical or radiological evidence of liver or lung metastases at the time 
of treatment. The number of lesions per patient ranged from three to forty nodules. 
There were both cutaneous and subcutaneous nodules with the diameter of the largest 
lesion being not more than two centimetres. In thirteen patients, the lesions were 
situated on the lower limb and in one patient, on the forearm.
All the treatments were carried out under general anaesthesia though local anaesthesia 
is sometimes practical. Since most of the patients were elderly or lived a great 
distance away, they stayed in hospital overnight.
The area of treatment was first injected with a vasoconstrictor agent (adrenaline) to 
reduce bleeding prior to treatment. The area to be treated was then washed with 
betadine. Before treatment, the tissue was cooled with laparotomy packs soaked in a 
bowl of semifrozen saline slush to minimise thermal damage344.
Figure 41 Sharplan 1030 Carbon D ioxide Laser
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The operator and theatre personnel followed the laser code regulations issued by the 
Department of Clinical Physics and Bioengineering, University of Glasgow and this 
included the use of protective eye glasses and face masks. Once the appropriate 
precautions were taken, laser treatment was commenced.
The depth and diameter of the excision was variable and dependent on the size and 
the type of lesion. In small cutaneous lesions, a smaller spot size beam with a smaller 
output was used which resulted in a superficial bum with a shallow crater. In large 
subcutaneous lesions, a larger spot size beam was required at a higher energy output 
to completely ablate the lesion and in these cases, the depth of excision was greater 
and a full thickness bum resulted.
Ablation of the lesion was considered complete when a circumference of healthy 
tissue was seen. The tissues were also chilled at frequent intervals during the 
operation. Once all the lesions were treated, the area was then dressed with sofratulle 
and a dry gauze applied over.
Each lesion was ablated with a focus laser beam of spot size between 0.5 and 1.0 mm 
with an output between 10 to 20 watts in the continuous mode. The plume generated 
was removed by a smoke evacuator. Figure 42 shows a lesion being ablated. Figure 
43 shows the appearance of the treated lesion in figure 42 as well as showing another 
lesion being treated.
5.4 RESULTS
The average time per treatment was 10-15 minutes and all the lesions were treated in 
one session. Since most of the lesions involved the full thickness of the skin, the 
resultant defects were multiple full thickness punctuate bums. Figure 44 shows a 
typical subcutaneous nodule and figure 45 shows the same nodule following laser 
treatment. Note that the treated lesion shows minimal bleeding with healthy 
surrounding tissue. Since the maximum diameter of lesions treated were not more 
than two centimetres, the wounds were small and healed without grafting.
Postoperative pain and bleeding were minimal or absent. Figure 46 shows the 
appearance of treated recurrences on day 1 postoperatively, the same lesions one week 
postoperatively (Figure 47) and six weeks postoperatively (Figure 48). Patients were 
reviewed at regular intervals postoperatively.
Figure 42 Laser ablation o f  a subcutaneous lesion
Figure 43 Appearance o f  the treated lesion from the figure above and laser 
treatment o f  the other recurrent nodules
Figure 44 Typical subcutaneous nodule prior to laser treatment
&
Figure 45 The same lesion immediately after laser ablation
Figure 46 Appearance o f  the laser treated lesions on day 1 post-operatively
Figure 47 The same lesions at one week following laser treatment
Figure 48 The same lesions at 6 weeks following laser treatment
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At the end of six weeks, all the wounds were healing with acceptable cosmetic results. 
At three months follow up, only one patient had a recurrence at the treated site. This 
could be explained by the fact that this was the first patient to be treated and reflected 
the learning curve of the surgeon which probably resulted in failure to ablate the 
lesion fully. Median follow up of twelve months showed the incidence of recurrence 
at the treated site to be minimal. If new lesions developed, they were treated with 
further laser treatment. In total 27 treatments were required in the first fifteen months 
for the 14 patients.
Five patients died at a median follow up of 9 months from their first laser treatment; 3 
were free of limb recurrences while 2 had recurrences at the time of death. Of the 9 
patients who are alive, 4 have had no recurrences following the first treatment and 5 
patients have required further treatments. In these five patients, 2 required two further 
treatments and 3 required three further treatments each. Six patients who at the first 
treatment had disease confined to the limb have since developed distant metastases.
5.5 DISCUSSION
Carbon dioxide laser ablation of cutaneous metastases of melanoma is an effective 
and safe alternative treatment to those currently used to control locally recurring 
disease. Since the aim of treatment is not to cure, the important consideration is that 
it can be carried out under local anaesthesia if necessary without much disruption to 
the patient's life. If these lesions are untreated they will enlarge, ulcerate and become 
painful.
The carbon dioxide laser with its high power density successfully ablates the lesions 
with minimal dissipation of heat to surrounding normal tissue and produces good 
healing. The use of a vasoconstrictor agent reduces intraoperative bleeding. It is 
important to apply iced packs following the laser treatment because cooling 
antagonises the continuing tissue damage by the vasoactive peptides released at the 
time of thermal injury. This has been shown to greatly diminish postoperative pain 
and swelling and also contribute to reduced healing time344.
The CC>2 laser is a more precise method compared to diathermy and cryosurgery as it 
can accurately delineate the area of treatment without having to include normal tissue 
to ensure tumour destruction as occurs when using diathermy or cryosurgery. It is 
also a treatment that is simple to master.
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The results of this study suggest that carbon dioxide laser treatment of cutaneous 
metastases should be considered as a serious alternative to the current modes of 
treatment available when ILP has failed or local surgical excision is not possible. 
Carbon dioxide laser has been shown to be effective in the control of local disease. 
Although some patients required several repeat laser sessions to control the disease, 
none required any other treatment. To date no patient has had to have an amputation 
to control the disease.
Carbon dioxide laser treatment has the advantage that it can be repeated several times 
without the high morbidity associated with isolated limb perfusion. It is however 
important to appreciate that laser treatment is not suitable for all patients particularly 
those with deep subcutaneous lesions, ulcerated lesions and lesions larger than 2  cm.
The treatment has very little morbidity and could be easily be carried out as a day 
case if necessary under local regional anaesthesia. Furthermore, with the lesions 
being infiltrated with a combination of lignocaine and adrenaline, there is very little 
postoperative pain or bleeding.
Following laser therapy, the time to recurrence may be short. This is not surprising as 
local recurrence is an indication of poor prognosis and locally aggressive disease. A 
single patient may need several treatments to control the disease. As seen in this 
study, almost half the number of patients developed distant metastases and 5 died, 
reinforcing the fact that prognosis is poor and cutaneous disease is a manifestation of 
almost inevitable distant metastases and eventual death.
Since cutaneous metastases from malignant melanoma is often the first stage of 
inevitable progression to widespread systemic disease, it could be argued that 
subjecting patients to ILP which is associated with moderate to high morbidity, a 
small but significant mortality may not be justified. There is a small (and difficult to 
define) percentage of patients, who develop cutaneous metastases but never go on to 
develop further disease and ILP treatment in this group may be difficult to justify.
In the light of this study and those of Waters and Clemens3 4 6  and Hill and 
Thomas347, a prospective randomised study is needed to compare isolated limb 
perfusion with carbon dioxide laser ablation in patients suitable for isolated limb 
perfusion with no other distant metastases.
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In Glasgow, ILP is the treatment of choice for lesions confined to the limb. It not 
only deals with cutaneous recurrence but in a significant percentage of patients has 
been shown to provide long term control by eradicating local disease. By modifying 
the aggressive nature of the disease the technique also improves survival. From the 
experience of over 300 ILPs carried out in this unit, the morbidity of this technique 
has been minimal.
Although there has been only one death (gastrointestinal bleed) within 30 day 
following ILP, it is still a considerably greater undertaking for the surgeon and the 
patient compared with laser ablation. All the major studies of therapeutic ILP 
(chapter 3) indicate that a small but definite number of patients with cutaneous limb 
recurrence can achieve a long term disease free interval after ILP. It would seem 
appropriate, therefore, to offer ILP as the initial treatment of choice for these patients.
5.6 CONCLUSION
Carbon dioxide laser ablation only destroys the lesions locally. Longer follow up is 
required before it can be concluded if this treatment affects the disease free interval or 
survival or if it is comparable to other modalities of current treatment for control of 
local recurrence. Results of this study support the use of carbon dioxide laser as an 
effective alternative treatment for those patients in whom ILP fails or is inappropriate.
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CHAPTER 6
INTRAOPERATIVE LYMPHATIC MAPPING USING PATENT BLUE 
DYE TO IDENTIFY REGIONAL MICROMETASTASES IN 
MALIGNANT MELANOMA
6.1 INTRODUCTION
Adjuvant treatment of stage I patients with ILP has not shown definite survival 
benefits over conventional surgical treatment in the form of wide local excision. The 
problem is reflected in the fact that in a large number of these patients, metastases 
may well have occurred by the time of diagnosis. Thus if long term control is to be 
achieved in these patients, the answer needs to be found in the biology of melanoma 
metastases and detection.
As early as the turn of this century, Handley3 explained the mode of spread of 
melanoma. Many of his observations remain valid today. He commented that 
dissemination of malignant cells first occur to the fine lymphatics followed by 
centrifugal spread to the main lymphatics and invasion of the blood stream. In the 
later stages, the slow process of lymphatic permeation recedes into insignificance as 
the patient dies with widespread deposits resulting from blood embolism.
The process of cancer metastasis consists of a series of steps which the tumour cell 
must complete to produce clinically relevant lesions. These steps are shown in figure 
49. The major steps involve progressive growth of the neoplastic cell with extensive 
vascularization. This is followed by invasion of the host's stroma. Thin walled 
venules and lymphatics offer little resistance to penetration and provide the most 
common pathways for the tumour cells to enter the circulation. Detachment and 
embolisation of small tumour cell aggregates occurs but rapid destruction of the 
majority of these cells follow.
Those tumour cells that survive aggregate in the capillary beds of the organs. 
Extravasation occurs next followed by proliferation within the organ. To produce 
detectable lesions, the metastases must develop a vascular network and evade the 
host's immune mechanism. Once they do so, the cells can invade host's stroma, 
penetrate blood vessels and enter the circulation to produce additional metastases.
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If treatment could be directed towards disrupting any part of this process and 
destroying the tumour cells, then there is a possibility of cure. The process needs to 
be halted at the early phase of neovascularization and invasion of stroma into the 
lymphatics and vascular tree.
Intraoperative lymphatic mapping may be a technique which allows identification of 
the lymph nodes that harbour tumour cells. Removal of such nodes may increase the 
chance of a cure, as this removes those cells that invade the lymphatics. However 
melanoma not only spreads through the lymphatics but also through the vascular tree. 
If a method could be developed to target these cells in the blood system, then these 
single metastatic cells could be mopped up and destroyed before they establish and 
develop a vascular network within the distant organs. The author proposes that the 
use of labelled radioactive isotopes may be such a treatment. These isotopes could be 
used in the ILP circuit to selectively destroy metastatic cells in the limb. Chapter 7 
gives the details and results of such treatment.
Radical lymph node clearance is generally recommended for melanoma patients with 
clinically suspicious nodes or biospy proven nodal disease. The role of 
lymphadenectomy in melanoma patients without clinical evidence of lymph node 
metastases remains controversial. Such patients present a therapeutic dilemma. 
Some surgeons advise immediate elective lymph node dissection3 4 8 *3 4 9  in all 
patients with high risk malignant melanoma (Breslow 1.5-4.0mm). They accept that 
many patients will undergo an unnecessary operation which is associated with 
significant morbidity. Others adopt a 'wait and see1 policy3 5 0 *3 5 1  and remove lymph 
nodes if and when they become clinically palpable. Neither policy is ideal.
Proponents of elective lymphadenectomy claim that the risk of developing regional 
node disease increases with increasing thickness of the primary melanoma. They 
argue that lymphadenectomy would most apply to the group with an intermediate 
thickness lesion in the range 1.51mm to 4.0mm where the risk of regional node 
metastases is high at 57% but the risk of distant metastases is low at 15%352.
Inevitably the argument against this policy is almost equally as strong and is mainly 
based on the fact that routine elective lymphadenectomy would subject large numbers 
of patients to an operation which carries a definite and quite considerable morbidity, a 
small but inevitable mortality, and who will ultimately prove to have no metastatic 
disease.
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Clearly, therefore, if a technique could be developed that would allow positive 
identification of the subgroup of patients with clinically occult nodal disease, it may 
well be that such patients would be most likely to benefit from radical 
lymphadenectomy. Lymphatic mapping may be such a technique. The technique 
was first described by Morton3 5 3  and Cochran3 5 4  but several workers in Europe tried 
to reproduce the results without success. The method had never before been assessed 
in the United Kingdom.
The aim of this study was to answer the following questions:
1) Is the technique practical?
2) Is the technique of identification of a sentinel node using patent blue dye 
sensitive in detecting nodal metastases?
3) Does skipping of the first nodal basin occur?
6.2 ANATOMY OF LYMPHATIC DRAINAGE
6.2.1 LYMPHATIC DRAINAGE OF LOWER LIMB
Most of the lymphatic fluid from the lower limb drains to a terminal group of 
inguinal nodes in the groin which are divided into superficial and deep groups.
The superficial inguinal lymph nodes are arranged in an upper and lower group; the 
former usually consists of five to six nodes forming a chain immediately below the 
inguinal ligament and the latter group consists of four to five nodes disposed 
vertically along the terminal part of the great saphenous vein. The superficial 
inguinal nodes drain into the external iliac lymph nodes.
The deep inguinal lymph nodes vary from one to three and are on the medial side of 
the femoral vein. The lowest node is situated just below the junction of the great 
saphenous vein and femoral vein, the middle in the femoral canal and the highest in 
the lateral part of the femoral ring.
Lymphatic drainage of the superficial tissue of the lower limb occurs via superficial 
lymph vessels. There are two main groups (the medial and the lateral group) which 
both drain into the lower group of the superficial inguinal nodes. The lymphatic 
drainage of the deeper tissue of the lower limb is via the deep lymph vessels which 
accompany main blood vessels and drain into the deep inguinal nodes. Figure 50 
shows a diagrammatic illustration of the lymphatic pathway of the lower limb.
Superficial inguinal nodes
Femoral vein
External iliac vein
Deep inguinal n o d es
Superficial pudendal 
lymphatic v e sse ls
Superficial inguinal nodes
Deep lymphatic v e sse ls
Long sa p h en o u s  vein
Popliteal node
Deep tibial lymphatic vesse ls
Deep lymphatic ve sse ls
Superficial lymphatic vesse ls
Long sa p h en o u s  vein
Figure 50 Diagrammatic illustration o f the lymphatic pathway o f the lower limb
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6.2.2 LYMPHATIC DRAINAGE OF UPPER LIMB
All the lymph vessels of the upper limb drain into a terminal group of lymph nodes in 
the axilla, either directly or via outlying groups of lymph nodes.
The axillary lymph nodes are numerous, varying from twenty to thirty in number and 
may be divided into five groups. They are the lateral group, the anterior or pectoral 
group, the posterior or subscapular group, the central group and the apical group.
The superficial tissues of the upper limb drain by superficial lymph vessels which 
have two main branches. The lateral lymph vessel accompanies the cephalic vein and 
ends in the infraclavicular nodes. The medial lymph vessels accompany the basilic 
vein and end in the lateral axillary nodes.
The deep tissue of the upper limb is drained by deep lymph vessels which accompany 
blood vessels and join to form a terminal collecting trunk which lies alongside the 
brachial vessels and ends in the axillary nodes. Figure 51 shows a diagrammatic 
illustration of the lymphatic pathway of the upper limb.
6.3 PRINCIPLE OF INTRA OPERATIVE LYMPH MAPPING USING 
BLUE DYE
This technique is based on the theory that the initial route of metastases in most 
patients with melanoma is via the lymphatics to regional nodes. It also assumes that 
the spread occurs in an orderly pattern with the metastatic cells draining into the first 
node in the lymph node group and there is no skipping of the nodal basin.
The technique of lymph mapping allows identification of a sentinel lymph node, 
which is the lymph node nearest the site of the primary melanoma. By identifying 
and removing this sentinel node (which is the most likely site for early metastases) it 
can be examined for occult melanoma cells. The sentinel node is the first node to be 
stained blue by this technique. If the examination of the node shows metastatic cells, 
then the patient may benefit from a complete lymph node clearance.
apical nodes
infracavicular nodessu b sp in o u s  node
lateral pectoral 
nod es
medial
pectoral
nodes
subareo lar
plexus
posterior
channel
cephalic
vein
posterior channel
basilic
vein supratrochlear
node
anterior lateral 
channel
posterior medial 
channel
anterior medial 
channelposterior lateral
channel
Figure 51 Diagrammatic illustration of the lymphatic pathway of the upper limb
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6.4 PATIENT DETAILS
The procedure of intraoperative lymph mapping using blue dye was carried out on 30 
patients between February 1992 and September 1993. The series included 22 females 
and 8  males whose mean age was 57 (range 25 to 80) years. According to the M. D. 
Anderson staging, 25 patients had stage I disease (primary disease), 1 patient had 
stage II disease (local recurrence) and 4 patients had stage IDA disease (intransit 
metastases/satellitosis, skin recurrence). One patient had the primary lesion intact but 
presented with satellitosis. The primary lesions were situated on the lower limb in 22 
patients and upper limb in 8 . The mean Breslow thickness was 3. 4mm (range 1.5-
8.1 mm). All patients had no evidence of distant metastases at other sites confirmed 
by ultrasound scan or CT scan and chest X-ray.
6.5 OPERATIVE TECHNIQUE
The procedure is carried out under general anaesthesia. The dye used is Patent Blue 
V. It comes in a prepacked vial containing 2.5% of Patent Blue V in a sterile isotonic 
solution. Patent Blue V can provoke an allergic reaction of varying degrees of 
severity. These reactions are rare and can be controlled with a corticosteroid. 0.5cc to 
l.Occ of the dye is injected intradermally around the site of the primary melanoma 
using a 25G insulin syringe (Figure 52).
If the primary melanoma has already been removed, the intradermal injection is made 
into either side of the excision scar. It is important that injection of the dye is 
intradermal as subcutaneous injection will result in passage of the dye into the deeper 
lymphatic channels along the veins, bypassing the nodes which drain the dermal 
plexus. As small a volume of dye as possible is used to prevent extravasation into the 
subcutaneous tissue. The tumour and surrounding skin will stain blue (Figure 53).
The injection site is gently massaged to encourage passage of the dye along the 
lymphatics. Immediately an incision is made over the lymph basin which is the site 
of the expected lymphatic drainage. The skin flap closest to the primary melanoma is 
then dissected free from the underlying tissue and lymphatic channels, taking care to 
remain superficial to the lymphatic channels to avoid dividing them. When a blue 
lymphatic channel is identified , it is followed through the fatty subcutaneous tissue 
of the lymph basin to the draining lymph node which turns blue-
Figure 52 Intradermal injection o f  patent blue dye using a 25G insulin syringe 
around the site o f  the malignant m elanoma
Figure 53 Appearance o f  the malignant m elanom a and the surrounding skin after 
the injection o f  patent blue dye
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Figures 54 to 57 illustrates the above technique. In figure 54, the earliest trace of the 
blue dye in the tiny lymphatics running parallel to the long saphenous vein is seen. 
In a veiy short time these lymphatics deepen in colour and the operator will gain an 
impression that they are draining towards a regional node, the so called sentinel node 
(Figure 55). Within a very few moments that staining increases and figure 56 shows 
afferent lymphatic channels approaching a node and an efferent channel heading away 
towards a second node. In some patients there can be more than one sentinel node. 
Two sentinel nodes are shown in figure 57.
Careful exploration is carried out around the sentinel node to identify any additional 
blue nodes. When the sentinel node has been identified it is carefully removed with 
control of all surrounding lymphatic channels. Two other non sentinel lymph nodes 
are also removed for examination. In the patients undergoing iliac limb perfusion, 
iliac nodes are also removed for examination.
6.6 PATHOLOGICAL TECHNIQUE
The fresh sentinel lymph node is bisected from the hilum to the periphery; one part is 
processed by routine haematoxylin and eosin (H&E) staining and the other part is 
processed for rapid immunoperoxidase staining. All the nodes are then fixed in 
formalin, embedded in paraffin, sectioned and examined by both H&E and 
immunohistochemical staining using S-100 protein antibody and melanoma reactive 
monoclonal antibody (NKIC3 ).
The rapid immunoperoxide staining technique used is as follows:
The solutions used for the technique are:
1) Tris buffer (T.B.) pH 7.6 6 . 6  gm Tris Hydrogen Chloride (HCL)
1.39gmTris Base 
1 litre distilled water
2) Tris buffered saline (T.B.S.) 900ml saline (8.5 gm Sodiun chloride/litre)
100 ml Tris buffer
3) Pronase 0.1% Pronase in Tris buffer (incubate for 
15 minutes at room temperature)
Figure 54 Earliest trace o f  dye in the tiny lymphatic channel parallel to the long 
saphaneous vein
Figure 55 Blue dye becom ing  s t ronger  in the lympha t i c  channel .
Figure 56 Afferent lymphatic channels are seen draining into the blue node with 
efferent channels draining away
Figure 57 T w o  sent inel nodes s ta ined blue
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4) Diaminobenzidene (DAB)-Chromagen Substrate
Stock 0.6 gm of 3.3 Diaminobenzidene in 100 ml
of Tris buffer aliquot into 5 ml amounts 
and stored at -20°C
Working solution Add one 5ml aliquot to 95ml of Tris buffer,
mix and add 1 drop of 30% w/v hydrogen 
and use immediately. (5 minutes at room 
temperature)
5) Vectastain Vasoactive Intestinal Peptide (VIP) Substrate Kit
To 5 ml of buffer add 3 drops of reagent 1 and mix well. Add 3 drops of reagent 2 
and mix well. Add 3 drops of reagent 3 and mix well. Add 3 drops of the hydrogen 
peroxide solution and mix well.
Peroxide Anti-Peroxide (PAP) method for polyclonal antibodies
1) Take sections to water.
2) Block endogenous peroxidase by immersing in 3% hydrogen peroxide for 15 
minutes.
3) Wash in T.B.S.
4) Carry out enzyme digestion with 0.1% pronase in tris buffer for 15 minutes at 
room temperature.
5) Incubate with normal swine serum diluted 1 in 5 for 10 minutes.
6 ) Pour off excess serum (do not wash).
7) Incubate with the appropriate primary antibody for 60 minutes at 37°C i.e. S-100 at 
1:200 dilution in Tris buffer.
8 ) Wash in T.B.S.
9) Incubate with swine antirabbit Immunoglobin G diluted 1/50 for 30 minutes.
10) Wash in T.B.S.
11) Incubate with rabbit peroxide anti-peroxidase (PAP) complex diluted 1/100 for 30 
minutes.
12) Wash in T.B.S.
13) Stain sections in Vectastain VIP substrate kit and incubate at room temperature 
until suitable staining develops: generally 2-15 minutes, alternately use DAB 
chromagen.
14) Wash in tap water.
15) Counterstain lightly in haematoxylin, blue in Scott's dehydrate, clear and mount.
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N.B. All dilutions are made in Tris buffer (pH 7.6) and all washes are in Tris buffered 
saline (T.B.S.). Supplier for S-100 and all other immunochemicals are Delco. Figure 
58 shows a positive lymph node using the H&E staining method and figure 59 shows 
a positive lymph node using the S-100 protein antibody.
6.7 RESULTS
OPERATIVE AND POST OPERATIVE COMPLICATIONS
There were no complications associated with the use of patent blue V dye for 
intraoperative mapping in this study. Five minutes following the injection of the dye, 
the skin of the patient becomes blue. This affects the anaesthetic monitoring of 
transcutaneous oxygen levels using pulse oximetry so the anaesthetist must be 
warned about the dye being used. All patients reported the presence of dye in their 
urine during the first 24 hours following the procedure. No hypersensitivity reactions 
were recorded.
PATHOLOGICAL EXAMINATION
A total of 32 sentinel node were identified. Micrometastases were found in 8  of the 
32 sentinel nodes. Six of these metastases were detected by both routine H&E and 
immunohistochemical staining. In 2, metastatic tumour cells were detected only in 
sections stained by immunohistochemical techniques.
SENTINEL AND NON SENTINEL NODE ANALYSIS
In 28 patients, 32 sentinel nodes were identified with two patients having two sentinel 
nodes. There were 8  positive sentinel nodes of which 7 were from the inguinal basin 
and one from the axillary basin. A total of 96 non sentinel nodes were removed of 
which 56 nodes were removed from the same lymph basin as the sentinel node 
(axillary or inguinal basin). Forty nodes were removed from the iliac lymph basin in 
2 2  patients undergoing iliac limb perfusion.
In relation to the Breslow thickness of the primary malignant melanoma, there were 4 
positive sentinel nodes in the group with thickness between 1.5 - 2.99 mm, 3 positive 
sentinel nodes in the group with thickness between 3.00-3.99 mm and 1 positive 
sentinel node in the group with thickness of equal or greater than 4.00 mm. All the 
patients with positive sentinel nodes had been staged as having stage I disease using 
the M. D. Anderson Staging System.
Figure 58 H&E staining o f  a sentinel lymph node show ing the presence o f  
m elanoma cells
(courtesy o f  Professor R M MacKie)
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Of the eight patients with a positive sentinel node, 6  showed ulceration in the primary 
tumour. In the 22 patients with negative sentinel nodes, only one had ulceration in 
the primary lesion. This was in the patient with Breslow thickness of 8.0mm with a 
subungual melanoma of the right thumb.
When the non sentinel nodes were examined, no micrometastases were found in non 
sentinel nodes in the first draining lymph basin. However in the 40 iliac nodes 
removed from the 2 2  patients undergoing iliac perfusion, one of the iliac nodes was 
positive for micrometastases in a patient with negative sentinel node. She had a 
nodular melanoma of the lower leg of Breslow thickness 2.58mm and no ulceration.
Of the 8  patients with positive sentinel nodes, 7 underwent en bloc 
lymphadenectomy. One patient did not undergo lymphadenectomy due to the her 
clinical condition. A total of 47 lymph nodes were removed. They were all negative 
both by H&E and immunohistochemical staining for metastastic melanoma cells.
Of the 30 patients who have had sentinel node biopsy, 22 patients with negative 
nodes have had no recurrence of melanoma. In 8  patients where micrometastases 
were identified, 2  have since developed recurrence, one of these patients having now 
died.
6 . 8  DISCUSSION
To date, the surgical world has had considerable difficulty in knowing how to deal 
with lymph nodes which may or may not contain metastatic malignancy. Most 
would agree that involved lymph nodes should be removed, but what if nodes are not 
clinically known to be involved and yet contain micrometastases? Such a situation is 
probably more common than realised and has important implications for the staging 
of disease and interpretation of therapeutic trials.
In 1992, Morton3 5 3  and Cochran et al3 5 4  at the John Wayne Institute for Cancer 
Treatment at UCLA School of Medicine, Los Angeles described the technique of 
lymphatic mapping. They detected micrometastases in 18% of sentinel nodes 
removed from patients with high risk (1.5mm-4.0mm) stage I disease. In the non 
sentinel nodes removed simultaneously, less than 1 % were found to contain 
micrometastases giving a very low false negative rate. Although their results showed 
that this technique appeared to be the answer to the dilemma as to which patients 
would benefit from elective lymph node clearance, there were several flaws in their 
study and questions still remain to be answered.
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Recently ELND has also been challenged by those who believe that lymph node 
metastases are primarily blood borne and occur in a random fashion to regional or 
distant lymph node groups via vascular lymphatic communication, thus challenging 
the conventional view of the orderly spread of metastatic cells along regional 
lymphatic channels to the draining nodes. Despite this fact, it has been shown that 
the five year survival of patients with multiple involved and clinically enlarged nodes 
after lymphadenectomy is only 15-25%351>355>356’357 whereas the survival of 
patients with one or two microscopically involved nodes after lymphadenectomy is as 
high as 80%76,355. This difference may appear substantial but the benefit of ELND 
is probably much less because some of these patients have subclinical distant 
haematogenous metastases in addition to nodal metastases.
Intraoperative lymph mapping may provide an alternative method of management 
without having to subject patients to unnecessary lymphadenectomy and reserve 
lymphadenectomy for patients in whom metastases are positively identified.
This technique may also be beneficial in those patients with clinically palpable lymph 
nodes which are suspicious of metastases. In a minority of these patients, 
examination of the removed nodes may show only reactive changes and no evidence 
of metastatic melanoma cells. This prevents unnecessary lymph node dissection in 
these patients whose sentinel nodes may contain no metastases.
It could be argued that fine needle aspiration cytology may be used for such a purpose 
but this is not ideal as the sentinel node may be missed or in nodes with partial 
micrometastases occupying the node, the sampling may miss the micrometastases 
resulting in false negative findings.
There is still a small group of patients who would benefit from removal of the 
sentinel node. These are patients who are at the very early stage of lymph node 
involvement and detection of these few micrometastases may be missed by the 
current immunohistochemical techniques and are classed as being node negative. But 
in reality their nodes are diseased. This is important as even a single node 
involvement has been shown to reduce survival.
Our experience with this technique leads to several conclusions. Intraoperative 
lymphatic mapping is a user friendly technique that is easy to master. We have not 
encountered allergic reactions to the dye. An important aspect of this technique is to 
warn the anaesthetist that the dye effects the transcutaneous oxygen monitoring as the 
skin of the patient becomes blue and to warn patients that it is natural to have staining
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at the site of injection and that for 24-48 hours, their urine will be blue and these 
reactions are temporary and will resolve spontaneously.
The technique of identification of micrometastases in the lymph node must be 
accurate. In this study both routine H&E and immunohistochemical staining were 
used. The two immunohistochemical stains used were S-100 protein antibody and 
NKIC3 antibody. S-100 protein antibody can identify melanocytic tumour even of a 
differentiation degree lacking melanin versus other soft tissue. Almost all human 
benign and malignant melanocytic tumours of the skin and metastases of human 
malignant melanoma stain for S-100. It also retains its reactivity in formalin fixed 
paraffin fixed processed material. In several studies using S-100 protein antibody to 
detect primary and secondary melanoma tissue, it has been shown that positive 
staining patterns are seen with 80%-90% of melanoma tissue358.
NKIC3 antibody also shows strong reactivity to paraffin processed tissue. Using 
NKIC3 on tumour cells with a conventional immunoperoxide technique, virtually all 
metastatic melanoma show positive staining. NKIC3 antibody staining pattern has 
been compared to S-100 protein antibody and was shown to give stronger staining of 
a higher percentage of cells and is a useful addition to the other antibodies for 
diagnostic purposes359. Neither of these antibodies should be used alone for 
detection of melanoma cells because these antibodies are not specific for melanoma 
cells and must be used in a package of antitumour antibodies.
The results in this study show that routine staining with H&E alone is not sensitive 
and specific enough to detect all micrometastases in lymph nodes. Cochran3 6 0  in a 
recent study showed that the number of lymph nodes demonstrating melanoma cells 
is significantly higher when S-100 protein antibody label is used in comparison with 
conventional H&E stained sections. It is therefore important to combine routine 
H&E staining with a battery of immunohistochemical staining which includes S-100 
and NKIC3 antibodies for improved sensitivity in the identification of 
micrometastases.
In this study, it was the practice to identify and remove the sentinel lymph node at the 
time of the perfusion. Radical lymphadenectomy was carried out as a separate 
procedure at a later date. However, it is possible to cany out frozen section analysis 
of the sentinel node and proceed to performing a radical lymphadenectomy if 
necessary at the same operation.
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Until the present study, the original results of Morton3 5 3  and Cochran3 5 4  had not 
been reproduced elsewhere. Our experience of this technique appears promising with 
detection of metastases in 25% of sentinel nodes. There was no technical difficulty in 
identifying the sentinel node, reinforcing the fact that the technique is practical.
The non sentinel nodes removed from the same lymphatic basin did not reveal any 
micrometastases in patients when the sentinel node was negative. This suggests that 
the sensitivity of the technique is high.
If this technique is to have a wide application it is critical that the theory of metastatic 
spread is sound and that lymphatic fluid drainage occurs in an orderly and non 
randomised fashion to the nearest draining node and lymphatic basin. If 
micrometastases can skip an entire nodal basin, then the sentinel node theory will not 
be applicable widely in clinical practice.
In this study, the author was in a unique position to sample not only the inguinal 
nodal basin but also the iliac node basin that was exposed at the time of routine limb 
perfusion surgery. In one patient in whom the sentinel and non sentinel nodes in the 
inguinal basin were negative, by the method described above, a positive node was 
encountered in the iliac region. This shows that skipping of the sentinel node and the 
first nodal basin can occur. This skipping was not shown in the original study.
When the prognostic factors in this group of patients were analysed with respect to 
predicting the sentinel node status, several interesting points arose. Firstly, it was not 
possible to predict the status of the sentinel node from the Breslow thickness of the 
original tumour. This is perhaps surprising as the proponents of elective 
lymphadenectomy claim that the risk of developing regional node disease increases 
with the thickness of the primary melanoma and propose that elective lymph node 
dissection is beneficial in those patients with intermediate thickness tumour (1.5- 
4.0mm).
Secondly, ulceration did appear to be significant in the prediction of sentinel node 
status. Six of the eight patients with positive sentinel nodes had ulceration in the 
primary tumour. In contrast, only one of the 22 patients with negative sentinel nodes 
had ulceration in the primary tumour. This was a patient who had the subungual 
melanoma. Although numbers in this study are small, it appears that ulceration as a 
prognostic factor is more sensitive in predicting sentinel node status and survival.
122
This study has shown that in patients found to have no evidence of nodal 
involvement by clinical and radiological methods, 26% in fact have microscopic 
metastases in the regional lymph nodes. In all the current staging systems, the 
presence of involved nodes reflects more advanced disease. In this study positive 
sentinel nodes were seen in 8  of the 25 patients with stage I disease. In the other 5 
patients with stage II and DIA disease the sentinel node was negative. Thus it appears 
that 32% (8/25) of patients with stage I disease have regional node involvement.
If the sentinel node status is taken into account in these patients, their accurate staging 
would be stage IIIB according to the M. D. Anderson Staging. Of the seven patients 
who underwent radical lymphadenectomy, in 2 patients a total of 5 further positive 
nodes were identified. Thus in 5 patients, the sentinel node was the only node 
containing micrometastases. At follow up, the two recurrences and one death 
occurred in the patients who had further positive nodes.
Clearly current staging techniques such as CT scanning and ultrasound are not 
sufficiently sensitive in identifying nodal involvement. Intraoperative lymphatic 
mapping is a tool that the surgeon can use not only to identify patients who may 
benefit from lymphadenectomy, but also to obtain a more accurate staging of the 
disease.
The other observation from this study is the suprising fact that there was no evidence 
of nodal disease in the patients with stage II and IIIA disease. This suggests that in 
melanoma although lymphatic invasion occurs earlier, the more important mode of 
spread appears to be haematogenous. This echoes the long standing finding of the 
early pioneer, William Handley, that as the disease advances, lymphatic permeation 
regresses and it is the vascular embolism of metastases that eventually kills.
Ulceration is an indication that the tumour has gained access to the blood stream and 
in such cases lymphadenectomy may be too late. If a cure is to be found in these 
patients, targeting and destroying subclinical melanoma metastases would be needed.
If 32% of patients with clinically stage I disease have nodal involvement, then this 
has important implications in the design and interpretation of therapeutic trials as a 
quarter of the patients will be understaged. The author suggests that to improve the 
accuracy of the current staging of melanoma, the sentinel node status should be 
included. The author suggests that the M. D. Anderson staging be altered as follows:
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STAGE CRITERIA
I Primary melanoma Sentinel node negative
II Local recurrence or local metastases within
3cm of the primary. Sentinel node negative.
IE Regional metastases
DIA Only sentinel node positive and skin
recurrence.
mB Sentinel node and one or more positive
non sentinel nodes
IILAB Local recurrence and sentinel node
positive and/or one or more positive non 
sentinel
IV Distant metastases
The staging outlined above may more accurately predict survival.
6.9 CONCLUSION
Intraoperative lymphatic mapping is an easy technique to master and appears to be 
highly sensitive in the identification of patients with nodal disease. This technique is 
applicable in all patients with no clinical or radiological evidence of nodal disease. 
These include patients with M. D. Anderson stage I, II and IDA as unsuspected 
metastases may be identified.
It appears that if the sentinel node status could be incorporated into the current 
staging system, then a more accurate staging of the disease can be achieved with more 
accurate prognosis. Furthermore, if 32% of patients with cutaneous malignant 
melanoma of a limb who are clinically stage I have nodal disease, this has 
considerable importance for the design and interpretation of therapeutic trials.
In conclusion, lymphatic mapping presents itself as a tool for the identification of 
melanoma dissemination by the lymphatics. This not only gives a more accurate 
staging of the primary lesion, but also selects patients with nodal disease for radical 
lymphadenectomy which removes the involved lymphatic pathway and may improve 
survival.
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CHAPTER 7
TARGETING RADIOTHERAPY IN THE TREATMENT OF 
MALIGNANT MELANOMA
7.1 THE ASSESSMENT OF THE BINDING ABILITY OF METHYLENE 
BLUE TO PIGMENTED MALIGNANT MELANOMA IN NUDE MICE.
7.1.1. INTRODUCTION
Malignant melanoma has a dismal prognosis once metastases occurs. It is known that 
even at the time of diagnosis of primary malignant melanoma, metastases to lymph 
nodes, liver, lung and central nervous system may have occurred. The current 
treatment modalities for dealing with micrometastases are limited. It is thus 
conceptually attractive to think of using targeted radiotherapy to treat such 
metastases. In theory, this could be done by using a compound that has a high 
binding affinity for melanin. This compound could be labelled with a radioisotope to 
target, scavenge and destroy these metastases.
Compounds with selective affinity for melanin have been known for many years and 
were first described by Potts361’362’363. These selective melanin "seekers" either 
bind to preformed melanin3 6 4  or are incorporated into the growing melanin365. The 
compounds originally used were the phenothiazine derivatives. Chlorpromazine was 
the first to be used for this purpose but it did not prove to be effective. Several other 
phenothiazines were tried and eventually methylthionine bromide (commonly known 
as methylene blue MTB) was chosen because of its great affinity for isolated natural 
melanin362, selective accumulation in pigmented tissues, and low toxicity. 
Link3 6 6 ’3 6 7  and colleagues showed that methylene blue was incorporated at least five 
times more effectively by cultured pigmented melanoma cells than by non pigmented 
tumour cells. She also showed that its distribution in vivo showed the highest and 
most stable level in pigmented melanomas368.
The experiments described in this chapter were designed to answer the following 
questions:
1) Can MTB effectively bind to melanoma cells?
2) Does MTB have any tumouricidal effect?
All the animal experiments described in this chapter were carried out with the 
approval of and in accordance with the Home Office rules and regulations.
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7.1.2. MATERIALS AND METHODS.
EXPERIMENT 1
The experiment was carried out in vivo using melanotic B16/F10 mouse melanoma. 
A primary melanotic B16/F10 mouse melanoma cell line was obtained by courtesy of 
Professor R. M. MacKie, Department of Dermatology, University of Glasgow. The 
sub-line had been constantly maintained by serial subcutaneous injections of animals 
with chips of tumour tissue. This pigmented subline was passaged every three weeks 
in the C57 mouse. A single cell suspension was isolated by dispersing 2-4 excised 
melanoma tumour fragments of lmm^ with 0.25% Trypsin in a phosphate buffer 
saline (PBS) which by the process of digestion eventually results in a dilution of 
lx l 0 ^ cells in 0.2mls of saline. For the experiments, Eagle's minimum essential 
medium (MEM) supplemented by 10% bovine serum was used.
Non radioactive methylene blue (MTB) was obtained from a prepack manufactured 
by Martindale Ltd. The MTB was then diluted with saline to give a dilution of one 
microgram in 0 .2 mls saline.
Athymic nude female mice of 50-60 days old were used in all the experiments and 
were obtained from Charles Rivers Ltd. The animals were kept in sterile cages and 
fed sterilised food and water. All the experiments were performed under strict aseptic 
techniques using a laminar flow cabinet. Inoculation of the melanoma cells and MTB 
was carried out on mice anaesthetised using intraperitoneal hypnovel. The animals 
were divided into three groups :
1 Group A ( control group) received only tumour cells ( 6  animals).
2 Group B received a mixture of MTB and tumour cells ( 6  animals).
3 Group C received tumour cells with MTB being administered at the first sign of 
tumour growth ( 6  animals).
According to the protocol submitted to the Home Office prior to the issue of the 
animal licence, due to the time and cost involved in the care of the nude mice, 
application for a maximum of 2 0  nude mice were made for the use in each 
experiment. Hence the maximum number of animals in each of the subgroups was 
six.
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B16/F10 mouse melanoma cells (lx l 0 ^ cells) were incubated for three hours in test- 
tubes containing 1ml of MEM and then centrifuged. The cells were then incubated 
either in a medium containing MTB or in a medium containing no MTB. Group A 
mice were injected with l x l 0 ^ cells in 0.2mls saline and 0.2mls saline, Group B mice 
were injected with a mixture of l x l 0 ^ cells in 0.2mls and 1 microgram MTB in 
0.2mls saline and Group C mice were injected with l x l 0 ^ cells in 0.2mls saline 
followed by 1 microgram MTB in 0.2mls saline intravenously into the tail vein when 
tumour growth was first noted.
All tumour cells were injected subcutaneously into the right thigh as the rate of 
growth of tumour at this site is more gradual and less likely to ulcerate. The animals 
were sacrificed when the tumour became larger than 1.5cm or when the tumour 
ulcerated or interfered with the locomotion of the animals.
The tumour growth was recorded daily at the same time each day using a venier 
calliper. Measurements of the greatest dimension (a) and the length perpendicular to 
this dimension (b) were recorded. Tumour volume was calculated using the formula 
below:
Tumour Volume(V) = (a)^x b x 0.5
EXPERIMENT 2
Experiment 2 was a repeat of experiment 1 using the same technique as outlined 
above. This experiment was carried out to confirm that the results obtained from 
experiment 1 were not due to chance.
1) Group A (control group) received only tumour cells (4 animals).
2) Group B received an admixture of MTB and tumour cells (4 animals).
3) Group C received tumour cells with MTB being administered at the first sign of 
tumour growth ( 1 2  animals).
There were more animals in group C than in group A or B because the results from 
experiment 1 had showed that there appeared to be a greater difference in the tumour 
growth rate in group C when compared to the control. Thus a larger number was 
needed to be studied in this group before any conclusion about the action of MTB 
could be made.
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7.1.3 RESULTS
The results of experiments 1 and 2 were analysed as described below:
1) Tumour volume for each animal in each group was calculated and a mean tumour 
volume and rate of growth derived. The average tumour volume on day 12 in each 
group was also calculated.
2) The mean tumour volume, rate of growth and tumour volume on day 12 was 
compared between the groups.
3) To confirm if there was a difference in the groups with respect to the variables 
shown above, the statistical analysis outlined in the paragraph below was used:
Statistical Analysis
For each group of animals, the results were subjected to the following statistical 
analysis. A mean and standard deviation of tumour volume was first calculated and 
plotted against time. The results were then linearised and plotted against time and the 
rate of tumour growth was calculated from this graph. To check that the rate of 
tumour growth was linear, a Pearson Test was used. In each group the tumour 
volume on day 1 2  was also compared and plotted.
One Way Analysis of Variance (95% confidence limit) was used within the groups in 
each experiment to look for differences in the tumour growth. Friedman's Test for the 
specific comparison was used to analyse the difference in tumour growth rate and 
tumour volume on day 1 2  in each group.
Experiment 1
Tumour growth was documented in all the 18 nude mice injected with tumour cells. 
Each animal developed tumour at the injected site with a total of 18 tumours in the 18 
animals. The first sign of tumour growth in group A was evident on day 5 following 
inoculation. The animals were sacrificed on day 15. In group B tumour growth was 
first seen on day 9 and the animals were sacrificed on day 15. In group C the first 
sign of tumour was seen on day 5 and the animals were sacrificed on day 15.
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The results calculated using the One Way Analysis Variance showed that the rate of 
growth was significantly different in group A, B and C (p =0.001). Using the 
Friedman's Test, the rate of growth was shown to be different with the greatest growth 
in group A followed by group C and then in group B (p = 0.001).
Experiment 2
Tumour growth was documented in all 20 animals with each animal showing a 
solitary tumour at the site of injection with a total of 20 tumours. The first sign of 
tumour growth in group A was evident on day 6  and the animals were sacrificed on 
day 14. In group B tumour growth was first recorded on day 11 and the animals were 
sacrificed on day 17. In group C tumour growth was first evident on day 6  and the 
animals were sacrificed on day 15.
When the Friedman's Test was used, the rate of growth was shown to be different 
with the greatest growth in group A followed by group C and then in group B (p = 
0.001). These findings were similar to those of experiment 1.
Figures 60 and 61 show the rate of tumour growth and tumour volume on day 12 in 
experiments 1 and 2  respectively.
Since group A animals in experiment 1 and 2 were the same, a One Way Variance 
analysis was used to see if these groups could be pooled to provide a larger sample 
size. When this was carried out, there was a significant difference between the 
controls (p = 0.01). This meant that the control groups could not be pooled. This 
however did not affect the analyses in the individual experiments.
If MTB has only a delaying effect and is not tumouricidal, then once the MTB 
• molecule is displaced from the tumour cells, they should be free to multiply and 
growth should return to a pattern similar to that shown by the control group. In order 
to investigate this, the data were dealt with in segments of 7 days length. Group A 
(the control) group covered days 6  to 12. Groups B and C were systematically lagged 
to see how far behind the tumour growth was from the control group. Day 6  to 12, 7 
to 13, 8  to 14, etc were compared to day 6  to 12 in the control group and examined 
for any similarity.
In experiment 1 in groups A and B there was a lag of 5 days. The groups were similar 
but discrepancies were apparent. Between groups A and C the lag was 1 day and 
again there were some discrepancies. Similar results were also seen in experiment 2.
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Formal analyses of the data was carried out using Repeated Measures Analysis of 
Variance. A significant group effect indicates an overall difference between the 
groups. The group day interaction measures the pattern across days for each group, 
and a significant interaction means the pattern differs for the two groups. When the 
results were lagged, there was a significant group effect between group A and B and 
also between groups A and C but there was no significant interaction between the 
groups. Thus although the growth rate was different, there was no difference in the 
growth pattern.
In summary, there was a significant difference in the growth rates in all the groups of 
animals. The growth rate was greatest in group A followed by group C and then 
group B.
7.1.4 DISCUSSION
Analysis of the results obtained in experiments 1 and 2 showed that there was a 
significant difference between the groups with the growth rate of group A greater than 
those of groups B and C. The addition of MTB therefore appeared to delay the onset 
of tumour growth.
If MTB has only a delaying effect and not a tumouricidal effect on the melanoma 
cells, when the results are lagged to that seen in the control, there should be no 
difference in the growth rate i.e. no significant interaction. When the results were 
lagged, there was a significant group effect between group A and B and between 
groups A and C. However no significant interaction between the groups were noted. 
This meant that although the growth rate was different, there was no differences in the 
growth pattern between the groups.
This clearly shows that MTB has no effect on tumour growth but does have a 
delaying action. These results provide confirmatory evidence that in order to achieve 
this delaying action, MTB must bind to melanin in the tumour cells. The MTB- 
melanin complex may inhibit the use of the melanin needed in the multiplication of 
the tumour cells. When experiment 1 was repeated (experiment 2) similar results 
were shown confirming that this was not a chance finding.
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The delay in time to growth should reflect the half life of MTB. This is known to be 
2.3 days. If radioactive isotopes are to be attached to the MTB molecule for targeted 
therapy, then the radioactive isotopes should have a half life shorter than that of MTB 
so that effective treatment can be delivered before MTB is displaced from the melanin 
in the tumour cells.
There was also a significant difference in growth in groups B and C. In group B 
MTB was incubated with the tumour cells prior to inoculation whilst in the group C 
MTB was injected intravenously only when the tumour became macroscopically 
visible. Thus the amount of tumour cells in the two groups were different at the time 
of MTB adminstration but both the groups received the same amount of MTB.
This meant that for the same volume of MTB used the proportion of cells that were 
bound to MTB was higher in group B than in group C and thus the number of cells 
available for multiplication was greater in group C than in group B animals.
7.1.5 CONCLUSION
Experiments 1 and 2 confirm that MTB binds to melanin in the tumour cells. MTB 
has no specific tumouricidal effect. If radioisotopes are to be labelled to MTB for 
targeted therapy, then the chosen isotope should have a similar half life to the MTB 
molecule.
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7.2 THE EFFICACY OF TARGETED RADIOTHERAPY USING 
RADIOACTIVE IODINE IN THE TREATMENT OF MALIGNANT 
MELANOMA IN NUDE MICE.
7.2.1 INTRODUCTION
Targeted radiotherapy is defined as a treatment selectively directed at a particular 
tissue, by using either a radioisotope exhibiting a high affinity to this tissue or a 
compound with such affinity used as a carrier for a suitable radioisotope. The 
selectiveness of the radioisotope uptake enables deposition of high radiation doses in 
the targeted tissue with only minor exposure to surrounding structures, unlike 
classical beam radiotherapy where both the targeted and adjacent tissues are 
irradiated.
The idea of targeted radiotherapy was first conceived when the Hungarian scientist, 
G. Hevesy3 6 9  together with F. Paneth3 7 0  reported the use of lead as a radioindicator 
in chemistry. The first clinical studies using radioisotopes compared the velocity of 
blood circulation in healthy individuals with that in patients with heart disease371. 
This led to several other studies with the eventual use of phosphorus in the treatment 
of leukaemia3 7 2  and the use of radioiodine for the diagnosis and treatment of thyroid 
disease373*374.
The main difficulty for the clinician treating malignant melanoma is that early 
random metastases can occur. If a melanoma specific compound could be labelled 
with an appropriate radioisotope, this compound could be used as a scavenger to 
"mop-up" single melanoma cells and tumours below the limit of clinical detectability. 
Methylene blue may be such a compound as it possesses great affinity for melanin. 
Potts3 6 1  showed that the binding affinity of methylene blue to melanin was 87%. 
Link3 6 8  and colleagues showed that its distribution in vivo was highest and most 
stable in pigmented melanoma but that uptake was also seen in normal organs which 
are pigmented such as the eyes and liver.
It has earlier been seen that adjuvant ILP with melphalan does not significantly 
improve the survival of patients with stage I disease. This failure may be related to 
the chemotherapeutic agent rather than the technique of ILP itself. However if a 
different agent can be found that is suitable for use in the ILP circuit, then a survival 
benefit may be demonstrated.
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Such an agent could be a labelled radioactive isotope with methylene blue. To test 
this hypothesis a series of experiments were conducted using several radioactive 
labelled isotopes in the nude mouse model used in experiments 1 and 2. These 
experiments were designed to answer the following questions:
1) Is targeted therapy possible?
2) Is there an optimal radioactive isotope?
3) Is MTB an effective carrier molecule for the chosen radionuclide?
4) What is the most effective route in the delivery of this treatment?
5) Can this therapy be delivered without detrimental effects on other organs in 
the body?
7.2.2 BIOLOGY OF RADIOISOTOPES
Ionising radiation is radiation which when incident upon matter can cause changes in 
the atomic or nuclear structure of the matter. One form of ionising radiation is 
electromagnetic which can be regarded as a wave form composed of transverse 
electric and magnetic fields propagated at the speed of light. This type of radiation 
includes X-rays (electronic in origin ) and gamma rays ( nuclear in origin ) and is 
highly penetrative in matter. The second type of ionising radiation is particulate and 
includes the proton, the neutron, the alpha and the beta particle. These particulate 
radiations are relatively much less penetrative than electromagnetic radiation.
Atomic nuclei are characterised by two numbers, the atomic number (Z) which is the 
number of protons in the nucleus and the mass number (A) which is the total number 
of protons and neutrons in the nucleus. A third number sometimes quoted is the 
neutron (N), A = N + Z
Nuclides can be stable or unstable, the latter undergoing radioactive decay to become 
stable. Nuclides having the same proton number are termed isotopes. Such a group 
comprises different nuclei of the same element. Since isotopes differ only in neutron 
number, they have the same chemical properties. Most elements have a mixture of 
stable and unstable isotopes. Isotopes containing an unstable arrangement of protons 
and neutrons will transform to a completely stable or a more stable combination of 
nucleons. These isotopes are said to be radioactive and are termed radioisotopes.
Radioactive decay occurs with the emission of a charged particle from the nucleus or 
the capture of an electron from one of the shells surrounding the nucleus. This results 
in a change in the balance between the protons and neutrons.
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When radioactive decay releases an electron or positron, the emission is termed beta 
decay; when it involves emission of a helium nucleus, it is termed an alpha particle. 
It is common for gamma radiation to accompany emission of a charged particle.
The range of beta particle penetration in tissue is a few millimetres and can be useful 
in selective therapeutic treatment. Alpha particle radiation gives a much higher 
localised radiation dose in tissues.
When cells are exposed to ionising radiation a proportion of them eventually die or 
lose their ability to divide. Some develop abnormal sets of chromosomes or transmit 
their chromosomes abnormally, while others exhibit heritable changes (i.e. gene 
mutations). Exposure of cells to ionising radiation therefore sets off a chain or 
network of reactions giving rise first to chemical and subsequently to metabolic or 
physiological changes.
Although different kinds of ionising radiation interact with matter in a basically 
similar manner they vary with regard to the spatial distribution of ionisation and other 
energy absorption events within the irradiated material. Differences in radiation 
quality are expressed in terms of linear energy transfer (LET), which can be defined 
as the average rate of energy deposition per micron of track of the incident particle or 
ejected electron.
Sparse ionising radiation has low, and dense ionising radiation high, LET. Radiation 
with different LET's kills cells with varying efficiency, some requiring greater dose to 
kill a certain proportion of cells than others. The ratio of the effectiveness of a given 
radiation to that of a standard is termed its relative biological effectiveness (RBE). 
Isotopes with high LET have high RBE.
Therapeutic radionuclides should emit radiation with a high LET in order to destroy 
tumour tissue. Radionuclides with potential for therapy fall into three main 
categories:
i) Beta emitting radionuclides.
ii) Alpha emitting radionuclides.
iii)Electron capture and internal conversion decaying radionuclides.
Beta emitting radionuclides have been and remain the only type of radionuclide to be 
used clinically. Beta particles are negatively charged and are relatively lighter than an 
alpha particle and thus travel through tissue more quickly and have less densely 
ionising properties and a lower LET.
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Beta emitters may be subdivided into those with low particle range (less than 
2 0 0 micrometers), those with a medium range (2 0 0 -1 0 0 0 micrometers) and those with 
a relatively long range (> 1mm).
Alpha emitting radionuclides produce alpha particles. Alpha particles are positively 
charged, relatively bigger, move slowly through tissue and penetrate only a short 
distance (50-90micrometers). Alpha particles are very densely ionising and have a 
high LET (80 keV per micron). Since tissue damage produced by alpha emitters is 
extensive, it is essential that the radionuclide label is firmly bound to the targeting 
pharmaceutical to avoid damage to normal tissue from dissociated radionuclides.
The electron capture and internal conversion decaying radionuclides release Auger 
electrons of low energy X-rays. The range of these low energy particles is extremely 
short (< 1 micrometers). In order to deliver a lethal dose to the tumour cell, it is 
essential that the radionuclide is internalised within the cell ideally within the 
nucleus.
For local intracellular treatment alpha emitting isotopes should therefore be better 
than beta emitting isotopes but they may not be as effective for radiotherapy of solid 
tumours as tissue penetration is poor. More densely ionising radiation like alpha 
particles have a greater probability of hitting the target. Alpha emitting radionuclides 
that have therapeutic potential are few and many have complex decay schemes. If the 
target is as complex as a mammalian cell then some critical part of the cell such as the 
nucleus may need to be hit before any damage will be achieved in the biological 
sense.
7.2.3 MATERIALS AND METHODS.
Three iodine isotopes were used in the following experiments. Iodine was chosen for 
these experiments because not only is iodine readily available, there are two different 
radioactive isotopes with varying properties, one an auger electron emitter, the other a 
beta emitter allowing for comparison. There is no iodine isotope that emits alpha 
radiation. I1 2 7  is stable and was used as the control. I125 is an auger electron emitter 
with high LET and mean range in tissue of one micrometer and a half life of 60 days. 
I1 3 1 is a beta emitter with a mean range in tissue of eighty micrometers and a half life 
of 8  days.
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Figure 62 shows the chemical structure of methylene blue. Methylene blue has a 
formula of C16 H18 S 3H20  and a molecular weight of 373.9 Dalton. Figure 63 shows 
the site to which methylene blue binds to melanin in the melanosome. The sites Rl, 
R2 and R3 represent the possible sites of iodine attachment.
Iodinated methylene blue was obtained by courtesy of Professor A. T. Elliott, 
Department of Clinical Physics and Bioengineering, University of Glasgow.
The electrophilic substitution method was used to make iodinated methylene blue. 
1% methylene blue, sodium iodide, potassium iodide, sterile water for injection and 
concentrated hydrochloric acid (ION) were mixed using the following method as 
described by Link:
1) 1.5 ml concentrated hydrochloric acid (HCL) was added to 100 ml water for 
injection.
2) 11.7 mg sodium iodide (Nal) and 77 mg potassium iodide (KI03) were weighed 
into a vial.
3) 20ml of sterile water was added and agitated until dissolved.
4) The following reagents were added in the stated order mixing thoroughly each 
time:
a) 0.5ml methylene blue
b) 1ml NaI/KI03
c) 0.5ml HCL
The labelling procedure was carried out as below:
1) 0.2ml of the above mixture was taken and added to sodium iodide (i.e. I1 2 5 ,1131, 
1127).
2) The vial containing the radioisotope and the mixture was incubated at 110° C for 
an hour.
3) On completion of the incubation, the reaction vial was cooled briefly prior to the 
separation on a C l8  semi-preparative column. Solvents used were 40% acetonitrile 
and 60% citric acid buffer.
4) The relevant fraction was collected and the acetonitrile component removed via a 
stream of free nitrogen gas.
5) The citric acid component was buffered with bicarbonate.
6 ) The methylene blue obtained should be radiochemically stable for up to two 
weeks. The amount of radioactivity used was 0.5 KBq per mouse.
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The experiments were carried out in vivo using a single cell line ( l x l 0 ^) of 
pigmented melanotic B16/F10 mouse melanoma. This pigmented subline was 
passaged eveiy three weeks in the C57 male mouse. A single cell line (1x 1 0 ^) was 
obtained as follows:
1) Excised tumour was washed in serum containing Ham's F-12 medium and was cut 
into very small fragments.
2) The supernatant was removed and the remaining fragment of tumour was placed in 
a flask containing 30ml of Ham's F-12 medium and three enzymes (0.02%DNase,
0.05%Pronase and 0.02%Collagenase).
3) The mixture was carefully stirred and then incubated for 15-20 minutes at 37° C.
4) The cells were recovered by centrifugation and washed 2-3 times with the serum 
containing F-12 medium before filtering through a cotton gauze.
5) The cells were counted using a haemocytometer, further centrifuged and then 
diluted to the density of lx l 0 ^ in the phosphate buffer as described in experiments 1 
and 2. Experiments utilising radioactive material were conducted in accordance with 
local rules formulated by Professor A. T. Elliott in conjunction with the Radiation 
Protection Adviser.
There were three groups of animals:
1) Group A mice were injected subcutaneously over the thigh with a single cell line of 
pigmented melanoma cells.
2) Group B mice were injected subcutaneously over the thigh with a mixture of 
l x l ()6 melanoma cells and stable or radioactive iodine labelled methylene blue.
3) Group C mice were injected subcutaneously over the thigh with l x l 0  ^melanoma 
cells and once tumour growth was evident, the mice were innoculated with either 
stable or radioactive iodine labelled methylene blue via the tail vein (intravenously).
The tumour growth was recorded daily by measuring the greatest dimension (a) and 
the length perpendicular to the greatest dimension(b). Figure 64 shows the typical 
appearance of tumour growth. Figure 65 shows the intravenous injection. The 
formula used to calculate the tumour volume is:
Tumour volume (v) = (a)2 x b x 0.5
Radioactivity measurements were carried out on alternate days examining the areas 
over the tumour, thyroid and liver using the Neoprobe Model 1000 Portable 
Radioisotope Counter (Figure 6 6 ). This counter is designed to detect and quantify 
gamma radiation. It consists of a sensitive collimated gamma ray detector and a
Figure 64 Typical appearance o f  tum our over the th igh  in the nude m ice
Figure  65 In travenous injection o f  labelled m ethy lene  b lue  into the tail vein
COUNT
MODE
Figure 66 Neoprobe model 1000 for measuring radioactivity
(courtesy of Mr P O'Dywer, Dept of Surgery, Western Infirmary, 
Glasgow)
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microcomputer based control unit for fast, easy and positive location of gamma 
emitting isotopes.
A hand held detector probe allows the detector to be positioned close to the source, 
yielding reliable resolution and detection efficiency. It also has an audible response 
which enables the user to scan tissue and "listen" for areas of elevated radioactivity. 
A digital count display screen displays the count in either a continuous read out mode 
or for a selected time interval.
Radioactivity measurements were carried out in the liver, thyroid and tumour to 
assess the quantity of the labelled isotopes in the liver and the thyroid in relation to 
that seen in the tumour. The time taken to achieve peak levels were also gauged.
The thyroid was examined because iodine is normally taken up by this organ. No 
thyroid blocking agent was used so that the amount of iodine that accumulated in the 
thyroid gland could be studied. This gave the indication of the amount of free iodine 
in the preparation at injection. Any increased activity in thyroid during the 
experiment would thus indicate breakdown of the labelled methylene blue in vivo. 
Since the liver is the biggest organ which is pigmented, in theory, labelled isotopes 
would also target this organ.
When the animals were sacrificed, radioactivity in the tumour, liver and thyroid were 
measured.
EXPERIMENT 3
In experiment 3, stable I1 2 7  was used. The experiment was carried out according to 
the protocol outlined above. The experiment consisted of 3 animal groups:
Group A (the control group) received only tumour cells subcutaneously (7 animals). 
Group B received an admix of tumour cells and I1 2 7  labelled MTB subcutaneously ( 6  
animal).
Group C received tumour cells subcutaneously and on tumour growth becoming 
evident received I12 7  labelled MTB intravenously (7 animals).
EXPERIMENT 4
In experiment 4, the radioactive iodine used was I125. Three groups of animals were 
used:
Group A (control group) received only tumour cells subcutaneously ( 6  animals).
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125Group B received an admix of tumour cells and I labelled MTB subcutaneously ( 6  
animals).
Group C received tumour cells subcutaneously and when tumour growth was evident,
125received I labelled MTB intravenously ( 6  animals).
EXPERIMENT 5
131In experiment 5, the isotope of iodine that was used was I . Similarly three groups 
of animals were used:
Group A (control group) received only tumour cells subcutaneously ( 6  animals). 
Group B received an admix of tumour cells and I131 labelled MTB subcutaneously ( 6  
animals).
Group C received tumour cells subcutaneously and once tumour was macroscopically
131visible, the animals received an intravenous dose of I labelled MTB ( 6  animals).
IN VITRO CELL CULTURE USING IODINE 125
Since there was no growth seen in the animals in group B in experiment 4, it was not 
possible to deduce whether the treatment was effective in destroying all the 
melanoma cells or the mixture that was injected into the nude mice in this group 
contained no melanoma cells. To assess what had happened, an in vitro cell plating 
experiment was designed and carried out.
125B16/F10 melanoma cells were exposed to the radioisotope I under in vitro 
conditions. Cell plating was carried as below:
1. B16/F10 cells were grown to near confluence, harvested and counted. Two 
aliquots of lx 106 cells were taken, centrifuged and resuspended in PBS.
2. One aliquot of cells was exposed to 1 Mbq of I125, while the other was kept as a 
control.
1253. After exposure to I , both sets of cells were centrifuged, then washed several 
times to remove exogenous iodine.
4. The concentration of the cell aliquots was adjusted by dilution with complete 
medium such that either 500 or 1000 cells were plated into 25 cm2 tissue culture 
flasks.
5. Cultures were incubated at 37°C for 6  days after which the formed colonies were 
fixed with methanol, stained with trypan blue and counted.
6 . The numbers of colonies formed by the cells exposed to I125 were compared to the 
numbers formed by the control cells, and the results expressed as % plating 
efficiency.
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7.2.4 RESULTS.
Statistical Analysis
All the results from experiments 3,4 and 5 were analysed as described below:
1) Tumour volume for each animal in each group was calculated and a mean tumour 
volume and rate of growth derived. The average tumour volume on day 12 in each 
group was also calculated
2) The rate of growth and tumour volume on day 12 between different groups were 
compared.
3) To confirm if there was a difference in the groups with respect to the variables 
shown above, the statistical analysis as outlined in experiments 1 and 2  was used.
4) The mean tumour volume and standard deviation on each day was calculated and 
plotted. The rate of growth was then obtained by linearising the results. The One 
Way Analysis of Variance was used to assess whether the results obtained in each 
group were statistically different. Friedman's test was used to assess whether the 
growth rate in the groups was significantly different.
5) Similar to experiments 1 and 2, the results were lagged. Formal analyses of the 
data was carried out using Repeated Measures Analysis of Variance. A significant 
group effect indicates an overall difference between the groups. The group day 
interaction measures the pattern across days for each group, and a significant 
interaction means the pattern differs for the two groups.
EXPERIMENT 3 (nude mice treated with iodine 127)
In group A, tumour growth was observed 5 days after inoculation of the tumour cells, 
just as had been seen in experiment 1, group A. The animals were sacrificed between 
days 12 and 14.
In group B growth of tumour became evident 9 days following inoculation of tumour 
cells with iodine 127 labelled MTB. The animals were sacrificed on day 15.
In group C tumour was evident on day 5. The animals were sacrificed on day 14.
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Analysis of the results showed that the rate of growth was maximal in group A and 
that this rate was statistically different to that in groups B and C (p = 0.001).
Analysis of the tumour volume on day 12 showed that the tumour bulk was largest in 
group A and least in group B.
When the results were lagged in group B with respect to group A, there was a 4 day 
lag with a significant group effect (p <0 .0 1 ) but no significant group interaction (p = 
0.09). When A and C were compared, there was no lag with no overall group effect 
(p = 0.09). A lag of zero indicates that the drug has no effect in reducing tumour 
growth.
EXPERIMENT 4 (nude mice treated with iodine 125)
In group A, tumour growth was observed 5 days after the inoculation of the tumour 
and the animals were sacrificed between days 14 to 20. There was minimal 
background radioactivity in the tumour, thyroid and liver.
In group B mice, there was no tumour growth. The animals were sacrificed on day 
20 after inoculation. Radioactivity was maximal at the site where the tumour cells 
were inoculated followed by the thyroid and then the liver and similar results were 
obtained when the animals were sacrificed and the organs examined. The 
radioactivity at the site of injection was three and a half times and nine times that seen 
in the thyroid and liver respectively.
In group C, tumour growth was evident on day 7 and the animals were sacrificed 
between days 18 to 21. Maximum radioactivity was seen in the thyroid, followed by 
the liver and then the tumour. When the animals were sacrificed, maximum 
radioactivity was demonstrated in the liver, followed by the thyroid and then the 
tumour.
One Way Analysis of Variance showed that tumour growth was maximal in group A 
and that the rate was significantly different (p = 0.001) to that seen in group C. Using 
the Friedman's Test the rate of growth was significantly greater in the group A 
animals than in group C (p = 0.001).
Analysis of tumour volume on day 12 again showed that maximal growth was in 
group A.
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When the results in group C were lagged and compared to group A, there was no 
overall group effect (p = 0.58) but a significant interaction was seen.
Analysis of radioactivity showed that in group B, radioactivity at the site of injection 
was maximal and that this was significantly different (p < 0 .0 0 1 ) to that in the thyroid 
and liver. In group C, radioactivity was greater in the liver and thyroid and this was 
significantly different (p < 0 .0 1 ) to that at the tumour site.
IN VITRO CELL CULTURE (melanoma cells treated with iodine 125)
The colonies were counted and expressed as plating efficiency. For each of the
experiment, there were 3 plates and the plating efficiencies for the control cells were
78%, 88.5% and 8 6 %. The mean value was 84.17% +/- 4.48. In the tumour cells 
10^exposed to I » the plating efficiencies were 76%, 75%, 83% and 77.25% with a 
mean of 79.0% +/- 2.84. The colonies formed by the tumour cells exposed to the 
radioactive Iodine12 5  was significantly less than in the control group.
EXPERIMENT 5 (nude mice treated with iodine 131)
In group A, tumour growth was evident on day 5 after the inoculation of the tumour 
cells. The animals were scarified between days 13 and 15. There was minimal 
background radioactivity in the tumour, liver and the thyroid.
In the group B, tumour growth was evident on day 9 following inoculation. The 
animals were sacrificed on day 18. Radioactivity was maximum in the tumour 
followed by the thyroid, then the liver. When the organs were examined, maximum 
radioactivity was seen in the thyroid followed by the liver and then tumour.
In the group C, tumour growth was seen on day 5 and the animals were sacrificed on 
day 15. In group C the radioactivity was maximal in the liver followed by the thyroid 
and then the tumour. When the animals were sacrificed and the organs examined, 
radioactivity was maximal in the thyroid, followed by liver and then tumour.
Analysis showed that the rate of tumour growth was maximal in group A and that this 
rate was significantly different to that in groups B and C (p < 0.001). Using the 
Friedman's Test, the rate of growth was significantly greater in group A followed by 
group C and with the least growth in group B animals (p = 0.001).
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Analysis of the tumour volume on day 12 showed that the tumour bulk was greatest 
in group A with the least in group B.
When the results were lagged in group B and compared to group A, there was no 
overall group effect (p = 0.13) or interaction (p = 0.09). Again lagging group C and 
comparing it against group A, there was also no overall group effect (p = 0.37) but a 
significant interaction (p <0 .0 1 ) was seen.
Thus in group B, it seemed the effect of the drug was to delay the tumour growth for 
4 days, and thereafter the pattern of growth was the same as that shown from the start 
by the control group.
In groups A and C the delay was around 2 days but although there was no overall 
difference between the groups, their pattern of growth varied from day to day and so 
it was not simply the case that group C followed the same pattern as the control group 
after this time.
Analysis of radioactivity showed that in group B, radioactivity at the site of injection 
was maximal and that this was significantly different (p < 0 .0 0 1 ) to that in the thyroid 
and liver. In group C, radioactivity was greater in the liver and thyroid and this was 
significantly different (p < 0 .0 1 ) to that at the tumour site.
Figure 67 shows the rate of tumour growth in experiments 3, 4 and 5. Figure 6 8  
shows the tumour volume on day 12 in experiments 3, 4 and 5. Figures 69-74 show 
the radioactivity of the various organs in experiments 4 and 5.
7.2.5 DISCUSSION.
The aim of these experiments was to test if targeted therapy was effective and to 
identify the most suitable isotope. The results obtained in the experiments confirm 
the hypothesis that targeted radiotherapy using radioactive iodine is effective in the 
control of tumour growth in an animal model.
The rate of tumour growth in the treated groups were significantly different to that of 
the control, suggesting that the radioactive isotopes were having some effect on the 
tumour growth. If radioactive isotopes (iodine 125 and 131) had only a delaying 
action, then when the results are lagged to the control group, there should be no 
significant difference. However, when the results were lagged to the control groups, 
the pattern of tumour growth was significantly different. This suggests that the
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treatment with the radioactive iodine was having an effect on reducing tumour growth 
and this effect was not simply one of delaying action.
Since there was no growth in group B in experiment 4, the experiment was repeated 
in vitro. The plating results showed that the growth of tumour cells was significantly 
retarded by I125.
From this animal model, it can be concluded that both the radioactive isotopes of 
iodine (I125 and I131) significantly effect the tumour growth. Iodine 127 has no effect 
on tumour growth.
However it was not possible to reach a definitive conclusion as to which was the more 
effective radionuclide. This was because different batches of animals and cells lines 
were used, making direct comparison of I125  and I131 not possible. Therefore in 
order to make a direct comparison, the experiments had to be repeated using animals 
from the same batch and using the same cell line simultaneously. This was carried 
out in section 7.4.
Results obtained in experiment 3 using stable I 127  labelled with MTB were similar to 
the results obtained when MTB was used alone. Here there was no significant group 
effect and there was no lag confirming that I12 7  has no tumouricidal effect. It also 
showed that iodine binds effectively to methylene blue without altering it's affinity 
for melanin. This is an important finding. It shows that MTB is a suitable carrier 
molecule for radionuclides of iodine.
The only spurious results that were obtained in these experiments were in group B in 
experiment 4. There was no growth observed in these animals. The radioactivity in 
the animals was high from day 1. This could be explained if there had been some 
contamination resulting in a different dose of radioactivity being used that was 
sufficiently large to kill all the melanoma cells or that there were no melanoma cells 
in the mixture that was inoculated into the animals.
In order to address this problem, a cell culture was set up using the same method in 
vitro to assess the effectiveness of iodine 125. This experiment showed that there 
was less tumour growth in the cell line isolated with MTB labelled iodine 125 than in 
the control. This suggests that a higher dose of I125  was possibly used (as the 
radioactivity was higher than that seen in group C) and this was sufficiently large to 
kill all the melanoma cells during the incubation period prior to inoculation.
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The results of these mouse melanoma studies raises several questions. High levels of 
radioactivity were recorded in the thyroid gland and the liver of the mice. These 
levels were greater in group C mice who received the isotope via the tail vein than in 
group B mice where the isotope was injected subcutaneously after incubation with the 
tumour cells.
This difference can be explained. Group B animals received a mixture of tumour 
cells and radioactive iodine which had already been incubated for three hours before 
subcutaneous injection thus giving the iodine labelled methylene blue time to bind to 
the melanoma cells. In this circumstances, there may have been less labelled 
methylene blue available to enter the circulation.
The greater activity in group C mice could be because the radioactive isotope was 
injected intravenously and gained immediate access to the systemic circulation. It 
would perfuse through organs such as the lung and liver prior to reaching to the skin. 
If pigmented cells are present as in the liver, the isotope will attach to the pigmented 
cells. This is reflected in the finding that the radioactivity count in the liver in all 
group C experiments was higher than in the tumour.
Despite the fact that the cells of the thyroid gland are not pigmented, there was still 
radioactivity detected in the thyroid gland. This meant that the labelled methylene 
blue may not be as stable in vivo with free iodine generated actively taken up by the 
thyroid cells. Thus if this treatment is to be used in the human situation, the thyroid 
would have to be blocked using oral potassium iodide and potassium perchlorate to 
minimise the radiation dose to the thyroid. Furthermore, the stability of the 
compound has to be assessed before it is applied to the clinical situation.
These experiments have shown that targeted radiotherapy using I1 2 5  and I131 is 
possible and that MTB is an effective carrier molecule. There is significant 
accumulation of the radionuclides in non targeted organs and this appears to be 
related to the mode of delivery.
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13  COMPARISON OF IODINE 125 AND IODINE 131 IN THE 
TREATMENT OF IN VIVO AND IN VITRO B16/F10 MELANOMA
It was not possible to conclude from the earlier experiments which of the two isotopes 
of iodine was superior. A further series of experiments were thus designed to address 
the following unanswered questions:
1) Which isotope is more effective?
2) Is the accumulation of the isotopes in other organs a constant feature?
7.3.1 MATERIALS AND METHODS
The materias and methods used to carry out these experiments were as described in
7.2 unless otherwise as stated below. Both in vivo and vitro experiments were carried 
out to confirm that the effect of radioactive iodine was not just a chance event and 
that the results observed in these experiments were seen in both the in vivo and in 
vitro situation. The experiments in this section were carried out using the same 
isotopes of iodine as in experiments 4 and 5. Both in vivo and in vitro experiments 
were carried out simultaneously using the same batch of tumour cells (from the same 
cell line) and the same batch of iodinated methylene blue. Since the number of 
animals used in these experiments were greater than the agreed number in the original 
protocol, written permission was obtained from the Home Office before the 
experiments described below were carried out.
IN VTVO EXPERIMENTS USING IODINE 125 AND 131
There were three groups of animals:
1) Group A mice were injected with a single cell line 1x10^ of pigmented melanoma 
cells subcutaneously ( 6  animals).
2) Group B was divided into two subgroups:
B1 mice were injected with a mixture of lx l0 ^ melanoma cells and I1 2 5  labelled 
methylene blue subcutaneously ( 6  animals).
B2 mice were injected with a mixture of lx l0^ melanoma cells and I131 labelled 
methylene blue subcutaneously ( 6  animals).
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3) Group C mice were divided into two subgroups:
Cl mice were injected with lx l 0 ^ melanoma cells subcutaneously and once tumour 
growth was evident, the mice were innoculated with the I125  labelled methylene blue 
intravenously via the tail vein ( 6  animals).
C2 mice were injected with 1x10^ melanoma cells subcutaneously and once tumour 
growth was evident, the mice were innoculated with the I131 labelled methylene blue 
intravenously via the tail vein ( 6  animals).
Radioactivity measurements were carried out on alternate days using the Neoprobe 
Model 1000 Portable Radioisotope Counter. The tumour growth was recorded daily 
by measuring the greatest dimension (a) and the length perpendicular to the greatest 
dimension(b). The formula used to calculate the tumour volume was:
Tumour volume (v) = (a) x b x 0.5
When the animals were sacrificed, the tumour, liver and thyroid glands were 
examined for radioactivity. The amount of radioactive used was 0.5 KBq per mice.
IN VITRO CELL CULTURE USING IODINE 125 AND 131
Culture of B16/F10 cells were exposed to the radioisotope in in vitro. Cell plating 
was carried as below:
1) B16/F10 cells were grown to near confluence, harvested by trypsinization and 
counted. Three aliquots of lx 10^ cells were taken, centrifuged and resuspended in 
PBS.
2) One aliquot of cells was exposed to 1 KBq of one to l!31 and one was 
maintained as a control. The cells were exposed to each iodine compound for 30 
minutes at room temperature.
3) After exposure, the cells were centrifuged (lOOOrpm for 5 minutes), then washed 
with PBS several times to remove exogenous iodine.
4) The concentration of the cell aliquots was adjusted by dilution with complete 
medium and approximately 100 cells were plated into 25 cm2 tissue culture flasks.
5) Cultures were incubated at 37°C for 7 days, with a medium change after 3 days. On 
day 7, the formed colonies were fixed with methanol, stained with methylene blue 
and counted.
6 ) The colonies were fixed and stained as below:
i) The monolayer was rinsed with PBS, and the rinse discarded.
ii) Fresh PBS was added, 5ml per 25 cm2.
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iii) Methanol was added slowly to the PBS with mixing. The bottle was tilted so that 
the PBS was on the side opposite to the monolayer. 1 ml methanol was added and 
the mixture was run over the cells. The bottle was tilted back and 1 ml added and the 
monolayer rinsed, and this was continued until 50% methanol was reached.
iv) The 50% methanol/PBS mixture was discarded and replaced with fresh methanol. 
This was left for 10 minutes.
v) The methanol was then discarded and replaced with fresh anhydrous methanol. 
The monolayer was rinsed and the methanol discarded.
vi) To stain, methylene blue was added, 2 ml per 25 cm2, making sure that the entire 
monolayer was covered and remained covered.
vii) After 2 minutes, the stain was diluted with 8  ml water and was agitated gently for 
a further 2  minutes.
viii) The stain was discarded and the monolayer washed vigorously in running tap 
water until any blue cloudy background stain was removed but not leached out of the 
cells.
ix) The water was poured off and the monolayer rinsed in deionised water and 
examined under the microscope while still wet.
7) For each isotope and the control, 3 platings were performed. The numbers of 
colonies formed by the cells exposed to I 125 and I13 Were compared to the numbers 
formed by the control cells, and the results expressed as % plating efficiency.
7.3.2 RESULTS
IN VIVO EXPERIMENTS
The mean tumour volume and standard deviation was calculated for each animal 
group. These results were then linearised and plotted against time to obtain the rate 
of tumour growth for each animal group. Since earlier experiments (1,2,3,4,5) had 
already shown that the radionuclides had a significant effect in slowing growth rate 
and not just a delaying effect, lagging of the results was not done. The statistical tests 
used were One Way Analysis of Variance and Friedman's Rank Comparison.
In the group A mice, tumour growth was evident on day 5 after inoculation of the 
tumour and the animals were sacrificed between days 1 0  and 1 2 .
In group B mice, tumour growth was evident first in group B2 mice on day 7 
followed by B1 on day 8 . The animals in this group were sacrificed between days 12 
and 16.
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In group C mice growth was evident on day 5 in both the subgroups Cl and C2. The 
animals were sacrificed between days 1 2  and 15.
When the rate of tumour growth was compared in the three groups, the rate of growth 
was greatest in group A (Figure 75).
When the rates of growth in group B animals were compared to the control, the 
growth rate was significantly different both by the One Way Analysis of Variance (p 
= 0.001) and Friedman's rank comparison test.
When the rates of growth in group C animals were compared to the control, the 
growth rate was also significantly different in Cl and C2 (p = 0.001).
When intra group growth rates were compared, the growth rate was slower in 
subgroup B1 than B2 and this was statistically significant (p = 0.002).
Similarly, when the intra group growth rate was compared in group C, although the 
growth rate of Cl was slower than C2, this did not reach statistical significance (p = 
0.228).
When inter group growth rates were compared, the growth was significantly slower in 
B1 than Cl (p = 0.018) and in B2 than in C2 (p = 0.001).
In summary, the addition of radioactive I125  and I131 labelled to methylene blue 
produces slower tumour growth when compared to no treatment. In group B animals 
those treated with iodine 125 had a slower tumour growth than iodine 131. However 
in group C, the growth rate of tumours in mice treated with iodine 125 and 131 was 
not significantly different. Thus it would appear that iodine 125 is superior to iodine 
131 in retarding tumour growth.
Radioactivity in the tumour, liver and thyroid of the Group A was similar to the 
background radioactivity. However in subgroups B1 and B2 radioactivity was 
maximal in the tumour followed by the thyroid and then the liver. In the subgroups 
Cl and C2, radioactivity was maximum in the liver, followed by the thyroid and then 
the tumour
Similarly, when the animals were sacrificed, maximal radioactivity was recorded in 
the tumour in groups B1 and B2. In groups Cl and C2, radioactivity was maximal in 
the liver and thyroid.
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Figure 75 R ate o f  tum our grow th  in groups A, B and C in vivo
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IN VITRO EXPERIMENTS USING IODINE 125 AND 131
Figure 76 shows the appearance of the melanoma cells in the control plate when 
examined under the microscope and figure 77 shows the melanoma cells treated with 
iodine 125 when examined under the microscope. Here it can be clearly seen that in a 
single field, there were less melanoma cells in the treated plate than in the control.
The colonies were counted and the results expressed as a percentage of the control. 
The results of the number of colonies and the percentage in relation to the control are 
tabulated in Table 13. Figure 78 shows a graphical illustration of the percentage 
efficiency of the plates treated with iodine 125 and 131 to the control. The results 
show that growth of the melanoma cells incubated with the iodine isotopes is 
significantly reduced when compared to the untreated control (p <0.001). There was 
approximately a reduction of 6 6 % and 33% in the tumour growth in the melanoma 
cells exposed to iodine 125 and iodine 131 respectively when compared to the 
control. When iodine 125 was compared to iodine 131, the reduction in tumour cells 
treated with iodine 125 was twice that of tumour cells treated with iodine 131 (p 
<0.001). Thus iodine 125 was also superior to iodine 131 in vitro.
7.3.3 DISCUSSION
Cellular DNA is the main target for ionising radiation. Radiation with high LET 
causes more permanent damage than that with low LET. Low LET radiation may 
cause initial damage which is subsequently modified by post irradiation cellular 
processes such as repair.
The factors that must be taken into account when selecting a therapeutic radionuclide 
include its chemistry, half-life and availability. The physical half-life of the 
radionuclide must be matched to the half-life of the prepared radiopharmaceutical in 
the tumour, namely the biological half-life.
Radiosensitivity is a significant factor affecting the response of tumour cells to 
radionuclide therapy. Hypoxic cells are recognised as being relatively radioresistant.
The results obtained in these experiments showed that when nude mice with 
melanoma were treated with I125  and I131 labelled methylene blue, the growth rate of 
the tumour was significantly reduced when compared to the nude mice that did not 
receive treatment. These experiments reinforce the results that were obtained in
Figure 76 C ontrol plate show ing tum our cell grow th in the in vitro  culture
Figure 77 Tumour cell plate treated with iodine 125 in the in vitro culture
NUMBER OF 
COLONIES
M EAN+S D % OF 
CONTROL
B16/F10
CONTROL
102 91 87 93.33 +/- 6.34
B16/F10 + I 125 28 36 36 33.33 +/- 3.77 35.72
B16/F10 + I 131 59 68 52 59.67 +/- 6.55 63.93
Table 13 Results of in vitro cell plating
Control I 125 I 131
Figure 78 Tumour growth in the in vitro experiment
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experiments 4 and 5 that targeted radiotherapy using radioactive I131 and I 125  
labelled methylene blue is effective in reducing the growth of melanoma.
If the in vivo and in vitro experiments could be compared, then the group that should 
be compared to is group B. In in vitro experiments, the reduction on the rate of 
tumour growth was significantly greater to that seen in group B animals. This 
reinforces the fact that it is not sufficient to demonstrate and conclude from in vitro 
experiments that a certain therapy is effective. In vivo studies are important as they 
reflect the problems that are encountered in the clinical situation more accurately. 
There may be several interacting factors in the host that may modify the treatment 
and reduce the efficacy of the treatment. The results of these experiments 
demonstrate that the reduction of rate of tumour growth is different in the in vivo and 
the in vitro situation although the same amount of tumour cells and radioactivity were 
used.
In the in vivo experiments, the growth rate of the tumour in the group B animals 
which received iodine 125 was slower than those that received iodine 131. There was 
no statistical difference in the growth rate in experiment C between animals treated 
with iodine 125 and 131. This difference is probably explained by the considerable 
difference in tumour bulk at the time of inoculation of the labelled methylene blue. 
This reinforces the principle of adjuvant therapy (section 2.1.2) that the effectiveness 
of the treatment is inversely proportional to the tumour burden, i.e. the smaller the 
tumour the better the response.
Furthermore, the route of adminstration was different in the groups B and C. In 
group B, the treatment was given subcutaneously but in group C, it was given 
intravenously. Thus in group C, the iodine labelled methylene blue gained access to 
the systemic circulation and became incorporated into the cells of organs that are 
pigmented. This resulted in less labelled methylene blue being available to target the 
melanoma cells.
Link3 6 7  and colleagues have compared the therapeutic effectiveness of iodine 125 
and astastine 211 in the treatment of pigmented melanoma in nude mice. Both these 
isotopes are auger electron emitters but astastine has a shorter half-life than iodine 
125. Experiments were performed both in vivo and in vitro. The effectiveness of the 
treatments were determined by lung colonogenic assay. They concluded that iodine 
125 was ineffective when incorporated into melanosomes distributed in the 
cytoplasm whilst astastine 2 1 1  was effective in the treatment of the tumour.
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However the results from the experiments reported here, contradict Link's findings. 
Both the in vitro and in vivo experiments show that iodine 125 significantly effects 
tumour growth. These differences could be explained by the different route of 
adminstration of labelled methylene blue.
When the animals were injected intravenously, the highest radioactivity count was 
not found in the tumour but in organs of the body that are pigmented and also in the 
thyroid. The reason that Link reported no effect was probably related to the fact that a 
significant amount of radioactive iodine was in the thyroid and not in the targeted 
tissue. Astatine does not normally accumulate in the thyroid. Thus, thyroid blocking 
should be carried out before such a conclusion can be reached.
From this series of both in vivo and in vitro experiments, it can be concluded that 
Iodine 125 and 131 have a significant effect on the tumour growth of melanoma in 
nude mice. Iodine 125 appears to be more effective in the control of tumour growth 
than iodine 131. This may be reflected in the chemistry of the isotope as iodine 125 
has a higher LET energy than iodine 131.
The route of adminstration is important if therapy is to have clinical application. As 
seen in experiments 4 and 5, radioactivity in group B was maximal in the tumour 
whilst in group C radioactivity was greater in the liver and the thyroid. If the 
treatment is to be used to destroy limb metastases, then the isolated limb perfusion 
circuit may be a route of delivery for this treatment. It would allow direct delivery of 
a radiopharmaceutical into the vascular bed perfusing the tumour and would results in 
high concentrations of the drug in the cells targeted without the systemic 
complication. Furthermore, since oxygenation can be maximised as already shown in 
chapter 4, hypoxia in the targeted cells can be prevented and treatment effect 
maximised. This localised form of treatment has already been shown to be effective 
in the treatment of unresectable liver tumours.
Metastatic deposits from melanoma tend to be found in the liver and the lung. It has 
already been shown that when the therapy is administered intravenously, a significant 
amount of iodine accumulates in the liver. Thus if this therapy is to be used to target 
and destroy blood bome metastases, then intravenously administered therapy is 
appropriate. It is however important to appropriately block the thyroid to prevent any 
free radioactive iodine from being taken up
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Another possible clinical application for targeted therapy is its use in direct 
intradermal injection of recurrent nodules similar to that seen with BCG. This may 
not only have the effect of reducing the size of the lesion but may also modify the 
disease process and ultimately improve disease free survival and the overall survival.
In all the experiments there were three groups of animals. The first group or group A 
is analogous to the patient with untreated tumour. The second or group B is 
analogous to the patient with primary melanoma receiving adjuvant therapy and the 
third or group C is analogous to the patient receiving therapeutic treatment. Thus in 
theory, targeted radiotherapy could be used after as an adjuvant or in the therapeutic 
setting as outlined above.
Before using the ILP circuit to deliver such treatment, further experiments are needed 
to examine the effects of combining radioactive iodine with melphalan in the isolated 
limb perfusion circuit in larger animals. This will involve the monitoring of time 
dependent bio-distribution of the isotope and calculating the optimal dose and time. 
The circuit could be used to assess the effect of tumour growth, appearance of distant 
metastases and side effects of treatment.
This treatment may have therapeutic potential to improve survival in the high risk 
stage I melanoma patient. The cure of metastases requires total destruction of all the 
tumour. Nothing short of that can produce long term remission. The presence of 
undetectable micrometastases will result in rapid tumour cell proliferation. If a cure 
is to be found for the patient who may have no evidence of clinically detectable 
tumour, a treatment aimed at identifying and targeting minute metastases is necessaiy 
as these cells will go on to form recurrencs of the tumour.
Again applying the adjuvant principles, when animals were inoculated with a known 
tumour dose and randomly allocated to single treatment modalities or combination 
modalities, the latter produced superior results. Thus in patients with high risk 
primary melanoma, the use of combined targeted radiotherapy and melphalan in the 
optimised ILP circuit may be beneficial. This treatment will selectively target and 
destroy those in transit metastatic cells that have gained access not only to the 
lymphatics but also to the blood stream. This may reduce the tumour sub-population 
that survive thus producing a longer remission and hopefully a cure. The use of a 
repeat perfusion or a double perfusion schedule technique may also be beneficial in 
stage I patients ensuring that all possible melanoma cells have been eradicated.
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7.3.4 CONCLUSION
Targeted radiotherapy using iodine 125 and 131 is effective in slowing the growth of 
B16/F10 malignant melanoma in the nude mice model. It appears that iodine 125 is 
superior to iodine 131. These results were also seen in vitro. Methylene blue is an 
effective carrier molecule to which the iodine radionuclides can be attached. 
Intravenous adminstration of the targeted therapy may result in accumulation of the 
radiopharmaceutical in non targeted organs. The use of local targeted therapy appears 
to be a solution and ILP may be the vehicle for such a treatment.
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CHAPTER 8  
CONCLUSION
The incidence of malignant melanoma is increasing worldwide at the rate of 6%-7% 
per year which is faster than any other cancer. In Scotland, 588 cases were registered 
in 1992, an increase from 507 in 1991. Melanoma is a curable malignancy if 
identified and surgically excised at an early stage. To quote Neville Davis 
"melanoma writes its message on the skin for all to see. But the eye cannot see what 
the mind does not know and so some see the writing but do not comprehend the 
message. Those who understand the message will save many lives by taking the 
appropriate action". Professional and public education campaigns therefore play an 
important part in programmes aimed at early detection.
In Scotland, melanoma is being actively monitored by the Scottish Melanoma Group 
(SMG). This group consist of physicians and surgeons whose aim is not only to 
improve the treatment of the disease but also to create an awareness amongst the 
general public of a malignancy with a potential cure if detected at an early stage. 
Gartnavel General Hospital in Glasgow is the only centre in Scotland and the North 
of England to provide isolated limb perfusion treatment for malignant melanoma of 
the extremities.
Surgery has long been the cornerstone in the treatment of malignant melanoma. Wide 
local excision of an early malignant melanoma can confer a 95% cure rate in certain 
patients. However, even as early as the 19th century, it was appreciated that local 
excision alone was not sufficient. At the turn of the century, elective 
lymphadenectomy became established in the treatment of melanoma. Handley 
showed that although melanoma spread first to the lymph nodes, it was blood borne 
spread that finally kills the patient. There were no changes in the treatment of 
melanoma for over fifty years. Primary and recurrent disease of the limb was treated 
surgically and in intolerable disease, amputation was the only option.
In 1957, isolated limb perfusion using melphalan was introduced for the treatment of 
limb melanoma. In patients with melanoma of the extremities, treatment with 
isolated limb perfusion has now been established for locally inoperable melanoma 
and as an adjunct to surgery in recurrent melanoma. ILP has been available in 
Glasgow since 1983. It was first used in the treatment of limb recurrences that failed 
to respond to local surgery and where amputation was the only option available.
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Since 1983, 103 patients (78 female, 25 male) with recurrent limb melanoma have 
undergone ILP. A total of 122 perfusions have been carried out. Although the 5 year 
survival of the group was only 26%, a high objective response was seen in the 
patients. 75% showed complete and 23% showed partial response to the first 
treatment of ILP with 47% showing complete and 53% showing partial response to 
repeat perfusion. It was interesting to see that when treatment was repeated, a 
significant response was seen even with the same chemotherapeutic agent. The poor 
survival seen in this unit when compared to those published, reflects the timing of 
referrals. Most of the patients referred had advanced disease and the most important 
consideration then was control of the disease and avoidance of amputation. This was 
successfully achieved as no patient underwent amputation either as a result of 
complications from ILP or from failure to control the disease.
From analysis of these results, the important message is that physicians should refer 
patients at an early stage of the disease. ILP can be used not only to control 
recurrences but also to modify the course of the disease, thus improving survival. 
There may however be another option for the treatment of limb recurrences, i.e. 
surgical excision of the recurrences followed by ILP with melphalan. This uses the 
principle of adjuvant therapy in that agents with activity against moderately advanced 
disease are more active against residual metastatic disease after debulking the tumour 
by surgery (section 2 .1 .2 ).
What is now needed is a randomised trial comparing surgical excision followed by 
secondary adjuvant therapy to ILP alone. At the moment, results from the Glasgow 
unit show that ILP is the most effective means of palliation for recurrent limb 
melanoma when compared to other treatment modalities such as radiotherapy or 
chemotherapy (section 2.2,2.3).
The role of ILP in the treatment of limb recurrence has been clearly established. 
However, the use of ILP as an adjuvant to surgery in primary melanoma remains 
controversial. In the Glasgow unit, between 1985 and 1993, patients with primary 
lesions greater than 1.5mm underwent adjuvant ILP. Ninety nine patients, 31 males 
and 6 8  females with a median age of 58 (range 21-84 years) and with a mean Breslow 
thickness of 3.2mm were treated by wide excision and ILP using melphalan. To date, 
the overall survival of the patients treated with ILP does not significantly differ from 
non perfused patients (from the SMG data base). However, for patients with lesions 
of 1.5mm to 2.99mm, analysis of both time to first recurrence and survival suggests a 
consistent trend towards benefit in the ILP group.
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Subungual melanoma is rare and experience in treating this condition with isolated 
limb perfusion is limited. From 1985 to 1993, 24 patients were treated with local 
amputation and ILP using melphalan and mild hyperthermia. The overall 2 year and 
5 year survival was 77% and 46% respectively. Sex and site did not influence 
survival. No difference in survival could be demonstrated between this group of 24 
patients and a group of 111 patients with subungual melanoma treated without ILP 
from the Scottish Melanoma Group. Subungual malignant melanoma is known to 
carry a poor prognosis. No added benefit was seen by using ILP. The routine use of 
ILP for patients with subungual melanoma is thus not recommended.
The results from the Glasgow unit suggest that the use of adjuvant ILP does not 
appear to confer survival benefits. The exact reason for this remains unclear. It is 
possible that the patients were either staged incorrectly or the "type" of melanoma 
seen in this part of the world is different from that seen elsewhere. Before defining 
the role adjuvant ILP several questions needed to be answered. Firstly, could the ILP 
circuit be improved further to maximise the efficacy of the chemotherapeutic agent? 
Secondly, could prognostic factors for survival be identified in patients with primary 
melanoma?
Having reviewed the results of ILP in Glasgow, experiments were designed to answer 
the question "How can the current management of limb malignant melanoma be 
improved?"
Isolated limb perfusion has been available for over 30 years. The main advantage of 
this treatment is that high doses of chemotherapeutic agents can be delivered locally 
without producing generalised toxicity. However since it's introduction in 1957, few 
changes have been made to the operation of the circuit. There are certain facts 
relating to the ILP circuit.
Firstly, the ILP circuit operates in a continuous blood flow mode whilst blood flow in 
normal blood vessels is pulsatile in nature. Secondly the ILP circuit is a confined 
space in which heated blood is circulated thus predisposing to the development of 
compartment syndrome. This has led to the practise by several investigators of 
performing routine prophylactic fasciotomy after ILP. Lastly, several studies have 
shown that the effects of chemotherapeutic agents can be enhanced by increasing the 
tissue oxygen tension.
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With the above facts in mind, several studies were designed and carried out to 
investigate if the ILP circuit could be improved. Twenty-two patients undergoing 
ILP were recruited into the first study to assess the physiological advantages of 
introducing pulsatility into the ILP circuit. Pulsatility was introduced by using a 
Stockert Frequency Control Module applied externally to the circuit and 
synchronised to the patient's electrocardiogram. Twenty-two patients matched for 
sex, age and site undergoing ILP in the standard continuous flow ILP circuit were 
used as controls.
Using pulsatile blood flow, the time taken to reach physiological oxygen saturation 
was shorter and there was less fluctuation in levels of oxygen tension. There was also 
less fluid shift in the pulsatile circuit compared to the non pulsatile circuit. However, 
there was no significant difference in the maximum oxygen levels achieved between 
the two groups. Introduction of pulsatility is advantageous as it produces a more 
stable circuit and thus better oxygenation.
The next study examined how the compartment pressures in the limbs were affected 
by ILP and to assess if there was a difference when the circuit was operated in the 
pulsatile and non pulsatile mode. Eight patients had pulsatile ILP and 8  had non 
pulsatile ILP. Pressures were measured using the wick technique.
Results of this study showed that with time there was a rise in the compartment 
pressure and the rate of rise in the non pulsatile group was significantly greater than 
in the pulsatile group. The lower rate of rise in compartment pressures in the pulsatile 
group is less likely to predispose this group to the compartment syndrome. Since the 
introduction of pulsatility into the ILP, neither routine prophylactic fasciotomy nor 
therapeutic fasciotomy has been needed to be performed.
The third study was designed to assess the use of vasoactive drugs in patients in 
whom satisfactory tissue oxygenation could not be achieved despite high flow rates. 
In theory, by reducing the peripheral arterial resistance using a vasodilator agent, the 
flow rate could be increased further with a resultant rise in the tissue oxygenation. 
The drug chosen was verapamil hydrochloride. Twenty-one patients undergoing ILP 
were recmited, with 16 undergoing non pulsatile and 5 undergoing pulsatile 
perfusion. After adminstration of the drug, a significant fall in the peripheral pressure 
and oxygen tension were seen. Although this fall was not sustained, there was no 
increase in the local oxygen. The effects were similar in both the pulsatile and the 
non pulsatile blood flow modes. Thus verapamil hydrochloride could not be used to 
improve local oxygen in the perfused tissues.
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From these studies it was clearly seen that the ILP circuit could be improved, 
optimising the tumouricidal action of the chemotherapeutic agent. The ILP circuit in 
the Glasgow unit is currently being operated in the pulsatile blood flow mode.
ILP is the treatment of choice in this unit for the management of recurrent limb 
malignant melanoma. However, in some patients ILP is not possible or fails to 
control the disease. The cutaneous metastases from melanoma, if left untreated, will 
grow, ulcerate and become painful. Other treatment options such as radiotherapy, 
immunotherapy and cryotherapy can be used to control the disease and are largely 
ineffective. These modes of treatment are also not without significant morbidity. A 
study using carbon dioxide laser to ablate these cutaneous lesions was carried out.
Results of this study showed that carbon dioxide laser is an effective alternative to 
ILP when ILP has failed or is not possible. It has the advantage over ILP in that a 
series of repeat treatments can be administered with little or no significant morbidity 
unlike ILP which is associated with moderate morbidity. The drawback of this 
treatment is that all underlying tumour cells are not being treated. This treatment is 
ideal in patients with terminal disease and allows control of the local disease without 
subjecting the patient to major surgery and at the same time maintains the quality of 
the patient's life. There may also be a small subgroup of patients who may benefit 
from carbon dioxide laser treatment as the first line of management.
As seen earlier, there were no prognostic factors predicting survival in the patients 
with primary melanoma and survival benefits were not demonstrated in these patients 
following adjuvant ILP. The answer may lie in the fact that these patients were not 
properly staged in the first instance. It is known that 20%-40% of patients with stage 
I melanoma harbour clinically undetectable micrometastases in the regional lymph 
nodes. Since none of these patients had lymph node sampling, a significant number 
of patients may thus be harbouring metastases in the regional lymph nodes. If this is 
so, then the staging and prognosis will be affected. If the role of adjuvant ILP therapy 
is to be defined, then proper staging is necessary.
Intraoperative lymphatic mapping may be such a technique that will allows selective 
sampling of the sentinel lymph node for metastases. This technique has been 
developed on the assumption that metastases embolise via the lymphatic channels to 
the regional lymph nodes. The technique is based on identifying the first or sentinel 
lymph node and examining it for micrometastases. The sentinel node is the draining 
lymph node nearest the primary melanoma.
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By using patent blue dye which is injected around the site of the primary melanoma, 
the regional lymphatic basin is explored and the blue lymphatic channels are followed 
to the first stained blue lymph node. This technique was performed in 25 patients 
with stage I disease and sentinel nodes were identified in all patients. Eight nodes 
were found to contain micrometastases. All these patients underwent adjuvant ILP. 
In those with negative sentinel nodes, there has been no recurrence or distant 
metastases. However in the patients with positive sentinel node analysis, 2 developed 
recurrences and 1 developed distant metastases and died of the disease at a mean 
follow up of 18 months.
The results from this study suggest, that if these 8  patients who were originally staged 
as being stage I are removed from this group, adjuvant ILP may be shown to improve 
the disease free interval and overall survival in the tme stage I patient. It is now the 
practise in this unit to perform lymphatic mapping on all patients to try and select 
those patients with microscopic nodal disease, for whom nodal clearance may be 
more appropriate than ILP.
It was seen that patients with nodal metastases also had a higher risk of developing 
distant metastases. This is not suprising as once lymphatic invasion has occurred, it 
is only a matter of time that blood borne metastases will arise. This was clearly seen 
in the ulcerated tumour in the "stage I" patients with positive sentinel nodes.
If a cure or long term remission is to be found in these patients, the subclinical 
metastases in the blood stream need to be destroyed before they become established 
in distant organs. A treatment modality that may be able to destroy such metastases 
is targeted radiotherapy.
An animal model was designed to assess the possible use of targeted radiotherapy in 
patients with nodal metastases. Targeted radiotherapy is a treatment in which 
selective uptake of a radionuclide allows deposition of a high radiation dose in the 
targeted tissue with little exposure of surrounding structures. Methylene blue has 
been shown to have a high affinity for melanin. By adding labelled radioactive iodine 
to methylene blue, melanoma cells which are rich in melanin might selectively take 
up the compound and be destroyed.
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Radioisotopes of iodine were injected into 3 groups of nude mice with B16/F10 
mouse melanoma. Group A (controls) received tumour cells subcutaneously, Group 
B received a subcutaneous mixture of tumour cells and radioactive labelled 
methylene blue and Group C received tumour cells subcutaneously and on 
macroscopic evidence of tumour growth received intravenous radioactive labelled 
methylene blue into the tail vein.
Parallel experiments were performed on B16/F10 melanoma cells grown as plate 
cultures. In both the animals and the cell cultures, the effects of different isotopes 
were compared. It was observed that the tumour growth was delayed in the treated 
groups and the effect was maximal using iodine 125. Targeted radiotherapy in an 
isolated circuit using iodine 125 labelled methylene may now be clinically possible. 
From the results of the above studies, targeted therapy for micrometastases is a 
realistic possibility.
In conclusion, how will the results obtained from these studies alter the current 
management of melanoma of the limb? Surgery should no longer be just confined to 
wide local excision of the primary melanoma or recurrent disease. Adjuvant and 
secondary adjuvant ILP are necessary if improvement in both disease free survival 
and overall survival is to be achieved.
In patients with high risk primary limb melanoma, a wide local excision and 
lymphatic mapping followed by ILP with melphalan is indicated. If the sentinel node 
is positive, the patient should undergo radical lymphadenectomy. In the small 
subgroup of patients with stage I subungual melanoma, intraoperative lymphatic 
mapping with radical lymphadenectomy if necessary should be performed. ILP with 
melphalan and TNF may be beneficial in patients with subungual melanoma.
In patients with stage II and ELLA limb melanoma ILP with melphalan should be 
offered at the first recurrence. The patients should also have intraoperative lymphatic 
mapping to identify the sentinel node for micrometastases. Patients with stage JUAB 
should undergo ILP with melphalan and also therapeutic lymphadenectomy. 
However in the patients with failed ILP or when ILP is not possible, the patient 
should be treated with carbon dioxide laser to control the cutaneous recurrences with 
the treatment repeated as often as needed.
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The introduction of the pulsatile blood flow mode in the perfusion circuit has 
improved ILP. With this mode of blood flow, no prophylactic or therapeutic 
fasciotomy has been performed following ILP. Pulsatility, thus not only improves 
the circuit, but also reduces the morbidity from the procedure.
Targeted radiotherapy using isotopes of iodine in an animal model has been shown to 
be effective in the treatment of melanoma. There have been reports of combination 
radiotherapy and chemotherapy producing improved control of tumour recurrences. 
Targeted radiotherapy could now be applied in the ILP circuit together with 
melphalan both in the adjuvant and therapeutic treatments. Targeted radiotherapy 
could also be administered intravenously to mop up the melanoma cells in the 
systemic circulation thereby reducing and delaying the development of metastases in 
distant organs. The other possibility is the use of intradermal targeted radiotherapy to 
treat local recurrences.
The role of surgery in the management of local and regional limb malignant 
melanoma is no longer confined to local excision or amputation. It has now been 
established that ILP offers improvement in survival and disease free survival in 
patient with limb malignant melanoma. The new challenge to the surgeon is now in 
improving prognosis in stage I disease. The answer may lie in the combined therapy 
of lymphatic mapping and targeting metastases in the limb using a combination of 
chemotherapy and targeted radiotherapy using the ILP circuit as the vehicle.
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